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SUMMARY
An investigation into the physico-chemical and molecular mechanical properties of 
tertiary amines which predispose them to rapid N-dealkylation by cytochrome P450 has 
been undertaken. The rate of disappearance of the substrate (ke) from microsomal 
incubations was used as the index for determining the effect of changing the nitrogen 
substituent group within the series. In addition, individual routes of metabolism (N- 
demethylation and N-dealkylation) were quantified.
Initially, untreated hepatic microsomal fractions from male and female rat, and Beagle 
dog were employed to investigate sex and species differences in the metabolism of the 
tertiary amines. The rate constants for metabolism were compared with physico­
chemical and molecular mechanical properties of the substrates but no significant 
dependence was found for metabolism on any of these parameters. The lack of 
significant finding was attributed to the heterogeneity of the constitutive cytochrome 
P450 system.
Rats were pretreated with phenobarbitone and dexamethasone to obtain a predominance 
of specific isoenzymes CYP2B1 and CYP3A, respectively. The hydrophobicity of the 
substrate, as measured by the distribution coefficient (log D), was an important 
determinant of the rate of metabolism in both induced microsomal fractions. In 
addition, the strength of binding of the substrate to the enzyme (Ks) was important in 
the phenobarbitone-induced microsomal fraction whereas increasing rate of metabolism 
in the dexamethasone-induced model showed a significant dependence on increasing 
size of the substrate (length, area and calculated molar refractivity).
Specific inhibitors of CYP2B1 (orphenadrine) and CYP3A (UK-122,802) were 
employed in phenobarbitone-induced microsomal fraction to further dissect out rate 
constants for metabolism attributable to these isoenzymes. The rate of metabolism
attributable to CYP2B1 showed a dependence on log D and the binding affinity of the 
substrates. In addition, the electron density of the nitrogen atom was an important 
determinant of metabolism and this may be related to the mechanism of N-dealkylation. 
Optimum values of calculated molar refractivity (7.45) and area (1320Â2) were 
calculated for the individual routes of metabolism. (N-demethylation and N- 
dealkylation) attributable to CYP2B1. This implies that the CYP2B1 active site is 
constrained. Support for this came from the observation that N,N-bis[2-2,4- 
dichlorophenoxy)-ethyl]methylamine (bisDME), whose calculated molar refractivity 
(CMR) and area exceed the optima, was not metabolized by CYP2B1. In addition, 
molecular modelling studies indicated that the active site of CYP2B1 is too constrained 
to readily accommodate the n-alkyl chain of 2-(2,4-dichlorophenoxy)-N-pentyl-N- 
methylethanamine (pentylDME) when the molecule is oriented for N-depentylation.
All of the tertiary amines were substrates for CYP3A. Little dependence was seen for 
the rate of metabolism attributable to this isoenzyme on any physico-chemical or 
molecular mechanical properties of the substrates. It is speculated that the series does 
not cover a wide enough range of lipophilicity or size for this to influence their 
interaction with CYP3A, which is visualized as having a large active site. This view is 
supported by the observations that bisDME was metabolized by CYP3A, and also that 
as CYP2B1 metabolism became impeded by size, eg. pentylDME, the role was taken 
over by CYP3A.
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CHAPTER 1
Introduction
2
INTRODUCTION
1.1. Cytochrome P450 nomenclature
The cytochrome P450 superfamily of enzymes (EC 1.14.14.1) are haem-containing 
enzymes, or haemoproteins (Sato et al.> 1965) that are defined by the absorption 
spectra of the Fe2+-carbon monoxide complex which has a characteristic absorption 
maximum near 450nm. This is attributed to a thiolate cysteinyl sulphur atom bound to 
the haem iron in the fifth coordination site (Omura and Sato, 1964b; Gibson and 
Tamburini, 1984). The enzymes function as the terminal component of an electron 
transport chain ubiquitously distributed throughout living organisms. Cytochrome 
P450 from a variety of sources has been characterized as being an atypical b-type 
cytochrome containing protoporphyrin DC as a prosthetic group. The term cytochrome 
is really a misnomer, since in most instances P450 acts as an oxygenase rather than 
simply as an electron carrier, and the term "haem-thiolate protein" is more accurate 
(Palmer and Reedijk, 1991).
The importance of the cytochromes P450 in the metabolism of both endogenous and 
exogenous compounds cannot be exaggerated and is illustrated by the fact that 221 
genes have been described in 31 eukaryotes (including 11 mammalian and 3 plant 
species) and in 11 prokaryotes (Nelson et al., 1993). Of the 36 gene families described 
so far, 12 exist in all mammals examined to date. During the years of research on 
cytochrome P450 a variety of nomenclatures have been used to describe the enzymes 
isolated in different laboratories. This plethora of names became very confusing and a 
unifying nomenclature based on structural homology was proposed by Nebert et al. 
(1987). This system of nomenclature is constantly evolving as more P450s are isolated 
and characterized. According to the most recent update (Nelson et a l, 1993), those 
cytochrome P450 proteins with >40% amino acid sequence homology are included in 
the same family. In mammals those that are >55% identical fall within the same
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subfamily, but this is dropped to >46% on inclusion of more distant species. The 
individual isoenzymes are numbered arbitrarily in order of discovery. Cytochromes 
P450 are therefore named with the root 'GYP' followed by a number designating the 
family, a letter for the subfamily and another number denoting the individual P450 
form. The term "P450" is acceptable as an abbreviation for "cytochrome P450". The 
main advantage of this unified nomenclature is that structurally identical or highly 
similar P450s are easily recognizable, regardless of source (species, tissue or 
organelle), the inducer, or the catalytic activity examined.
1.2. Multiplicity and function of cytochrome P450.
Since P450 is present in all eukaryotes examined and at least some prokaryotes, the 
enzymes are believed to be ancient, probably evolving some 3.5 billion years ago 
(Nelson et al.y 1993). The mammalian P450 families can be functionally divided into 2 
major classes: those involved in synthesis of steroids and bile acids, and those that 
primarily metabolize xenobiotics (Gonzalez, 1992). The main functions of some 
mammalian P450 subfamilies are given in table 1.1. The P450s involved in steroid and 
cholesterol metabolism are well conserved in mammals with respect to their catalytic 
activities. It is believed that the steroidogenic P450s are among the oldest and were 
probably essential for maintenance of membrane integrity and turnover in some 
prokaryotes and early eukaryotes. Xenobiotic-metabolizing P450s probably evolved in 
more differentiated organisms for detoxification of foreign substances, particularly 
plant metabolites (Nebert and Gonzalez, 1987).
As a consequence of cytochrome P450 evolution there are an enormous number of 
isoenzymes resulting in inter-species and inter-individual variation. Humans and rats 
are thought to have diverged from common ancestors some 80 million years ago, with 
one of the consequences being the emergence of polymorphism in human drug 
metabolism leading to marked differences in the response of individuals to the
4
Table 1.1. Mammalian cytochrome P450 families.
P450
family
Number of 
subfamilies
Reactions
CYP1 1 xenobiotic metabolism
CYP2 8 xenobiotic and steroid metabolism
CYP3 2 xenobiotic and steroid metabolism
CYP4 3 fatty acid co- and 0)-l hydroxylations
CYP7 1 cholesterol 7a-hydroxylase
CYP11 2 steroid l ip-hydroxylase
CYP17 1 steroid 17a-hydroxylase
CYP19 1 aromatase
CYP21 1 steroid 21-hydroxylase
CYP27 1 cholesterol 27-hydroxylase
Adapted from Gonzalez, 1992; Nelson et a i, 1993.
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toxic and carcinogenic effects of drugs and environmental pollutants (Nebert and 
Gonzalez, 1987).
Another aspect of inter-individual variation involves enzyme induction. Early studies
(Remmer and Merker, 1963) showed clearly that repeated administration of
phenobarbitone caused a quantitative increase of the smooth endoplasmic reticulum in
the liver with a concomitant increase in drug metabolizing enzymes, notably
families
cytochrome P450. The major inducible of P450 are CYP1A, CYP2B, CYP3A, 
CYP2E and CYP4A. The classic inducers of CYP1A and CYP2B are polycyclic 
aromatic compounds (such as 3-methylcholanthrene) and phenobarbitone, respectively 
(Ryan et aL> 1979). Pregnenelone-16oc-carbonitrile was found to induce a novel 
cytochrome P450 of the CYP3A subfamily (Elshourbagy and Guzelian, 1980). 
Glucocorticoids, such as dexamethasone, also induce CYP3A as does phenobarbitone 
(Heuman et al., 1982). Agents that induce CYP2E are known as "ethanol-type" 
inducers since ethanol was the first compound found to induce this subfamily (Koop et 
a l, 1982). Several compounds are now known to induce CYP2E1, such as acetone 
and isoniazid (Koop et a l, 1985). Finally, the class of compounds known as 
peroxisome proliferators induce the CYP4A subfamily. They include the prototype 
inducer clofibrate and related hypolipidaemic drugs (Gibson et a l, 1982; Tamburini et 
a l, 1984) as well as phthalates used in plasticizers (Lake et a l, 1987). Induction of 
CYP1A, CYP2B, CYP3A and CYP4A is thought to reflect a stimulation of the 
transcription of their corresponding genes, as reviewed by Okey (1990). hi contrast, 
the induction of CYP2E appears to reflect mRNA stabilization (Song et al, 1989).
1.2.1. CYP2B.
The CYP2 family is now recognized as the largest and most diverse of the P450 
families, consisting of eight subfamilies which have been identified to date (Nelson et 
a l, 1993). The CYP2B gene subfamily has at least ten members. CYP2B1 and 
CYP2B2 are the major phenobarbitone-inducible isoenzymes in rat (Ryan et a l, 1979)
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and consequently are amongst the most widely studied isoenzymes. They have 97% 
amino acid sequence homology (Yuan et al.y 1983) and overlapping substrate 
specificity, although the activity of CYP2B1 is generally greater than that of CYP2B2 
(Guengerich et al.y 1982). CYP2B1 and CYP2B2 are present at low levels 
consdtutively in the liver and CYP2B1 has been identified in the lung (Imaoka et a l, 
1989). CYP2B1 is responsible for the regioselecdve 16a- and 16P-hydroxylation of 
testosterone (Imaoka et a l, 1989) and the O-depentylation of pentoxyresorufin is 
regarded as a specific marker for this isoenzyme in rat (Lubet et a l, 1985). Other 
isoenzymes identified in the rat are CYP2B3 (Labbé et al., 1988) and CYP2B8 
(Giachelli et al, 1989). The latter isoenzyme is present at low constitutive levels in the 
liver and is induced approximately 6-fold after phenobarbitone administration.
Two isoenzymes have been identified in the rabbit, CYP2B4 (Heinemann and Ozols,
1983) and CYP2B5 (Casser et a l, 1988). CYP2B4 is phenobarbitone-inducible and 
has 70% amino acid sequence homology with CYP2B1.
CYP2B11 is a major constitutive isoenzyme in the Beagle dog (Graves et a l, 1990). It 
is unique because among dogs, monkeys, rats and humans, only the dog CYP2B 
isoenzyme is capable of metabolizing polychlorinated biphenyls, such as 
2,2',4,4',5,5-hexachlorobiphenyl (Duignan et a l, 1987).
The first demonstration of the presence of the CYP2B gene subfamily in humans came 
with the identification of the CYP2B6 gene in liver (Miles et al, 1988), which encodes 
a P450 with 74% amino acid sequence homology to CYP2B1. However, whether the 
CYP2B6 gene is expressed at the enzyme level has yet to be positively demonstrated, 
so the role of the CYP2B subfamily in human drug metabolism may be limited.
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1.2.2. CYP3A.
Two members of the CYP3A subfamily have been identified in rat. CYP3A1 and 
CYP3A2 are 89% homologous as determined by amino acid sequence analysis 
(Gonzalez et al., 1986). Marked differences exist in the sex specificity and inducibility 
of these two isoenzymes. CYP3A1 is not expressed constitutively in untreated adult 
animals but is readily inducible by phenobarbitone and glucocorticoids, such as 
dexamethasone and pregnenelone-16a-carbonitrile (Gonzalez et al., 1986). In marked 
contrast, CYP3A2 is induced by phenobarbitone, not glucocorticoid, administration 
and is expressed constitutively only in adult male rats. These forms of rat P450 are 
responsible for erythromycin N-demethylation (Elshourbagy and Guzelian, 1980), 
nifedipine oxidation (Guengerich et al., 1986) and testosterone 6^-hydroxylation 
(Sonderfan et al., 1987).
The rabbit isoenzyme CYP3A6 is expressed constitutively and is readily inducible by 
dexamethasone and rifampicin (Potenza et al., 1989).
In the Beagle dog an isoenzyme has been identified (CYP3A12) that has 69% amino 
acid sequence homology with CYP3A1 (Ciaccio et al., 1991). CYP3A12 is induced 
after phenobarbitone administration (approximately 3-fold) and has a similar substrate 
specificity as the rat isoenzymes (Ciaccio and Halpert, 1989).
The CYP3A family of P450s are the most abundantly expressed in human liver. 
CYP3A3 and CYP3A4 are very similar, having only eleven amino acid substitutions 
and no known differences in substrate specificity (Aoyama et al., 1989). A third 
CYP3A form, designated CYP3A5, is expressed in only 10-20% of adult human livers 
analyzed (Aoyama et al., 1989). CYP3A7 is the major P450 in human foetal liver 
(Komori et al., 1989a) although its role there is not entirely clear. The human CYP3A 
subfamily is responsible for the metabolism of a wide range of endogenous compounds 
and xenobiotics (Smith and Jones, 1992). In rats, dogs and humans the substrate
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specificity of the CYP3A subfamily is similar although rates of clearance may vary 
between species (Smith, 1991).
1.3. Cytochrome P450 catalysis.
The cytochrome P450-mediated mixed-function oxidases (monooxygenases) are of 
central importance in the metabolism of a wide variety of xenobiotics. In mammals the 
enzyme system has been found in most tissues examined, although it is in greatest 
abundance in the liver (Porter and Coon, 1991). The principal role of cytochrome 
P450 in the metabolism of xenobiotics is the introduction or development of a polar 
functional group into the molecule which may then be excreted or continue into phase II 
metabolism. The types of reaction catalyzed by P450 may be oxidative, reductive or 
peroxidatic (Guengerich, 1991).
Cytochrome P450 is the terminal oxidase component of an electron transport system 
responsible for many oxidative reactions. The active site contains iron protoporphyrin 
IX bound in part by hydrophobic forces. The fifth ligand is a thiolate anion provided 
by a cysteine residue and the sixth coordinate position may be occupied by an 
exchangeable water molecule. Upon reduction of the iron, oxygen can be bound in the 
sixth position (White and Coon, 1982). The haemoprotein serves as both oxygen and 
substrate binding locus for the mixed-function oxidation reaction and undergoes 
oxidation/reduction of the haem iron which is mandatory for catalytic function.
The oxidative reaction catalyzed by P450 involves cleavage of molecular oxygen 
followed by insertion of one atom into the substrate and the reduction of the second to 
water, according to the following equation:
SH + 0 2 + NADPH + H+ ->  SOH + H20  + NADP+
9
where SH represents the substrate. For this reason the above reaction has been termed 
"mixed-function oxidation" (Mason, 1965).
One of the best characterized cytochrome P450 systems is that in the mammalian liver, 
where it is principally associated with the smooth endoplasmic reticulum. The system 
comprises two main components (i) NADPH-cytochrome P450 reductase which 
mediates the transfer of electrons from NADPH to (ii) cytochrome P450, which serves 
as the terminal electron acceptor and site of substrate oxidation. The cytochrome P450 
mechanism can be seen in terms of a "cytochrome P450 cycle" (Gibson and Tamburini,
1984) as detailed in figure 1.1. A number of steps in the cycle have been examined and 
the nature of the processes elucidated.
The binding of the substrate to cytochrome P450 is possibly the most studied of the
entire cycle (step 1, figure 1.1). The addition of hydrophobic substrates to microsomal
or purified cytochrome P450 gives rise to a spectral change (an increase in absorbance
between 380-390nm and a decrease in absorbance between 417-422nm) known as the
type I spectral change (Schenkman et al., 1981). This spectral change has been
attributed to an interaction between the substrate and the apoprotein (including
displacement of the endogenous ligand) which results in changes in the electron
distribution of the iron atom. The type H spectral change (an increase in absorbance
between 420-426nm and a decrease between 380-4lOnm) does not represent a substrate
interaction with the apoprotein, but is probably due to an interaction with the 
haemoprotein of an incoming ligand (Schenkman et a l, 1981).
The type I spectral change has been attributed to a change in the distribution of the ferric 
(Fe3+) d-electrons from a low spin (s=l/2) to a high spin (s=5/2) state. These two 
ferric spin states exhibit different Soret absorbances, with the low and high spin states 
absorbing at 412 and 390nm, respectively (Schenkman et a l, 1981). The observation
10
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Figure 1.1. Cytochrome P450 catalytic cycle. Fe represents the haem iron atom at 
the active site, SH the substrate and SOH the product.
The numbered stages are elaborated in the text
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of a spin equilibrium in the presence and absence of substrate led to the proposal of a 
thermodynamically closed four state model to explain the interaction of a substrate with 
cytochrome P450 (Sligar, 1976; Gibson and Tamburini, 1984). The model is 
presented in figure 1.2. As a consequence of this thermodynamically closed model, it 
is possible to quantify the micro-equilibrium constants (K1-K4) and these, together 
with the spectral dissociation (or binding) constant Ks, completely describe the binding 
of a substrate to cytochrome P450. Cytochrome P450 is conceptualized as an 
equilibrium mixture of high and low conformational states described by the equilibrium 
constants Ki and K2 in the absence and presence of substrate, respectively. The other 
micro-equilibrium constants represent the dissociation constants of the substrate-protein 
complex in its high (K4) and low (K3) spin state forms.
The alteration in spin state of cytochrome P450 has the effect of changing the mid-point 
redox potential from -400mV to -180mV for the low and high spin forms, respectively 
(Sligar et al., 1979). This is significant because it facilitates the next stage of the P450 
catalytic cycle (step 2 , figure 1.1) which is the one electron reduction of substrate- 
bound cytochrome P450 by NADPH-cytochrome P450 reductase (Gibson and 
Tamburini, 1984). The reductase is a flavoprotein which contains FMN and FAD and 
which donates the electron from the FMNHz/FADH-complex (Guengerich, 1983). 
The substrate-bound cytochrome ferrous iron then binds molecular oxygen rapidly to 
form an oxygenated complex (step 3, figure 1.1). Transfer of a second electron from 
NADPH-cytochrome P450 reductase, or possibly cytochrome bg (Schenkman et al., 
1976), generates an activated iron-oxygen complex (step 4, figure 1.1). The next step 
is not well understood but involves splitting of the oxygen-oxygen bond with the 
uptake of two protons at some stage and the generation of an "activated oxygen" 
species, formally designated (SH)Fe3+=0, with the simultaneous release of a water 
molecule (step 5, figure 1.1). Oxygen is then incorporated into the substrate (steps 6 
and 7, figure 1.1), possibly by a process involving hydrogen atom abstraction from the 
substrate (Groves et a i, 1978). Finally, the oxygenated product dissociates to leave
12
Fe:3+ v
K
K,
K
Fe3+ ---------------is
s
— Fe?+-Shs
K
^ rFe?+-SIs
Fe^g- enzyme in the high spin state with no substrate bound 
Fejg - enzyme in the low spin state with no substrate bound 
Fehs“S " enzyme in the high spin state with substrate bound 
Fels~S " enzyme in the low spin state with substrate bound
Figure 1.2. Spin state model for the interaction between cytochrome P450 and a 
substrate.
Reproduced from Gibson and Tamburini, 1984.
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the iron in the original ferric state (step 8, figure 1.1).
The overall oxygenation reactions carried out by cytochrome P450 include carbon 
hydroxylation, heteroatom oxygenation, heteroatom release (dealkylation) and 
epoxidation (Guengerich and MacDonald, 1984). The chemistry in the different 
reactions is thought to be rather invariant and the key influence on catalytic specificity is 
the apoprotein (Guengerich and MacDonald, 1990) and that a single protein can 
catalyze all types of reactions, depending on the substrate presented.
1.3.1. Mechanism of N-dealkylation.
A large body of evidence supports the view that heteroatom release with amines (N- 
dealkyladon) proceeds after a 1-electron transfer reactions (figure 1.3). Examination of 
the kinetic isotope effects of cytochrome P450 reactions has found that for aliphatic 
carbon oxidation (Groves et a/., 1978) the effects were large (k^/kp>=ll.^) whereas 
studies on the N-demethylation of compounds, such as N,N-dimethylaniline, have 
yielded effects in the order of 1-2 (Miwa et al., 1983). These low values are similar to 
those measured in amine electrochemical oxidation (Shono et al., 1982). In addition, 
evidence for incorporation of 180  (from 18C>2) into the carbonyl function (McMahon et 
al., 1969) and arguments against N-oxide intermediates (Guengerich, 1984) support 
the proposed mechanism.
In the scheme shown in figure 1.3, oxygenated P450 abstracts an electron from the 
nitrogen yielding an aminium radical (stepl). It has been proposed that the rapid cc- 
hydrogen deprotonation necessary to yield the low kinetic isotope effects seen (step 2 , 
figure 1.3) may result from the use of a specific base to abstract the proton (Guengerich 
and MacDonald, 1990). Since many P450s catalyze N-dealkylation it seems unlikely 
that all the primary sequences would contain the appropriate base at the required 
position. This led Okazaki and Guengerich (1993) to suggest that base catalysis is an
c h 3
I
R -N : -
R'
c h 3 c h 2
1 II
n ; — >- R-N* _
1 2 1
R’ R'
CH2 
^ R - n :  
R’
CH2OH
R -N : —
I 4 
R'
HCHO
+
R -N H
I
R'
[FeO]3+ [FeO] 2 + [FeOH] 3 + Fe 3 + Fe 3 +
Figure 1.3. Proposed mechanism of N-dealkylation.
Adapted from Guengerich, 1990.
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intrinsic part of the reaction with [FeO]2+ acting in this capacity. Deprotonation yields 
a carbon-centred radical (step 2, figure 1.3) and oxygen rebound to this radical occurs 
(step 3) giving a carbinolamine. The carbinolamine collapses by rearrangement (step 4, 
figure 1.3) yielding the N-dealkylated product and an aldehyde.
1.4. Inhibition of cytochrome P450.
In the safety evaluation of drugs and other chemicals there is concern to determine their 
potential to cause inhibition of the enzymes of drug metabolism. Such interactions may 
alter the pharmacological effects of concurrent medication, modify the toxicity or 
carcinogenicity of xenobiotics, or alter the levels of important endogenous compounds. 
A number of cytochrome P450 inhibitors have been developed into therapeutic agents, 
such as several antifungal drugs which were designed as inhibitors of a cytochrome 
P450 isoenzyme involved in the C14 déméthylation of sterols. A problem with this, 
however, is that a potent inhibitor of cytochrome P450 may lose its specificity and at 
high doses is likely to elicit a wide range of biological effects that could be deleterious 
to the organism. For example, ketoconazole is an antifungal drug that reportedly 
inhibits many P450 reactions including testicular steroidigenesis (Kan et al., 1985), 
vitamin D homeostasis (Henry, 1985), most hepatic biotransformations (Murray and 
Zaluzny, 1988), and adrenal corticosteroid production (Nagai et al., 1986). The 
development of agents that are preferential inhibitors of specific cytochrome P450s is 
therefore desirable. Specific inhibitors are also useful as indicators of the activity of 
different P450s (Smith and Jones, 1992) as well as probes for mapping active sites 
(Kunze et al., 1983).
Monoclonal antibodies have been developed to several of the major P450 isoforms and 
have proven useful for the detection and immunopurification of immunochemically 
related P450 enzymes (Thomas et al., 1987; Guengerich et al., 1982). In addition, 
many of these antibodies have been used to evaluate the contribution of a particular
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isoenzyme to overall microsomal metabolism of several substrates (Waxman et al., 
1987; Fujino et al, 1990). However, to obtain effective inhibition of P450 activity the 
relative level of antibody to P450 protein tends to be prohibitively high. For example, a 
ratio of 0.1 jig antibody per pmol purified P450 was required for complete inhibition of 
catalytic activity (Fujino et a l, 1990). Thus the quantity of antibody required for 
complete inhibition in a microsomal incubation would be impractical.
The nature of the cytochrome P450 catalytic cycle (figure 1.1) clearly shows that there 
are a number of potential points of interaction with inhibitors. In practice only three 
steps have been found vulnerable to inhibition: (i) the binding of substrate, (ii) the 
binding of molecular oxygen, and (iii) the transfer of oxygen to the substrate (Ortiz de 
Montellano and Reich, 1986). Cytochrome P450 inhibitors may be divided into three 
categories: reversible, metabolic intermediate complexing agents and autocatalytic 
inactivators.
1.4.1. Reversible inhibition.
Inhibitors that compete reversibly with substrates for occupancy of the active site 
include compounds that produce a characteristic type II spectrum (section 1.3) on 
interaction with the enzyme. This interaction is optimally performed by compounds 
that carry a heteroatom (such as nitrogen) possessing a free electron pair for 
coordination with the haem atom, and a suitably hydrophobic area of the molecule for 
interaction with the active site. For the most part these inhibitors are nitrogen- 
containing aliphatic and aromatic compounds (Ortiz de Montellano and Reich, 1986). 
Interactions with reversible inhibitors are usually of a transient nature and once the 
inhibitory agent has been eliminated from the organism the normal function of the P450 
enzyme continues.
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1.4.2. Metabolic intermediate complexation.
A number of drugs and other foreign compounds are converted by P450 from inactive 
chemicals to effective inhibitors. The observation that metabolic intermediates 
sequester the P450 in a catalytically non-functional state led to the use of the term 
"metabolic intermediate (MI) complex" (Franklin, 1977).
A number of compounds have been associated with MI complex formation, including
some alkylamine derivatives. One of the first alkylamines shown to elicit MI
complexation was SKF 525-A (Buening and Franklin, 1976), but with a lack of
selectivity. More recent studies with another alkylamine, orphenadrine, have helped to
relatively
identify the complexing species as well as indicating that this compound is ajspecific 
inhibitor of CYP2B1 (Bast et al., 1983; Reidy et al., 1989). Orphenadrine is thought 
to undergo successive oxidation steps to yield a nitroso analogue that generates the MI 
complex with P450 (figure 1.4). It may be that P450 isoenzymes not subject to MI 
complexation are involved in the earlier oxidation steps, with CYP2B1 being 
responsible for the final step leading to its inactivation. This comes from evidence that 
a reconstituted system incorporating purified CYP2B1 did not generate the MI complex 
with orphenadrine (Murray and Reidy, 1990). MI complex-forming agents may, 
therefore, be of great value in the development of specific P450 inhibitors because they 
rely upon the catalytic function of one (or relatively few) P450s.
1.4.3. Autocatalytic inactivation.
Autocatalytic inactivators (or "suicide inhibitors") of P450 include a variety of 
compounds that alkylate the enzyme and inactivate its function. The inhibition of P450 
by cyclopropylamines has been attributed to autocatalytic inactivation (Hanzlik et al., 
1979). The mechanism is believed to be a consequence of initial amine nitrogen 
oxidation to generate a radical cation, followed by rapid ring-opening in the enzyme 
cavity to form a highly reactive carbon-centred radical (MacDonald et a l, 1982). Such 
a reactive species could react with the haem moiety of the enzyme (figure 1.5).
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Figure 1.4. (a) Oxidative metabolism of orphenadrine to the nitroso analogue that 
generates a metabolic intermediate complex with cytochrome P450, and (b) the 
structure of the orphenadrine metabolite-ligating species.
Adapted from Murray and Reidy, 1990.
Figure 1.5. Mechanism postulated for the production of a carbon-centred radical 
from cyclopropylamines that inactivates cytochrome P450.
Adapted from MacDonald etal.y 1982.
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1.5. Quantitative structure-activity relationships.
Quantitative structure-activity relationships (QSARs) are important in rationalizing 
molecular factors involved in cytochrome P450-dependent activity of substrates, 
inducers and inhibitors in order to assist in novel molecular design and to aid an 
understanding of the physico-chemical processes involved in cytochrome P450- 
mediated reactions. The metabolism of molecules may be dependent upon their 
physico-chemical properties. For example, electronic effects within a molecule control 
bond order, governing how susceptible a bond is to metabolic attack. Steric factors 
may shield a bond from metabolic attack or may even prevent the molecule from 
interacting with the enzyme. Thus QSAR studies may help identify structural features 
in drug molecules that are essential for activity and enable tentative predictions of 
biological properties of new molecules to be made.
Cytochrome P450 metabolizes a wide range of structurally diverse compounds, with an 
apparent lack of substrate specificity, due to the presence of multiple isoenzymes 
(section 1.2). Early studies, however, recognized the importance of increasing 
lipophilicity for increasing metabolic rate of substrates (Gaudette and Brodie, 1959). 
This is now attributed to the fact that the P450 enzymes are protected by a lipoidal 
membrane through which the substrate has to pass to gain access to the enzyme. A 
distinction should be made between two commonly encountered measures of 
hydrophobicity. The partition coefficient (log P) is defined as the ratio of 
concentrations of a compound at equilibrium between organic and aqueous phases. It 
therefore describes the intrinsic lipophilicity of a molecule in the absence of dissociation 
or ionization. The distribution coefficient (log D) describes the overall ratio of drug 
(ionized and unionized) between organic and aqueous phases, thus taking into account 
the intrinsic lipophilicity of the molecule as well as its degree of ionization (Manners et 
a/., 1988).
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Electronic features of molecules have also been correlated with biological activity. 
Catalytic rates have been correlated with the Hammett substituent constant (a) for a 
series of toluene derivatives (White and McCarthy, 1986) and a series of N,N- 
dimethylanilines (Burstyn et al., 1991). The Hammett substituent constant describes 
the electron-directing effect of a substituent on the acid dissociation constant of benzoic 
acid (Dearden, 1990). This parameter may be modified to give the Taft parameter (a*) 
which describes the inductive effect of a substituent group on any parent molecule 
(Perrin et al., 1981). Other electronic features that are commonly used in QSARs are
(i) calculated molar refractivity (CMR), which is related to molecular volume as well as 
the polarizability of the molecule (Dearden, 1990), (ii) charge on atoms of substituent 
groups, and (iii) pKa.
The size and shape of molecules and substituents are also important for the control of 
biological activity. Steric parameters that may be correlated with biological activity 
include molecular weight, volume, surface area, length and depth. Baarnhielm and 
Westeriund (1986) reported that the microsomal oxidation rate of a series of 1,4- 
dihydropyridines increased with increasing steric bulk. In addition, Devinsky and 
Gorrod (1987) found that for a series of N,N-dimethylalkylamines their N-oxidation 
rate increased with increasing chain length of the substituent group up to C12, but 
thereafter decreased.
The main difficulty is in the interpretation of QSARs. Microsomal incubations, which 
usually serve as in vitro models for QSAR studies, are heterogeneous so any QSARs 
cannot be attributed to any particular enzyme. This problem can be partially overcome 
by the use of microsomal fractions obtained after treatment with a P450 inducer. This 
generally ensures the predominance of one P450 subfamily, if not one isoenzyme, to 
which any QSARs may be tentatively attributed. Some QSAR studies have employed 
reconstituted systems incorporating purified P450 enzymes (eg. White and McCarthy, 
1986). A major deficiency of this type of study is that the purified enzyme may exhibit
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catalytic activities that it lacks in situ. For example, CYP3A1 exhibits little or no 
catalytic activity towards ethylmorphine in a reconstituted system, whereas induction of 
CYP3A1 by pregnenelone-16a-carbonitrile is thought to account for the high level of 
ethylmorphine N-demethylase activity reported in microsomal preparations 
(Elshourbagy and Guzelian, 1980).
1.6. Tertiary amines.
The tertiary amine functional group is an important feature present in many drugs, 
including amphetamines, analgesics, local anaesthetics and tricyclic antidepressants. 
Consequently the metabolism and possible deactivation of this functional group is of 
great importance.
The xenobiotic metabolism of tertiary amines has been extensively reviewed (Testa and 
Tenner, 1979; Rose and Castagnoli, 1983). In general, the amine function undergoes 
phase I biotransformation which takes the form of N-dealkylation, yielding a secondary 
amine and the aldehyde corresponding to the group removed (section 1.3.1), or N- 
oxidation which yields the tertiary amine with an oxygen atom datively bound to the 
nitrogen. Evidence derived from induction and inhibition studies supports the 
argument that N-dealkylation and N-oxidation are catalyzed by two enzyme systems - 
cytochrome P450 and mixed-function amine oxidase (Ziegler and Mitchell, 1972), 
respectively. Phenobarbitone, which induces cytochrome P450, facilitates N- 
dealkylation but has little effect on N-oxidation (Prough and Ziegler, 1977). Similarly, 
SKF 525-A, an inhibitor of cytochrome P450 (Buening and Franklin, 1976), inhibits 
N-dealkylation but has no effect on N-oxidation (Beckett, 1971). Conversely, 
dithiothreitol inhibits N-oxide formation, with little effect on N-dealkylation (Beckett et 
al.y 1971). In addition, studies employing purified mixed-function amine oxidase 
indicated that this enzyme system was not responsible for the N-dealkylation of tertiary 
amines (Prough and Ziegler, 1977). In summary, N-oxidation may be supported by
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cytochrome P450 and amine oxidase, but N-dealkylation of tertiary amines is carried 
out exclusively by P450.
Examination of the literature reveals that many groups attached to the nitrogen atom are 
removed via N-dealkylation, provided that the functional group has an a-carbon atom 
carrying at least one hydrogen. With this in mind, a series of tertiary amines was 
synthesized in order to study the mechanism of cytochrome P450-mediated N- 
dealkylation (Jones, 1989). The series is based on the 2-(2,4-dichlorophenoxy)-N- 
methylethanamine structure and will hereafter be referred to as the "DME derivative" 
series. The rationale for the design of the DME derivative series was as follows:
(i) the route chosen for study was N-demethylation, so the methyl substituent on the 
nitrogen remains constant throughout the series;
(ii) the 2,4-dichlorophenol ring system was chosen because it is reasonably lipophilic 
and should interact with cytochrome P450, also the blocked 4-position means that 
P450-mediated para hydroxylation is unlikely;
(iii) two methylene units between the nitrogen atom and the 2,4-dichlorophenol ring 
reduce the influence of the electronic configuration of the aromatic ring on the nitrogen;
(iv) the changes made to the remaining substituent are designed to change the steric and 
physico-chemical properties of the molecule in order to explore the effect of such 
alterations on the rate of metabolism.
The structures of all the DME derivatives, and the abbreviations routinely used for 
each, are given in figure 1.6. The series may be divided into three groups: those with 
n-alkyl substituent groups (figure 1.6A), those with branched or unsaturated alkyl 
substituent groups (figure 1.6B), and those that have aromatic rings in their substituent 
groups (figure 1.6C).
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OCH2CH2N
zCH
\  2-(2,4-dichlorophenoxy)-N,N-dimethylethanamine 
CHg
(methylDME)
OCH2CH2N
z,c h 2c h 3
\  2-(2,4-dichlorophenoxy)-N-ethyl-N-methylethanamine 
CH3
(ethylDME)
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OCH2CH2N
zc h 2c h 2c h 3
\ 2-(2,4-dichlorophenoxy)-N-propyl-N-methylethanamine 
(n-propylDME)
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\  2-(2,4-dicMorophenoxy)-N-butyl-N-methylethanamine 
CH3
(n-butylDME)
OCH2CH2N
zc h 2c h 2c h 2c h 2c h 3
\  2-(2,4-dichlorophenoxy)-N-pentyl-N-methylethanamine 
CH3
(pentylDME)
Figure 1.6A. Structures of the DME derivatives with n-alkyl substituent groups.
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CH- (iso-propylDME)
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\
CH2— C =  CH
2-(2,4-dichlorophenoxy)-N-propynyl-N-methylethanamine 
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Figure 1.6B. Structures of the DME derivatives with branched or unsaturated alkyl 
substituent groups.
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2-(2,4-dichlorophenoxy)-N-phenyl-N-methylethanamine
(phenylDME)
C I
CH
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2-(2,4-dichlorophenoxy)-N-benzyl-N-methylethanamine
(benzylDME)
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CH
2-(2,4-dichlorophenoxy)-N-phenethyl-N-methylethanamine
(phenethylDME)
C I
C l CI
o c h 2c h 2n c h 2c h 2o
CH:
CI
N,N-bis[2-(2,4-dichlorophenoxy)-ethyl]methylamine
(bisDME)
Figure 1.6C. Structures of the DME derivatives with aromatic substituent groups.
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1.7. Aims of the study
Many compounds which are potentially active as drugs contain tertiary amine functions 
that may be deactivated by cytochrome P450-mediated N-dealkylation before reaching 
their target receptors. Future drug design may be improved by a better understanding 
of the chemical and physico-chemical properties of these drugs that predispose them to 
N-dealkylation.
In order to understand further cytochrome P450-mediated N-dealkylation the rates of 
disappearance of a series of N-substituted tertiary amines have been determined in 
hepatic microsomal fractions from male and female rat, and from Beagle dog. The rate 
constants for metabolism of the tertiary amines have been compared with the physico­
chemical and molecular mechanical properties of the substrates to identify correlations 
which may explain observed differences in rates of metabolism.
However, structure-activity relationships derived from untreated hepatic microsomal 
fractions are difficult to interpret due to the heterogeneity of the constitutive cytochrome 
P450 superfamily. Therefore, hepatic microsomal fractions from rats pretreated with 
cytochrome P450 inducers (phenobarbitone and dexamethasone) have also been used 
as in vitro metabolism models. In addition, specific cytochrome P450 inhibitors have 
been employed to dissect out the rate constants attributable to single isoenzymes and 
these values were used to produce more meaningful quantitative structure-activity 
relationships.
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CHAPTER 2
Materials and Methods
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MATERIALS
All reagents used were of at least analytical grade and were obtained from the following 
sources:
Sigma Chemical Company Ltd (Poole, Dorset, UK)
Benzphetamine, boric acid, bovine serum albumin, codeine, dexamethasone (phosphate 
salt), dimethyl sulphoxide, ethoxyresorufin, formaldehyde, 30%(v/v) hydrogen 
peroxide, isocitrate dehydrogenase, isocitric acid, lauric acid, manganese chloride, 
morphine, NADPH, norcodeine, octane sulphonic acid, orphenadrine (hydrochloride), 
pentoxyresorufin, resorufin, sodium hydrogen carbonate, trizma base.
British Drug Houses Ltd (Poole, Dorset, UK)
Acetylacetone, ammonium acetate, ammonium persulphate, copper sulphate, 
dipotassium hydrogen phosphate, Folin Ciocalteau reagent, glycine, magnesium 
chloride, phenobarbitone (sodium salt), potassium chloride, potassium dihydrogen 
orthophosphate, sodium carbonate, sodium chloride, sodium dihydrogen phosphate, 
sodium dithionite, sodium potassium tartrate, sucrose, trichloroacetic acid.
Fisons Scientific Equipment (Loughborough, Leicestershire, UK)
All solvents were of analytical grade, unless otherwise stated.
Glacial acetic acid, acetonitrile (HPLC grade), dichloromethane, diethylether, methyl- 
fgrf-butyl ether (HPLC grade), glycerol, hexane, hydrochloric acid, isopropanol, 
methanol (analytical and HPLC grade), sodium hydroxide.
Other sources
[1-14C] lauric acid (Amersham Radiochemicals, Buckinghamshire, UK)
Spherisorb S5CN and S50DS HPLC columns (25 x 0.46cm) (Hichrom, Reading, UK)
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Felodipine and amlodipine were kind gifts from Pfizer Central Research (Kent, UK) as 
was the CYP3A inhibitor (UK-122,802).
The DME derivatives were synthesized by Dr. B.C. Jones (Jones, 1989).
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METHODS
2.1. Animals
Male Wistar rats (200-250g) were obtained from the University of Surrey breeding unit 
Male and female Sprague-Dawley rats (200-250g) came from Charles River Ltd 
(Mansion, Kent). Animals were housed in cages with sawdust bedding and were 
allowed access to food (Spratts Animal Diet No. 1) and water ad libitum. A twelve hour 
light/dark cycle was maintained at 22°C and 50% relative humidity. All animals were 
starved overnight prior to killing by cervical dislocation.
2.2. Animal pretreatment
Phenobarbitone
A stock solution of 1% (w/v) phenobarbitone (sodium salt) was prepared and stored at 
4°C. This solution was diluted daily (1 in 10) and the pH was altered to 7.0 using 
concentrated hydrochloric acid. Phenobarbitone (0.1% (w/v)) was administered for 5 
days in the drinking water. The animals were killed on the sixth day.
Dexamethasone
Dexamethasone (phosphate salt) was dissolved in water and the solution administered 
by gavage for 3 days at a dose level of 100mg/kg. Animals were killed 24 hours after 
the final dose.
2.3. Isolation of hepatic microsomal fraction
Hepatic microsomal fractions were prepared by ultracentrifugation, as described 
previously (Chinje et al., 1991).
The livers, following excision, were rinsed and perfused with 0.9%(w/v) saline to
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remove contaminating blood, blotted dry and weighed. All subsequent steps were 
performed at 4°C. The livers were scissor-minced and homogenized in 3 volumes (w/v) 
of 0.25M sucrose using a Potter-Elvehjem glass-Teflon homogenizes The homogenate 
was centrifuged at 12,500g for 20min. The supernatant was decanted and centrifuged at 
105,000g for 60min. The supernatant was discarded and the pellet resuspended in 
50mM potassium phosphate buffer (pH 7.25) containing 20%(v/v) glycerol. The 
microsomal suspensions were stored at -80°C until required, without loss of original 
activity. This was monitored by measuring the content of total cytochrome P450 
(section 2.5) at regular intervals during storage.
2.4. Determination of protein concentration
The concentration of protein in hepatic microsomal fractions was determined by the 
method of Lowry et al. (1951). Microsomal fractions were diluted 1:50 with 50mM 
potassium phosphate buffer (pH 7.25) containing 20%(v/v) glycerol and were assayed 
in triplicate. Bovine serum albumin (0-80 pg/ml) was used to construct the protein 
standard curve.
2.5. Determination of cytochrome P450
Total carbon monoxide-discernible cytochrome P450 was determined by the method of 
Omura and Sato (1964a) using a difference absorption coefficient (450-490nm) of 
91mM"lcm~l for the sodium dithionite-reduced carbon monoxide adduct. Microsomal 
fractions were diluted 1:20 with 50mM potassium phosphate buffer (pH 7.25) 
containing 20%(v/v) glycerol prior to analysis.
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2.6. Characterization of microsomal fractions
2.6.1. Benzphetamine N-demethylase activity
Benzphetamine N-demethylase activity was measured by the formation of 
formaldehyde, which was quantified by the method of Nash (1953).
Reagents:
Stock concentration 
150mM in water 
400mM in water
15mM in water 
40mM in water
Component 
Magnesium chloride 
Potassium phosphate 
buffer, pH 7.4 
Microsomal fraction 
Benzphetamine 
NADPH
Final concentration 
15mM
50mM
l|iM cytochrome P450
1.5mM
ImM
Distilled water was added to give a final incubation volume of 1ml.
All the components of the incubation except the NADPH were preincubated at 37°C for 
5min prior to initiation of the reaction by the addition of NADPH (25pi). The reaction 
was terminated after 10min by the addition of 0.5ml ice-cold 12.5% (w/v) 
trichloroacetic acid (TCA). After centrifugation at 1500g for 10min, the supernatant 
(1ml) was removed for the determination of formaldehyde by the Nash assay.
Nash assay 
Reagent:
Ammonium acetate (150g) was dissolved in 900ml distilled water. Acetylacetone (2ml) 
was added and the pH adjusted to 6.0 by the addition of glacial acetic acid. The volume 
was then adjusted to 1 litre.
Method:
The Nash reagent (1ml) was added to the supernatant (1ml) from the TCA precipitation,
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mixed and heated in the dark at 60°C for 10min. After cooling, the absorbance at 
412nm was recorded. A standard curve was constructed using 1ml volumes containing 
formaldehyde from 0 to 140|iM.
2.6.2. Alkoxyresorufin O-dealkylase
The method of Burke and Mayer (1974) was used for the measurement of resorufin 
from ethoxyresorufin and pentoxyresorufin by their respective O-dealkylation reactions. 
The reaction mixture, prepared in a fluorimeter cuvette, consisted of 2ml 0.1M Tris-HCl 
buffer (pH 7.8), 50pl microsomal fraction (approx. Img protein) and either 3|il 
ethoxyresorufin (0.53mM in DMSO) or 5|i.l pentoxyresorufin (ImM in DMSO). All 
fluorimetric assays were performed on a Perkin Elmer LS-5 luminescence 
spectrophotometer set at an excitation wavelength of 510nm and emission wavelength of 
586nm with excitation and emission slit widths of lOnm and 2.5nm, respectively. A 
baseline of fluorescence was recorded prior to initiation of the reaction by addition of 
10f.il NADPH (50mM). The reaction was monitored continuously until a measurable 
gradient was obtained and the initial rate calculated from the slope. The instrument was 
calibrated using lOpl aliquots of resorufin (O.lmM in DMSO) added to a cuvette 
containing buffer and microsomal fraction.
2.6.3. Lauric acid hydroxylase
The combined 11- and 12-hydroxy metabolites of lauric acid were quantified by thin 
layer chromatography. Samples were prepared according to the method of Orton and 
Parker (1982).
Reaction mixtures contained Img microsomal protein and 0.2mM (O.ljiCi) of 14C- 
lauric acid. The volume was made up to 2ml with distilled water. The reaction mixtures 
were preincubated at 37°C prior to addition of 40|il NADPH (40mM). After a 10min 
incubation the reaction was terminated by addition of 0.2ml hydrochloric acid (600mM). 
The hydroxylauric acids and unmetabolized substrate were extracted into diethylether 
(10ml) for 10min using an end-over-end shaker. The ether layer was removed and
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evaporated to dryness under a stream of nitrogen. The resulting residues were 
reconstituted in 60|xl methanol and 20jil was spotted onto silica gel GF TLC plates 
(Merck 20x20cm). The plates were developed in a hexane-diethylether-glacial acetic acid 
system (140:56:3 by volume). The radioactive areas corresponding to combined 11- and 
12-hydroxylauric acid metabolites and unmetabolized substrate were detected and 
quantified by a LB 2842 Automatic TLC-Linear Analyzer (Berthold (UK) Ltd., Leeds).
2.6.4. Codeine O- and N-demethylation
The O- and N-demethylation of codeine was measured by the appearance of morphine 
and norcodeine metabolites respectively as described by Persson et al. (1989).
Reagents:
Stock concentration 
200mM
lOOmM in water 
161mM in methanol
Component 
Tris-HCl buffer, 
pH 7.4
Magnesium chloride 
Microsomal fraction 
Codeine
Final concentration
50mM
5mM
0.5|iM cytochrome P450 
500jiM
NADPH-generating system
ImM in water Manganese chloride 5|iM
lOOmM in water Isocitric acid 5mM
Isocitrate dehydrogenase 1 Unit/ml 
20mM in water NADPH ImM
Distilled water was added to make a final incubation volume of 1ml. All components of 
the reaction mixture except the NADPH were preincubated at 37°C. The reaction was 
started by addition of 50|xl NADPH and terminated after 30min by addition of 1ml 
sodium bicarbonate buffer (1M, pH 10). Codeine, morphine and norcodeine were
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extracted by addition of 4ml dichloromethane containing 15%(v/v) isopropanol, mixing 
and centrifugation for 5min at 1500g to clarify the phases. An aliquot (3ml) of the 
lower organic phase was evaporated to dryness under a stream of nitrogen. The residue 
was reconstituted in lOOjil of mobile phase and 40|il was injected into a HPLC.
HPLC system:
Column: Spherisorb S50DS (25 x 0.46 cm)
Mobile phase: 80%(v/v) octanesulphonate (0.01M potassium dihydrogen
Flow rate: 1 ml min’l 
UV detection at 210nm
Using this system morphine, norcodeine and codeine, had retention times of 13,20 and 
25min, respectively. Metabolites were quantified by comparison of their peak heights to 
standard curves for morphine and norcodeine (0-100  ng/ml).
2.7. Incubation system for cytochrome P450-dependent metabolism of 
DME derivatives by microsomal fraction.
orthophosphate / lOmM octanesulphonic acid, pH 3) 
20%(v/v) acetonitrile
Reagents:
Stock concentration Component 
Tris-HCl buffer, 
pH 7.4
Magnesium chloride 
Microsomal fraction
Final concentration
200mM
50mM
Approx. 0.5mM in 
methanol
lOOmM in water
DME derivative
5mM
O.SjjM  cytochrome P450 
IjiM
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NADPH-generating system
ImM in water Manganese chloride 5jiM
5mMlOOmM in water Isocitric acid
Isocitrate dehydrogenase 1 Unit/ml
20mM in water NADPH ImM
Distilled water was added to give a final incubation volume of 6ml.
All the components of the incubation, with the exception of the substrate, were 
preincubated at 37°C for 5min. The reaction was started by addition of the substrate 
(12|il) and terminated by addition of 0.5ml volumes from the incubation to 4ml methyl- 
te/t-butyl ether (TBME) at appropriate time points between 0-10min to provide 10 
samples. After mixing the tubes were centrifuged (1500g, 10min) to clarify the phases 
and the upper organic layer was transferred to a clean glass tube. The ether-extracted 
samples were evaporated to dryness under a stream of nitrogen and the dried extracts 
were sealed with parafilm and stored at -20°C until required.
1 See section 2.12, page 47, for details of replication of experiments.
HPLC analysis:
HPLC analysis was performed using a Waters Associate Model 510 pump, a Waters 
Intelligent Sample Processor (WISP) Model 710, and a Severn Analytical SA6500 
variable wavelength detector. Chromatograms were stored on a NEC APCIV 
Powermate 2 computer and were processed using the Waters Maxima 820 
Chromatography Workstation package.
Column: Spherisorb S5CN (25 x 0.46 cm)
Mobile phase: Appropriate mixtures of acetonitrile and octanesulphonate (0.01M
potassium dihydrogen orthophosphate/5mM octanesulphonic acid, pH 3) 
Flow rate: 1 ml min"l 
UV detection at 230nm
38
The dried ether extracts were reconstituted in lOOjil of mobile phase and 80|il was 
injected onto the column, using the WISP. The ratio of acetonitrile to octanesulphonate 
in the mobile phase was optimized to give adequate separation of the substrate, 
metabolite(s) and internal standard. The disappearance of substrate was monitored and 
quantified by comparison to an internal standard.
Calculations:
The metabolic rate constant (kg) for disappearance of the substrate was calculated from a 
plot of log substrate concentration against time, using the following equation:
Slope = k g /2.303
The half-life (X\p) for disappearance of the substrate could then be calculated from kg:
ti/2 = 0.693 /  kg
The ratio of metabolites was determined by plotting a graph of the concentrations of the 
N-dealkylated (x-axis) against the N-demethylated (y-axis) metabolites. The slope of 
this plot is equal to the ratio of N-demethylation:N-dealkylation rates. This ratio was 
then used to determine the rate constants for appearance of the N-demethylated and N- 
dealkylated metabolites, kym and k<ja respectively, from the following equation:
ke = kdm + kda + kyn 
The appearance of any other metabolite(s) (kun) was taken into account when
calculating kdm and kda-
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2.8. Incubation system for cytochrome P450-dependent metabolism of 
felodipine in microsomal fraction.
The oxidation of felodipine to its corresponding pyridine derivative was measured using 
the incubation system described in section 2.7. Felodipine (IpM final concentration) 
dissolved in methanol was used as substrate and amlodipine (in methanol) as the internal 
standard. The reaction was terminated at appropriate time points between 0-10min by 
the addition of 2ml 0.2M sodium borate (pH 9). Felodipine was then extracted into 
5ml TBME, containing Inmol standard, by mixing and centrifugation (1500g, 5min). 
The upper ether layer was removed and evaporated to dryness under a stream of 
nitrogen. The residue was reconstituted in lOOjil mobile phase and 80jil was injected 
into a liquid chromatograph using the following conditions:
Column: Spherisorb S5CN (25x0.46cm)
Mobile phase: 30%(v/v) acetonitrile
70%(v/v) octanesulphonate (0.01M KH2PO4 ,5mM octanesulphonic
acid, pH 3)
Flow rate: 1ml min'l 
UV detection at 230nm
Felodipine and amlodipine had retention times of 10.5 and 15 min respectively. 
Felodipine was quantified by comparison of its peak height with that of amlodipine. 
The half-life of metabolism for felodipine was calculated as described in section 2.7.
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2.9. Identification of metabolites of the DME derivatives by atmospheric 
pressure ionization-mass spectrometry (APIMS)
The standard hepatic microsomal incubation system described in section 2.7. was 
employed using phenobarbitone-induced rat hepatic microsomal fraction, with each 
DME substrate present at a concentration of lOjiM. The incubation was allowed to 
proceed for one half-life and then terminated by addition of TBME. Extraction was 
carried out as described in section 2.7.
APIMS analysis was carried out at Pfizer Central Research (Sandwich, Kent) by Mrs. 
P. Wright and Mr. W. Herron. The dried ether extracts were reconstituted in 200JJ.1 of a 
l:l(v/v) mixture of methanol and water and lOjil was injected onto an HPLC system of 
the following specifications:
Column: 3g-C18 (3x0.46cm)
Mobile phase: Methanol and water (95:5 by volume) containing 20mM ammonium 
acetate
Flow rate: 1ml m hrl
This HPLC system was linked directly to a PE SCIEX API III Biomolecular Mass 
Analyzer via a Heated Nebulizer (500°C) LC/MS interface. Many mass spectra were 
recorded per minute and the data set were interrogated for the presence of the DME 
derivatives, by comparison with authentic standards, and their metabolite(s).
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2.10. Determination of physico-chemical constants and molecular 
mechanical properties of the DME derivatives.
The following physico-chemical constants and molecular mechanical properties for the 
DME series were determined by Dr. B.C. Jones (1989). All values are listed in the 
appendix (tables 4-7).
2.10.1. Calculation of intrinsic lipophilicity (log P) and molar 
refractivity (CMR)
The intrinsic lipophilicity (log P) of all the compounds was determined using the 
Pomona College MedChem data base. This system calculates the lipophilicity of a 
compound by addition of fragmental constants for the different chemical groups present 
in the molecule. This method was also used to calculate the molar refractivity (CMR). 
Molar refractivity is related to molecular volume so the addition of fragments of known 
refracdvities to give the molar refractivity also yields an estimate of molecular volume.
2.10.2. Determination of log D
The distribution coefficient (D) was determined as described by Stopher and McClean 
(1990).
Octanol (200ml) and 50mM potassium phosphate buffer (pH 7.4, 200ml) were mixed 
together for Hi, centrifuged and the octanol and buffer phases separated and stored at 
4eC until required.
Each of the DME derivatives (Img) was dissolved in phosphate buffer-saturated octanol 
(2ml) and the octanol-saturated phosphate buffer (2ml) added. The two phase system 
was mixed for Ih and then centrifuged to clarify the layers. The octanol phase (1ml) 
was retained, the octanol at the interface discarded and the phosphate buffer phase (1ml) 
collected. Each phase was analyzed for the compound using HPLC.
The partition coefficient was determined from the following equation using the peak area 
of the compound in each phase:
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log D = log peak area in octanol phase
peak area in buffer phase
2.10.3. Calculation of pKa values for the DME derivatives.
The high lipophilicity of the DME derivatives made it very difficult to determine their 
pKa's in aqueous solution. It was necessary to obtain a value for the pKa so that an 
appreciation of the ratio of unionized to ionized compound could be obtained.
A method for the determination of the pKa of these compounds that uses the Taft 
parameter (a*) for the substituent group's inductive effect was obtained (Perrin et al., 
1981). The pKa of a tertiary amine can be determined using the following equation:
pKa = 9.61 - 3.30x 
where, x = the sum of o* over the whole molecule.
Therefore the values of a* for all the substituents were obtained for each molecule and 
summed to give an estimate of the pKa.
2.10.4. Molecular analysis
The determination of the molecular mechanical properties of the DME derivatives was 
carried out using the COSMIC suite of programmes obtained from SmithKline Beecham 
(Welwyn, UK) which was run on a Sigmex 6130 molecular graphics workstation 
coupled to a Microvax II computer.
The structures of the compounds were optimized for both energy and geometry to 
enable certain features of the molecules to be determined. These included the length of 
the molecule measured from the chlorine atom in the four position to the last atom in the 
variable nitrogen substituent, Van der Waals molecular volume and molecular surface 
area. The atomic partial charge on the nitrogen atom and the carbon atoms attached to it 
were also obtained.
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2.11. Determination of the spectral constants for the DME derivatives.
The spectral binding constants for the DME derivatives were determined by Dr. B.C. 
Jones (1989). All values are listed in the appendix (table 8).
2.11.1. Quantification of the spin equilibrium of hepatic microsomal 
cytochrome P450.
The spin equilibrium of hepatic microsomal cytochrome P450 was determined by the 
method of Cinti et al. (1979) using temperature to perturb the position of the spin 
equilibrium.
2.11.2. Measurement of substrate-induced binding spectra.
The substrate-induced binding spectra were routinely performed by the method of 
Schenkman et al. (1967).
The hepatic microsomal fraction from rats pretreated with phenobarbitone was diluted 
with 50mM potassium phosphate buffer (pH 7.4) containing 20%(v/v) glycerol to give 
a final concentration of IpM cytochrome P450. This solution was divided between two 
1ml masked cuvettes and placed in the thermostated cuvette housing of a Uvikon 860 
spectrophotometer. After recording a baseline of equal absorbance between 500 and 
350nm, substrate dissolved in dimethylsulphoxide (DMSO) was added in pi amounts to 
the sample cuvette. To reduce any effects due to the solvent, an equal volume of DMSO 
was added to the reference cuvette. The contents of the cuvettes were mixed and the 
spectrum repetitively scanned between 500 and 350nm until there was no further 
development in the difference spectrum. This procedure was repeated until the addition 
of the substrate failed to produce any further spectral change.
The resultant peak to trough absorbance values were measured and the data analyzed by 
the Hanes-Woolf method to determine the spectral binding parameters, Ks (spectral 
binding constant) and the percentage of cytochrome P450 converted to high spin by 
addition of the substrate (%HS).
44
Using the model detailed in figure 1.2(section 1.3), Gibson and Tamburini (1984) were 
able to derive the following expression which defines Ks in terms of the micro- 
equilibrium constants Kq, Kz, Kg and
1/KS =  (K2  +  1) /  [Kg(Ki + 1)]
Since this is a thermodynamically closed model then:
K i.K g = K2 .K4
Using these equations it is possible to formulate a series of expressions for a given 
compound so that using its Ks, %HS and percentage high spin fraction present in the 
absence of substrate (Fhs) the equilibrium constants K2, Kg and K4 can be calculated.
2.12. Quantitative structure activity relationships (QSAR's).
All the biological, physico-chemical, spectral and molecular mechanical data for each of 
the compounds was stored on computer and each of the biological parameters (ke and 
ti/2) examined for relationships between it and up to two of the physico-chemical, 
spectral and molecular mechanical variables. Two basic types of relationship were 
sought:
i) linear relationships of the general form:
y = mx + c
ii) multi-linear relationships of the form:
y = ax + bz + c
where y is the biological parameter, x and z are physicochemical and/or spectral and/or 
molecular mechanical parameters.
All linear relationships found here were determined using Cricket Graph (Version 
1.3.2., Cricket Software) and Microsoft Excel (Version 3.0) on an Apple Macintosh
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Classic II computer (Apple Computer Inc., California). All multi-linear relationships 
were determined by Dr. D.F.V. Lewis on the CDC 7600 computer of the University of 
Manchester Regional Computer Centre via a remote site link from the University of 
Surrey Prime computer.
The above systems generated many correlations the majority of which were of no 
significance since the correlation coefficient was too low for the relationship between the 
variables to be meaningful. In the case of multi-linear relationships where the two 
variables were themselves highly correlated, the relationship was ignored. Also three 
statistical criteria were used to determine if the relationship generated was of value:
i) the correlation coefficient (r): in general, all relationships where the r value was 
significant at the 0 .1% level were examined,
ii) the standard deviation (s) of the y values from the regression: in general, 
relationships that had a low s value were chosen since this indicates that the y values 
calculated from the regression equation were in good agreement,
iii) the variance ratio (F): in general, relationships were chosen if they had a high F 
value.
The DME series was divided into two groups for the purpose of searching for QSAR’s. 
The first group, known as the "alkyl" group, consisted of compounds 1-7 (methyl, 
ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl and n-pentylDME). This is a closely 
related series of compounds. The second group was the full series of DME derivatives. 
The number of observation points used to derive the equation for this group was thirteen 
unless otherwise stated.
The significance of the difference between two correlation coefficients was tested as 
described by Sokal and Rohlf (1969). The r values were transformed to their 
corresponding z values by consultation with a z-transformation table. A Student's t-test
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was then applied to determine the significance of the difference in correlation 
coefficients.
Replication of experiments:
Each of the ke determinations in control arid dexamethasone-induced hepatic 
microsomal fractions were performed in duplicate. Those carried out in 
phenobarbitone-induced hepatic microsomal fractions were performed six times. 
Linear regression analysis of the resulting substrate disappearance plots (section 2.7) 
yielded the slope and the standard error of the slope. These values for replicated 
experiments were not significantly different as judged using a Student's t-test. 
Therefore, the ke values presented are representative from a single typical 
determination.
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CHAPTER 3
Development of an HPLC assay for quantification of the DME derivatives and
their metabolites
48
SUMMARY
The development of a reverse phase HPLC assay for detection of the DME derivatives 
and their metabolites at concentrations of less than IjiM is described. All of the 
compounds showed first order kinetics for disappearance of the substrate. Some of the 
series exhibited biphasic kinetics and the possibility that this is due to inhibition of 
cytochrome P450 by a metabolite is discussed.
The metabolites of the DME derivatives have been identified by atmospheric pressure 
ionization-mass spectrometry (APIMS) and this information was used to aid in the 
identification of the metabolites by HPLC.
Calculation of first order metabolic rate constants is described as well as the derivation 
of the rate constants for formation of the N-desmethyl and N-desalkyl (ie. removal of 
the R substituent) metabolites.
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INTRODUCTION
It has been shown that the DME derivatives are substrates for cytochrome P450 and 
that their major route of metabolism is probably N-demethylation (Jones, 1989). This 
previous work monitored the metabolism of these compounds, at relatively high 
substrate concentrations (10-1500|iM), by determining the rate of formation of 
formaldehyde as a measure of the rate of N-demethylation. Although this appeared to 
be a major metabolic route it is likely that these compounds undergo N-dealkyladon 
(i.e. removal of the R substituent) as well. It was important, therefore, to develop a 
sensitive assay for the detection of the DME derivatives as well as their metabolites.
This chapter describes the development of an HPLC assay for the detection of the DME 
derivatives at concentrations of less than IjxM. The method for calculation of the first 
order rate constants for metabolism of the DME derivatives in vitro is explained. In 
addition, the identification of metabolites of the DME derivatives using atmospheric 
pressure ionization-mass spectrometry (APIMS) is described. This in turn has aided in 
the identification and quantification of these metabolites by HPLC.
In order to achieve first order reaction kinetics, a substrate concentration below the 
Km values for the DME derivatives was chosen. The Km values for the compounds 
ranged from 30-300jiM (Jones, 1989). In addition, a low substrate concentration 
confines the reaction to the isoenzyme principally responsible for the metabolism of 
the DME derivatives. A concentration of IjiM should be relevant to the circulating 
concentration of substrate likely to be seen if the compound was administered in vivo.
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RESULTS AND DISCUSSION
3.1. Detection and quantification of DME derivatives by HPLC.
The in vitro metabolism of the DME derivatives was carried out using the incubation 
system described in section 2.7 at a substrate concentration of IjiM . In order to 
determine the first order rate constants for metabolism (ke), an incubation volume of 
6ml was used and 0.5ml aliquots were removed at intervals to give 10 time points. The 
time intervals used were 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0 and 10 minutes. The 
reaction was stopped by addition of the timed samples to 4ml methyl-tert-butyl ether 
(TBME) which already contained Inmol of a DME derivative as internal standard. An 
internal standard should have physical properties as close as possible to those of the test 
compound and chromatograph near to but distinct from it. The compounds of the DME 
series are closely related enough to satisfy the first criterion so an appropriate internal 
standard was chosen so that it did not co-chromatograph with the substrate, and 
preferably had a longer retention time so that it was unlikely to interfere with any 
metabolites. Introduction of the internal standard at the solvent extraction stage was 
preferable so that it would undergo the same extraction process as the substrate. Any 
loss of standard was thus identical to the loss of substrate. The high lipophilicity of the 
DME derivatives ensured that their extraction efficiency into TBME was >90%. This 
was determined using 1ml of the standard incubation system described in section 2 .7 , 
excluding the NADPH regenerating system, to which was added lOpl (approx. 5gM) 
DME derivative standard. After extraction into TBME, the samples were prepared for 
HPLC analysis (section 2.7). The dried extracts were reconstituted in mobile phase 
(lOOjil) and 50jxl was injected onto the HPLC. In addition, a standard curve was 
constructed by evaporating aliquots of standard (5-25gl) under nitrogen. The standards 
were then prepared for HPLC in the same way as the samples. The extraction 
efficiency was calculated by comparing the peak height of the DME extract with the 
standard curve. The calculation for propenylDME is shown in figure 3.1. Since all the
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î
I 100- y = 8.37(±6.33) + 14.50(±0.42)x 
r = 0.999
0 10 20 30
Standard (|il)
Extract standard) Peak height (mm) Extraction efficiency (%)
10 148 ± 4  96
Figure 3.1. Calculation of the extraction efficiency of propenylDME into methyl-tert- 
butyl ether (TBME). The mean peak height (± s.e.m.) of three samples of extracted 
DME derivative (lOjil) was compared to a standard curve (5-25|xl DME derivative) and 
an extraction efficiency of 96% calculated.
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DME derivatives had similar extraction efficiency values it was not necessary to 
perform a correction to allow for differences in their recovery.
A reverse phase HPLC system was used so that compounds eluted in order of 
decreasing polarity. This meant that any microsomal impurities in the sample eluted 
from the column first, followed by the DME derivatives in increasing order of 
lipophilicity. The mobile phase consisted of a mixture of an organic solvent 
(acetonitrile) and octane sulphonate buffer, pH 3. All of the basic DME derivatives 
were ionized at the acid pH of the buffer so an ion-pairing agent was introduced into the 
mobile phase. Ion-pairing aids in the resolution of ionized compounds. A counter ion 
of opposite charge to the test compound is used. Thus to aid the separation of basic 
compounds, which would be present as their conjugate cations, an alkylsulphonate is 
used. The mechanism by which ion-pairing results in better separation is unclear but 
two theories have been proposed. The first suggests that the ion-pair behaves as a 
single neutral species, whilst the second suggests that an active ion-exchange surface is 
produced in which the counter ion, which has considerable lipophilic properties, and 
the ions to be separated are adsorbed by the non-polar stationary phase. An isocratic 
system was found to be adequate for compound separation and generally a mixture of 
55% acetonitrile:45% octane sulphonate was used. In this mobile phase all the DME 
derivatives had retention times of less than 20min (table 3.1). Occasionally it was 
necessary to alter the mobile phase in order to separate metabolites of the DME 
derivatives, particularly if inhibitors were included in the incubation. The retention 
times of the DME derivatives in all the mobile phases employed are given in table 3.1.
The presence of a chromophore (the aromatic group) common to all the DME 
derivatives meant that their detection could be carried out using a variable wavelength 
ultraviolet-visible detector. A scan of the compounds between 200-300nm indicated 
that they had an absorption maxima at 230nm and this wavelength was used for their
u.v. detection.
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Table 3.1. Retention times of the DME derivatives.
DME derivative Retention times (min) in 
acetonitrile 
40% 45%
% (v/v) 
55%
1. Methyl 11.3 10.4 9.1
2. Ethyl 12.8 11.6 9.6
3. n-Propyl 15.1 13.2 10.6
4. iso-Propyl 14.5 12.6 10.6
5. n-Butyl 17.8 14.7 11.5
6 . tert-Butyl 17.1 14.3 11.3
7. n-Pentyl 20.6 16.6 12.1
8 . Phenyl 11.1 8.3 <8
9. Benzyl 21.1 15.9 12.3
10. Phenethyl 23.9 17.5 12.5
11. Propenyl 14.4 12.1 10.1
12. Propynyl 13.4 n.d. 9.6
13. Bis 30.7 22.8 13.7
n.d. = not determined
Bis = N,N-bis-[2-(2,4-dichlorophenoxy)ethyl]methylamine
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After separation by HPLC the substrate was quantified by comparison to the internal 
standard. The peak height ratio of substraterstandard was calculated and used to 
determine the concentration of substrate present in the sample. Having determined the 
concentration of substrate remaining at each time point the rate constant for metabolism 
(ke) was calculated.
3.1.1. Determination of ke for the DME derivatives.
A logarithmic plot of substrate concentration against time (linear scale) was constructed. 
The disappearance of substrates was first-order and was linear for at least 5min for 
most of the DME derivatives. The plot for disappearance of n-propylDME in control 
male rat microsomal fraction is given in figure 3.2a. The semilogarithmic plots for 
some of the DME derivatives became biphasic before the end of the incubation This 
was particularly noticeable for propynylDME (figure 3.2b). It has been reported (Hall 
and Hanzlik, 1991) that the formation of the N-demethylated product from a series of 
tertiary amides was biphasic with time. The authors attributed this to the inactivation of 
a minor but kinetically significant cytochrome P450 isoenzyme. This may also be true 
for the DME series since it is recognised that a number of alkylamine derivatives are 
converted by cytochrome P450 to reactive intermediates that sequester the enzyme in a 
catalytically inactive complexed state (section 1.4.2). The metabolic intermediate (MI) 
complex thus formed is detected spectrally by an absorbance maximum near 455nm. 
The ligand for MI complexes can originate from primary, secondary or tertiary aliphatic 
or aromatic amines, and in general the rate of complex formation is greater for 
secondary amines than either tertiary or primary amines (Lindeke, 1988). The nature of 
the MI complex-forming species formed from amines is unclear. It is thought that the 
MI complex does not involve a primary metabolite of the amine (Bast et al.y 1982) but 
rather metabolites formed as a consequence of further oxidative degradation (fig. 3 .3). 
A good correspondence was found between the rate of N-demethylation of the 
secondary amine tofenacine and MI complex formation (Bast et a/., 1982). The 
secondary amine could be N-demethylated via N-hydroxylation or a-carbon atom
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Figure 3.2. Log plots for the calculation of metabolic rate constants (ke) of (a) n- 
propylDME which is linear and (b) propynylDME which exhibits a biphasic nature. 
Log C is the logarithm of substrate concentration (|JM).
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Adapted from Bast and Noordhoek, 1982.
Figure 3.3. Proposed mechanism of metabolism of tertiary amines leading to the 
formation of an intermediate which sequesters cytochrome P450 irreversibly.
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al.y 1982). The secondary amine could be N-demethylated via N-hydroxylation or oc- 
carbon atom oxidation to give a secondary N-hydroxylamine or a primary amine, 
respectively (structures 3 and 4, fig. 3.3). The authors concluded that the main 
mechanism was via N-oxidation followed by rearrangement and N-demethylation to 
yield a primary N-hydroxylamine (structure 5, fig. 3.3). The N-hydroxylamine is 
unstable and may oxidize to a nitroso compound which could readily ligand to the 
reduced iron of cytochrome P450 (structure 6 , fig. 3.3). In support of this theory, 
secondary N-hydroxylamines and nitrones appear as distinct intermediates in the 
microsomal oxidation of secondary amines (Lindeke, 1982). A lag time was observed 
prior to MI complex formation with tertiary amines (Bast et a i, 1984) which the 
authors attributed to a requirement for initial N-demethylation to yield a secondary 
amine which was then metabolized to form the MI complex, as outlined above.
In the light of this evidence, the metabolite profile of propynylDME was examined 
more closely to determine if the biphasic semilogarithmic plot could be due to MI 
complex formation (fig. 3.4). It was found that the concentration of the N-desmethyl 
metabolite increased up to the 1.5min time point of the incubation, and then began to 
decline. At the same time, a peak appeared with a retention time of 7.5min and its 
height increased steadily for the continued length of the incubation. It can be speculated 
that this peak was due to the formation of a secondary metabolite (metabolite X). 
Examination of the semilogarithmic plot for propynylDME (fig. 3.2b) indicates that the 
slower phase of metabolism begins after approximately 2.5min and therefore coincides 
with a significant presence of metabolite X in the incubation (fig. 3.4). Thus the 
biphasic semilogarithmic plot can be tentatively attributed to the formation of an MI 
complex, effectively inactivating one or more cytochrome P450 isoenzymes, possibly 
by an analogue formed from further metabolism of a secondary amine derivative. 
Metabolite X appears to be formed primarily from the N-desmethyl metabolite (figure 
3.4) and this tentatively suggests that X is the primary amine or a derivative of i t
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Figure 3.4. Metabolite profile for propynylDME incubated with hepatic microsomal 
fraction from phenobarbitone-induced rat.
Key: (+) N-desalkyl metabolite, tR=9.3min;
(O) N-desmethyl metabolite, tR=10.4min;
(#) metabolite X, tR=7.5min. 
tR = retention time.
Note:
Mass balance in the incubation of propynylDME, taking 2min as a point of reference:
Compound Concentration (uM)
N-desalkyl 0.35
N-desmethyl 0.28
Metabolite X 0.06
PropynylDME
(from figure 3.2b) 0.24
Total 0.92
Thus greater than 90% of propynylDME is accounted for.
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The initial linear phase of the semilogarithmic plot was used to calculate ke. Linear 
regression analysis gave the equation of the line and the slope was used to calculate ke, 
as described in section 2.7. In addition, the regression analysis yielded the standard 
error of the slope and this was used to assess the accuracy of the calculated ke values. 
The value for ke describes the fraction of substrate that is metabolized in unit time, 
therefore a high value for ke indicates a rapid rate of metabolism. The metabolic half- 
life (ti/2) for each compound was calculated from the ke (section 2 .7).
3.2. Identification of metabolites of the DME derivatives by atmospheric 
pressure ionization-mass spectrometry (APIMS).
The standard incubation system described in section 2.7. was employed using 
phenobarbitone-induced rat microsomes and a substrate concentration of 10pM. The 
incubation was terminated after one half-life by dividing it into two 5ml aliquots and 
extracting with 20ml TBME. One aliquot was then prepared for APIMS (section 2.9) 
and the second reserved for HPLC analysis (section 3.3).
Since the DME derivatives contained two chlorine atoms, their molecular ion (M+) was 
influenced by the two naturally occurring isotopes and their relative abundances 
(35C1:37C1 75.5:24.5).
Ion Isotope combination Relative abundance
M+ 35ci + 35(21 100
M++2 35(21 + 37(21 32.5
M++2 37q  + 35(21 32.5
M++4 37(21 + 37(21 10.6
The mass spectrometer recorded many mass spectra per minute which were interrogated 
for spectra that contained the characteristic isotope pattern of two chlorine atoms
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(M+:M++2:M++4 100:65:10.6). This enabled easy identification of the parent DME
derivatives and their metabolites.
The positive ion mass spectrum of authentic ethylDME (m/z 248) is given in figure 3.5. 
The parent compound was also detected in the extract of the microsomal incubation 
with ethylDME (table 3.2). The assignment of tentative structures implies that 
ethylDME is N-demethylated (m/z 234) and N-deethylated (m/z 220). The positive ion 
spectra for these two metabolites are given in figure 3.6. No other metabolites were 
detected, even though the possible loss of the chlorine atoms was considered. 
Examination of the relative intensity of the mass spectra for the metabolites indicated 
that the desmethyl metabolite was present in greater amounts than the desethyl 
metabolite.
Incubation extracts for each of the DME derivatives were injected onto the HPLC- 
APIMS and the mass spectra were interrogated as described above for ethylDME. The 
metabolites found for each of the compounds are summarized in table 3.3. All of the 
compounds were N-demethylated to some degree. Most of the compounds were N- 
dealkylated, except iso-propylDME, tert-butylDME, propenylDME and phenylDME. 
Although phenylDME was not N-dephenylated, an additional metabolite of molecular 
ion (M+16)+ was detected.
Tert-butylDME and phenylDME do not have alpha hydrogen atoms on their R 
substituent groups and this explains why they were not N-dealkylated since electron 
abstraction from the nitrogen followed by proton transferral from the alpha hydrogen is 
thought to be the mechanism of N-dealkylation (Okazaki and Guengerich, 1993). 
PropenylDME and iso-propylDME both have alpha hydrogens so some other 
explanation is required. It is possible that this metabolic pathway does occur but at a 
slow rate so that after one half-life the desalkyl metabolite cannot be detected.
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Table 3.2. Mass spectral data for ethylDME and its metabolites.
Molecular ion Relationship of molecular ion 
to ethylDME (M+)
Tentative identification
248 0 Mass spectrum identical to that 
of authentic ethylDME
234 [M-14]+ Desmethyl DME. Difference of 
14 mass units indicative of loss 
of methyl group
220 [M-28]+ DesethylDME. Difference of 
28 mass units indicative of loss 
of ethyl group
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Table 3.3. Summary of the metabolites found for the DME derivatives by APIMS 
and HPLC.
DME derivative Metabolites identified by APIMS Metabolites identified by HPLC
Desmethyl Desalkyl Desmethyl Desalkyl
1. Methyl + _a + _a
2. Ethyl + + + +
3. n-Propyl + + + +
4. iso-Propyl + - + -
5. n-Butyl + + + +
6. tert-Butyl + - + -
7. n-Pentyl + + + +
8 . Phenyl + _b + -
9. Benzyl + + + +
10. Phenethyl + + + +
11. Propenyl + _c + +c
12. Propynyl + + + +
13. Bis + + + +
+ = metabolite observed 
- = metabolite not observed
a = for methylDME N-dealkylation is the same as N-demethylation 
b = although not N-dephenylated an additional metabolite of molecular ion (M+16)+ 
was identified
c = desalkyl metabolite not detected for propenylDME by APIMS but positively 
characterized by comparison to an authentic standard by HPLC
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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In the case of phenylDME, the formation of a metabolite with a molecular ion of m/z 
312 (M+16)+ is indicative of insertion of an oxygen atom into the parent molecule, so a 
hydroxylated product is likely. Hydroxylation of the phenyl ring is a likely possibility 
since aromatic hydroxylation is readily carried out by cytochrome P450. 
Hydroxylation of the dichlorophenoxy ring is unlikely due to the presence of the two 
chlorine atoms, and since this functional group is common to all the DME derivatives, 
hydroxylated products would have been expected for many of the compounds, not just 
phenylDME.
3.3. Quantification of metabolites of the DME derivatives by HPLC.
The second aliquot from section 3.2. was prepared for HPLC analysis as described in 
section 2.7. A mobile phase containing acetonitrile and octanesulphonate in the ratio 
55:45 gave adequate separation of the DME derivatives and their metabolites. The 
metabolites found for each compound are summarized in table 3.3.
The parent DME derivatives were identified by comparison to authentic standards. It 
was also possible to characterize positively the N-dealkylated metabolite (removal of the 
R substituent) since its structure was common for all the DME derivatives (2-(2,4- 
dichlorophenoxy)-N-methylethanamine) and a standard was available. Most of the 
compounds were N-dealkylated, except iso-propylDME and tert-butylDME. For all of 
the DME derivatives a metabolite peak was present which had a retention time 
approximately 1.5min less than the parent compound. This second peak was 
tentatively identified as the N-demethylated metabolite, since removal of the N-methyl 
group would be likely to alter the retention time for each compound in a similar way - 
hence the constancy of this second peak relative to the parent. This identification was 
supported by the APIMS data (section 3.2) which indicated that all of the compounds 
produced the N-demethylated metabolite, the only other metabolite being the N- 
dealkylated metabolite which had already been identified.
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PhenylDME had a very short retention time in 55% acetonitrile:45% octanesulphonate 
(<8min) so the mobile phase was altered to 40% acetonitrile and 60% octanesulphonate 
to increase the retention time and aid separation of the metabolites from the parent 
compound. Two metabolite peaks were identified with retention times of 8min and 
10min (parent 11.5min). The 10min peak was tentatively identified as the N- 
demethylated metabolite. The APIMS data (section 3.2) indicated that phenylDME was 
also hydroxylated and that this metabolite was more polar than the N-demethylated 
metabolite. Therefore, the 8min HPLC peak was tentatively attributed to an 
hydroxylated metabolite.
PropenylDME gave two metabolite peaks on the HPLC. The desalkyl metabolite was 
identified for this compound by comparison to an authentic standard, although this 
metabolite was not detected by APIMS. The second metabolite peak detected by the 
HPLC was tentatively identified as the desmethyl metabolite.
Having identified the metabolite peaks for all the DME derivatives and their retention 
times, it was possible to use this data to identify and quantify the N-dealkylated and N- 
demethylated metabolites in all future experiments. The ratio of metabolite formation 
(N-demethylation:N-dealkylation) was calculated as described in section 2.7. This 
information was then used to derive the first order rate constants for N-demethylation 
(kdm) and N-dealkylation (ktfa).
In addition to metabolite peaks attributable to the N-desmethyl and N-desalkyl 
derivatives, a third peak with a retention time of 7.5min appeared in control male and 
female rat microsomal incubations of all the DME derivatives, except tert-butylDME. 
This is the same peak as was identified and described as metabolite X in the incubation 
with propynylDME in phenobarbitone-induced microsomes (section 3.1.1). One way 
to produce a metabolite that is common to all the DME derivatives is by removal of both 
the N-methyl group and the R substituent (N-di-dealkylation). This could yield a
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primary amine (structure 4, fig. 3.3) by a-carbon oxidation or a secondary N- 
hydroxylamine via N-hydroxylation (structure 3, fig. 3.3). Further metabolism of 
either of these derivatives may yield a primary N-hydroxylamine (structure 5, fig. 3.3). 
Metabolite X could therefore be either a primary amine or N-hydroxylamine, but it is 
likely that it is the primary amine since the N-hydroxylamine would be very polar and 
elute from the HPLC column rapidly. N-di-dealkylation as a route to formation of 
metabolite X is further supported by its absence from the incubation with tert- 
butylDME, since removal of the tert-butyl substituent does not occur in any of the 
microsomal fractions studied (see chapter 4). Other possible common metabolites are 
the N-oxide and the aldehyde resulting from removal of the third nitrogen substituent 
(i.e. the 2,4-dichlorophenoxy moiety). However, both of these metabolites could be 
formed from tert-butylDME and the absence of metabolite X from the incubation with 
this compound indicates that it is neither of these possible metabolites.
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CHAPTER 4
Sex and species differences in the in vitro metabolism of the DME derivatives
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SUMMARY
The sex difference in the metabolism of the DME derivatives has been investigated 
using untreated rat hepatic microsomal fractions as in vitro models. In general, the 
values of kg were lower in the female than in the male rat, but trends within the series 
were very similar for both sexes. This may be due to substrate overlap between 
constitutive CYP3A and CYP2C isoenzymes. No significant correlations were found 
for ke with physico-chemical or molecular mechanical descriptors of the DME 
derivatives in the female rat. The lipophilicity (log D) of the substrate was found to 
influence the rate of metabolism of the DME derivatives in male rat hepatic microsomal 
fraction.
The species differences in the metabolism of the DME series has been investigated 
using female Beagle dog hepatic microsomal fraction. The ke values obtained in dog 
were generally lower than those in the male rat. No significant dependence on any of 
the physico-chemical or molecular mechanical parameters tested was found for 
metabolism of the DME derivatives by dog hepatic microsomal fraction.
N-demethylation was the preferred route of metabolism for most of the substrates in all 
of the microsomal fractions studied.
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INTRODUCTION
A series of N-substituted dichlorophenoxy-N-methylethanamines (DME derivatives) 
were synthesized to determine the effect of changing the nitrogen substituent on the in 
vitro metabolism of these compounds. It has been demonstrated (Jones, 1989) that the 
metabolism of these compounds is catalyzed by the cytochrome P450-dependent 
monooxygenase system. Sex-related differences in cytochrome P450-mediated 
xenobiotic metabolism have been reported for several species, with the most striking 
differences observed in rats (Kato, 1974). Although a 10-30% lower level of total liver 
microsomal cytochrome P450 in female in comparison with the male rat is consistent 
with the slower metabolism of many compounds by the female, it is now accepted that 
the sex-related differences observed are attributable to the presence of different male 
and female cytochromes P450 (Waxman, 1984; Waxman et al.> 1985). In addition, 
considerable inter-species variation is seen in the metabolism of xenobiotics. It is 
known that homologous forms of cytochrome P450 exist among species but their 
substrate specificities are not necessarily the same since a single amino acid substitution 
can dramatically alter the catalytic properties of these enzymes (Johnson, 1992). 
Constitutive levels of cytochromes P450 also vary between species and this may 
contribute to the inter-species variation in drug metabolism. For example, levels of 
constitutive cytochrome P450 isoenzymes found in the Beagle dog are present at 
different basal levels to the homologous forms in rat (Duignan et al., 1988).
Since the rat and the Beagle dog are routinely used in toxicity studies and safety 
evaluation, it was of interest to determine whether species differences existed in the in 
vitro metabolism of the DME derivatives and if they could be related to their 
cytochrome P450 isoenzymes. Sex-related differences in metabolism were also 
investigated in rat for similar reasons.
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RESULTS
4.1. Characterization of microsomal fractions.
Sprague-Dawley 1
The microsomal fractions from control male and femalejrat and control female dog were 
characterized for various enzyme activities using the methods outlined in section 2.6 
(table 4.1). Male rat had the highest level of total cytochrome P450 on a nmol/mg 
protein basis, whereas female rat and control dog were equivalent. Benzphetamine N- 
demethylase activity is a general measure of cytochrome P450 activity, although 
benzphetamine has been shown to be preferentially metabolized by CYP2B1 in rat 
(Levin, 1990). The male rat had the highest level of benzphetamine N-demethylase 
activity of the microsomal fractions studied. Ethoxyresorufin O-deethylase (EROD) 
activity is specific to CYP1A1 in rat (Burke and Mayer, 1974). The activity of this 
P450 isoenzyme was similar in male and female rat but was much higher in dog. 
Pentoxyresorufin O-depentylase (PROD) activity is specific to CYP2B1 in rat (Lubet et 
a i, 1985). This P450 isoenzyme was not present in any appreciable quantity in the 
microsomal fractions studied. Codeine is a substrate for two P450 isoenzyme 
subfamilies. Codeine O-demethylation is carried out by the CYP2D subfamily, 
whereas its N-demethylation is supported by the CYP3A subfamily (Ladona et 
al.,1991). Codeine O-demethylation was not carried out to any appreciable extent in 
any of the microsomal fractions studied, although the rat fractions had several-fold 
higher activity than dog. Codeine N-demethylation activity was highest in the male rat. 
The 12-hydroxylation of lauric acid is specific to the CYP4A subfamily
(Gibson et al., 1982). This activity was detected in male rat and dog but not in the 
female rat
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Table 4.1. Characterization of microsomal fractions.
Enzyme marker Male rat Female rat Beagle dog 
(female)
Cytochrome P450a 1.14 0.70 0.70
Benzphetamine N-demethylase^ 14.2 3.9 4.2
Ethoxyresorufin O-deethylase^ 0.015 0.013 0.070
Pentoxyresorufin O-depentylase^ • 0.003 0.003 0.009
Codeine O-demethylaseb 0.083 0.050 0.001
Codeine N-demethylase^ 0.841 0.041 0.098
Lauric acid hydroxylase^ 0.78 0 .00 0.50
Results are mean of at least 3 determinations, s.e.m. values did not exceed 10% of the 
mean value, 
a = nmol/mg protein 
b = nmol/min/mg protein
Both male and female rats were of the Sprague-Dawley strain.
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4.2. Determination of metabolic rate constants for the DME derivatives 
in vitro.
The metabolic rate constants (ke) for the DME derivatives were determined in vitro 
using male and female rat and female dog hepatic microsomal fractions, as described in 
section 2.7. An initial substrate concentration of 1(J.M was employed and HPLC 
separation carried out as described in section 3.1.
The value of ke for methylDME has been halved. This is because the variable R
*
substituent for this compound is the same as the constant N-methyl group. The bond 
between the second methylene group and the nitrogen atom is not rigid so free rotation 
about this bond should enable removal of either N-methyl group with equal ease. All 
the other DME derivatives have different, bulkier R substituents which may hinder 
rotation of the nitrogen atom or favour a particular orientation within the active site and 
cause preferential removal of one of the N-alkyl groups. It has been assumed, 
therefore, that methylDME has more likelihood of being metabolized and its ke value 
has been halved to account for this.
* ie. MethylDME is symmetrical, whereas all the other DME derivatives are 
asymmetrical
4.2.1. Male rat hepatic microsomal fraction.
The values for ke and half-life (tj/2) in male rat hepatic microsomal fraction are given in 
table 4.2. All of the DME derivatives were metabolized efficiently with half-life values 
ranging from 0.15 min.nmol P450"1 (bisDME) to 3.5 min.nmol P450-1 (tert- 
butylDME). The values of ke for the n-alkyl series decreased from C^-Cg, but this 
trend was reversed for C4 and C5. Increasing the number of branches in the alkyl chain 
from none (methylDME) to three (tert-butylDME) had the effect of decreasing values of 
ke. Increasing the degree of unsaturation in the alkyl group from fully saturated (n- 
propylDME) to fully unsaturated (propynylDME) led to a marked increase in kg. The 
inclusion of an aromatic system in the substituent group caused a large increase in ke, 
relative to methylDME. Within the aromatic series, ke values decreased as the aromatic
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Table 4.2. Metabolic rate constants and half-life values for the DME derivatives in
male rat microsomal fraction.
Substituent ke Half-life
1. Methyl 0.68 ± 0.030 1.02 ± 0.05
2. Ethyl 0.54 ± 0.009 1.28 ± 0.02
3. n-Propyl 0.42 ± 0.004 1.65 ± 0.02
4. iso-Propyl 0.23 ± 0.003 3.01 ± 0.04
5. n-Butyl 0.66 ± 0.014 1.05 ± 0.03
6 . tert-Butyl 0.20 ± 0.003 3.47 ± 0.05
7. n-Pentyl 0.77 ± 0.014 0.90 ± 0.02
8. Phenyl 3.94 ± 0.299 0.18 ± 0.02
9. Benzyl 3.54 ±0.111 0.20  ± 0.01
10. Phenethyl 1.29 ± 0.037 0.54 ± 0.02
11. Propenyl 1.18 ±0.037 0.59 ± 0.02
12. Propynyl 2.81 ±0.166 0.25 ± 0.02
13. Bis 4.51 ± 0.267 0.15 ±0.01
ke = nmol P450.min-1. Values were derived from the slope of the semilogarithmic plot 
of substrate concentration against time. Linear regression analysis yielded the standard 
error of the slope from which the standard error for ke was derived.
Half-life = min.nmol P450'1. Values were derived from ke.
Note: After calculation of ti/2, values of ke were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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group became further from the nitrogen atom. This trend was reversed, however, for 
bisDME.
4.2.2. Female rat hepatic microsomal fraction.
The values for ke and tj/2 determined in female rat microsomal fraction are given in 
table 4.3. All of the DME derivatives were rapidly metabolized with tj/2 values ranging 
from 0.43 min.nmol P450-1 (benzylDME) to 6.93 min.nmol P450"l (iso-propylDME). 
The trends in ke seen for the female rat were very similar to those seen for the male. 
The values for ke decreased from Cj-Cg in the n-alkyl chain series. This trend was 
reversed for C4 and C5. The value for ke decreased as the number of branches in the 
alkyl group increased from zero (methylDME) to three (tert-butylDME). The 
introduction of an aromatic ring into the substituent group (phenylDME) led to an 
increase in ke relative to methylDME. The insertion of one methylene group between 
the nitrogen and the aromatic ring (benzylDME) further increased the ke value. 
However, ke decreased as the aromatic system became further away from the nitrogen 
atom (bisDME).
4.2.3. Female dog hepatic microsomal fraction.
The rate constants for metabolism in dog microsomal fraction are given in table 4.4. 
Half-life values for the DME derivatives ranged from 0.09 min.nmol P450-1 
(phenylDME) to 5.33 min.nmol P450-1 (iso-propylDME). No real change in ke was 
seen with increasing chain length from C1-C4 , although pentylDME was the most 
rapidly metabolized of the n-alkyl series. Increasing the number of branches in the 
alkyl chain from zero (methylDME) to two (iso-propylDME) or three (tert-butylDME) 
led to a decrease in metabolic rate constant. The inclusion of an aromatic group in the 
substituent (phenylDME) caused a 17-fold increase in kg relative to methylDME. As 
the aromatic group became further from the nitrogen, by insertion of methylene groups, 
ke decreased.
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Table 4.3. Metabolic rate constants and half-life values for the DME derivatives in
female rat microsomal fraction.
Substituent ke Half-life
1. Methyl 0.41 ± 0.016 1.69 ± 0.07
2. Ethyl 0.39 ± 0.009 1.78 ± 0.04
3. n-Propyl 0.33 ± 0.005 2.10 ±0.03
4. iso-Propyl 0.10  + 0.002 6.93 ±0.14
5. n-Butyl 0.66 ± 0.023 1.05 ± 0.04
6 . tert-Butyl 0.11 + 0.003 6.30 ±0.18
7. n-Pentyl 0.70 ±0.014 0.99 ± 0.02
8. Phenyl 0.73 ± 0.037 0.95 ± 0.05
9. Benzyl 1.60 ±0.018 0.43 ± 0.01
10. Phenethyl 1.31 ±0.064 0.53 ± 0.03
11. Propenyl 0.71 ± 0.018 0.98 ± 0.03
12. Propynyl 0.54 ± 0.009 1.28 ± 0.03
13. Bis 0.29 ± 0.046 2.39 ± 0.40
ke = nmol P450.min-1. Values were derived from the slope of the semilogarithmic plot 
of substrate concentration against time. Linear regression analysis yielded the standard 
error of the slope from which the standard error for ke was derived.
Half-life = min.nmol P450-1. Values were derived from ke.
Note: After calculation of ti/2, values of ke were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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Table 4.4. Metabolic rate constants and half-life values for the DME derivatives in
female dog microsomal fraction.
Substituent ke Half-life
1. Methyl 0.45 ± 0.016 1.54 ±0.05
2. Ethyl 0.47 ± 0.009 1.47 ± 0.03
3. n-Propyl 0.43 ± 0.014 1.61 ± 0.05
4. iso-Propyl 0.13 ±0.005 5.33 ± 0.20
5. n-Butyl 0.50 ± 0.018 1.39 ± 0.05
6 . tert-Butyl 0.17 ± 0.005 4.08 ±0.12
7. n-Pentyl 0.64 ± 0.018 1.08 ± 0.02
8 . Phenyl 7.79 ± 1.327 0.09 ± 0.02
9. Benzyl 2.51 ±0.147 0.28 ± 0.02
10. Phenethyl 1.12 ±0.046 0.62 ± 0.03
11. Propenyl 1.49 ± 0.092 0.47 ± 0.03
12. Propynyl 0.84 ±0.037 0.83 ± 0.04
13. Bis 0.37 ± 0.018 1.87 ± 0.09
ke = nmol P450.min"1. Values were derived from the slope of the semilogarithmic plot 
of substrate concentration against time. Linear regression analysis yielded the standard 
error of the slope from which the standard error for ke was derived.
Half-life = min.nmol P450'1. Values were derived from ke.
Note: After calculation of ti/2, values of ke were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
78
4.3. Quantification of metabolites of the DME derivatives formed in  
vitro.
Metabolites of the DME derivatives formed in the incubation systems described in 
section 4.2. were identified and quantified (section 3.2).
4.3.1. Male rat hepatic microsomal fraction.
The rate constants for formation of metabolites of the DME derivatives in male rat 
hepatic microsomal fraction are given in table 4.5. In general only two metabolites 
were formed from each DME derivative, these were the N-demethylated and N- 
dealkylated (removal of substituent group) metabolites. Since the N-substituents on 
methylDME are identical, it has been assumed that either methyl group could be 
removed with equal ease (see section 4.2). Hence, the ratio of N-demethylation:N- 
dealkylation is assumed to be 1.0. Exceptionally, both ethylDME and propenylDME 
gave a third metabolite. This metabolite was quantified and taken into account when 
calculating kdm and kda for these compounds. One compound (tert-butylDME) 
underwent N-demethylation exclusively.
Generally, the ratio of N-demethylation:N-dealkylation increased with increasing alkyl 
chain length. Introducing branching into the alkyl substituent caused an increase in the 
ratio. At three branches (tert-butylDME) only N-demethylation occurred. Increasing 
the degree of unsaturation in the alkyl substituent caused a decrease in the metabolite 
ratio. No particular trends were seen on inclusion of an aromatic system.
The rate of N-dealkylation (kda) decreased from C1-C5 in the alkyl series. This was 
mirrored by an increase in the rate of N-demethylation (kdm)- N-dealkylation rate 
decreased as the number of branches in the alkyl chain increased from none 
(methylDME) to two (iso-propylDME) and, as already noted, tert-butylDME was not 
N-dealkylated. The rates of both N-demethylation and N-dealkylation increased with
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Table 4.5. Rate constants for formation of metabolites in male rat hepatic microsomal
fraction.
No. Substituent Ratio
(kdm*kda)
kdm kda kun
1 Methyl 1.00 0.34 ±0.015 0.34 ± 0.015 0
2 Ethyl 0.59 ± 0.03 0.17 ± 0.009 0.29 ± 0.006 0.09 ± 0.009
3 n-Propyl 1.62 ± 0.04 0.26 ± 0.005 0.16 ± 0.004 0
5 n-Butyl 3.47 ± 0.14 0.52 ±0.015 0.15 ±0.008 0
7 n-Pentyl 6.60 ± 0.30 0.66  ± 0.016 0.10  ±0.006 0
1 Methyl 1.00 0.34 ±0.015 0.34 ± 0.015 0
2 Ethyl 0.59 ± 0.03 0.17 ±0.009 0.29 ± 0.006 0.09 ± 0.009
4 iso-Propyl 4.75 ± 0.52 0.19 ± 0.005 0.04 ± 0.004 0
6 tert-Butyl * 0.20 ± 0.003 0 0
3 n-Propyl 1.62 ± 0.04 0.26 ± 0.005 0.16 ± 0.004 0
11 Propenyl 1.27 ± 0.23 0.52 ± 0.060 0.41 ± 0.045 0.25 ± 0.044
12 Propynyl 0.97 ± 0.08 1.38 ± 0.139 1.43 ±0.143 0
8 Phenyl n.d. n.d. n.d. n.d.
9 Benzyl 2.69 ± 0.24 2.58 ± 0.143 0.96 ± 0.092 0
10 Phenethyl 4.16 ±0.13 1.04 ±0.036 0.25 ± 0.014 0
13 Bis 0.57 ± 0.03 1.64 ±0.152 2.87 ± 0.226 0
ke = kdm + kda + kun Equation 4.1.
kdm = rate constant for N-demethylation.
kda = rate constant for N-dealkylation.
kun = rate constant for formation of unidentified metabolite.
All rate constants are in units of nmol P450.min-1 and were calculated using equation
4.1.
* = compound only N-demethylated.
n.d. = not determined, due to short retention time.
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increasing unsaturation of the alkyl substituent. Inclusion of an aromatic group 
increased kdm and kda relative to methylDME. Generally, increasing the number of 
methylene groups between the nitrogen and the aromatic ring caused a decrease in kdm 
and kda- BisDME was an exception, having the highest kda value of the whole series.
4.3.2. Female rat hepatic microsomal fraction.
The rate constants for formation of metabolites in female rat hepatic microsomal fraction 
are given in table 4.6. EthylDME, n-propylDME, tert-butylDME and propenylDME 
gave unknown metabolites in addition to the expected N-demethylated and N- 
dealkylated metabolites. The formation of these unidentified metabolites was taken into 
account when calculating kdm and kda for these compounds. Tert-butylDME did not 
undergo N-dealkylation, although it was metabolized to an unidentified metabolite.
The ratio of N-demethylation:N-dealkylation increased with increasing alkyl chain 
length from C2-C5. This was due to an increase in kdm with concomitant attenuation 
of N-dealkylation rate. The metabolite ratio decreased as the degree of unsaturation in 
the alkyl substituent increased. This change was due mainly to an increase in kda- The 
inclusion of an aromatic system in the substituent group caused the compound to be 
preferentially N-demethylated.
4.3.3. Female dog hepatic microsomal fraction.
The rate constants for N-demethylation and N-dealkylation are given in table 4.7. 
EthylDME, n-propylDME, iso-propylDME, tert-butylDME, propenylDME and 
bisDME gave unidentified metabolites which were taken into account when calculating 
kdm and kda-
N-demethylation was the predominant route of metabolism for all the compounds 
studied, except bisDME and propynylDME. The ratio of N-demethylation:N- 
dealkylation increased with increasing alkyl chain length of the substituent group from
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Table 4.6. Rate constants for formation of metabolites in female rat hepatic
microsomal fraction.
No. Substituent Ratio
(kdm-kda)
kdm kda kun
1 Methyl 1.00 0.21 ± 0.008 0.21 ± 0.008 0
2 Ethyl 0.50 ± 0.03 0.11 ±0.003 0.22 ± 0.009 0.06 ± 0.005
3 n-Propyl 0.86 ± 0.04 0.12 ± 0.005 0.14 ±0.003 0.07 ± 0.005
5 n-Butyl 3.13 ±0.14 0.50 ± 0.024 0.16 ± 0.011 0
7 n-Pentyl 7.63 ± 0.96 0.61 ± 0.021 0.08 ± 0.010 0
1 Methyl 1.00 0.21 ± 0.008 0.21 ± 0.008 0
2 Ethyl 0.50 ± 0.03 0.11 ±0.003 0.22 ± 0.009 0.06 ± 0.005
4 iso-Propyl 2.33 ± 0.09 0.07 ± 0.002 0.03 ± 0.001 0
6 tert-Butyl * 0.07 ± 0.003 0 0.04 ± 0.002
3 n-Propyl 0.86 ± 0.04 0.12 ± 0.005 0.14 ±0.003 0.07 ± 0.005
11 Propenyl 0.62 ± 0.02 0.21 ± 0.007 0.34 ± 0.010 0.16 ± 0.010
12 Propynyl 0.22  ± 0.01 0.10 ± 0.005 0.45 ± 0.009 0
8 Phenyl n.d. n.d. n.d. n.d.
9 Benzyl 4.71 ±0.18 1.32 ± 0.024 0.28 ± 0.012 0
10 Phenethyl 12.10 ± 1.33 1.21 ± 0.069 0.10 ±0.015 0
13 Bis 2.22 ± 0.17 0.20 ± 0.036 0.09 ± 0.018 0
ke = kdm + kda + kun Equation 4.1.
kdm = rate constant for N-demethylation.
kda = rate constant for N-dealkylation.
kUn = rate constant for formation of unidentified metabolite.
All rate constants are in units of nmol P450.min'1 and were calculated using equation
4.1.
* = compound only N-demethylated.
n.d. = not determined, due to short retention time.
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Table 4.7. Rate constants for formation of metabolites in female dog hepatic
microsomal fraction.
No. Substituent Ratio
(kdm-kda)
kdm kda kun
1 Methyl 1.00 0.23 ± 0.008 0.23 ± 0.008 0
2 Ethyl 4.25 ± 1.08 0.14 ± 0.010 0.03 ± 0.015 0.30 ± 0.027
3 n-Propyl 5.73 ± 0.45 0.27 ± 0.013 0.05 ± 0.006 0.12 ±0.013
5 n-Butyl 15.17 ±0.46 0.47 ± 0.017 0.03 ± 0.001 0
7 n-Pentyl 6.94 ± 0.57 0.56 ± 0.020 0.08 ± 0.008 0
1 Methyl 1.00 0.23 ± 0.008 0.23 ± 0.008 0
2 Ethyl 4.25 ± 1.08 0.14 ±0.010 0.03 ± 0.015 0.30 ± 0.027
4 iso-Propyl 10.34 ±2.15 0.10 ± 0.005 0.01 ± 0.001 0.03 ± 0.002
6 tert-Butyl * 0.13 ± 0.005 0 0.05 ± 0.002
3 n-Propyl 5.73 ± 0.45 0.27 ± 0.013 0.05 ± 0.006 0.12 ±0.013
11 Propenyl 3.65 ± 0.15 0.66 ±0.171 0.18 ± 0.027 0.65 ±0.171
12 Propynyl 0.45 ± 0.08 0.26 ± 0.044 0.58 ± 0.057 0
8 Phenyl n.d. n.d. n.d. n.d.
9 Benzyl 44.0 ± 2.89 2.46 ±0.115 0.06 ± 0.007 0
10 Phenethyl 3.05 ± 0.25 0.84 ± 0.052 0.28 ± 0.026 0
13 Bis 0.61 ± 0.07 0.12  ± 0.011 0.19 ± 0.020 0.07 ± 0.007
ke = kdm + kda + kUn Equation 4.1.
kdm -  rate constant for N-demethylation.
kda = rate constant for N-dealkylation.
kun = rate constant for formation of unidentified metabolite.
All rate constants are in units of nmol P450.min-1 and were calculated using equation
4.1.
* = compound only N-demethylated. 
n.d. = not determined
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C 1-C4 . This trend was reversed for pentylDME. As branching in the substituent 
increased from none (methylDME) to two (iso-propylDME) the metabolite ratio 
increased. The compound containing three branches (tert-butylDME) was not N- 
dealkylated. Increasing the degree of unsaturation in the substituent group caused an 
increase in kda* N-dealkylation became the predominant pathway when the compound 
was fully unsaturated (propynylDME). Introduction of a benzyl substituent caused the 
compound to be preferentially N-demethylated. When the aromatic ring was further 
from the nitrogen (phenethylDME and bisDME) the metabolite ratio decreased until N- 
dealkylation was the predominant pathway for bisDME.
4.4. Structure-activity relationships derived for the DME derivatives in 
hepatic microsomal fractions.
Quantitative structure-activity relationships (QSAR's) were sought for the biological 
data (ke and ti/2 values) obtained for the DME derivatives in hepatic microsomal 
fractions from male and female rat and female dog. The biological data was compared 
with various hydrophobic and steric descriptors of the DME derivatives, as described in 
section 2 .12.
No significant dependence on any of the physico-chemical or molecular mechanical 
parameters tested (section 2.10) was found for the metabolism of the DME derivatives 
in male rat microsomal fraction. A trend of increasing metabolic rate constant, ke, (i.e. 
faster metabolism) with increasing log D (distribution coefficient) was observed but this 
was only significant at the 5% level.
ke = 1.44 (±0.48) logD - 2.74 (±1.48) 
s = 1.19 r2 = 0.451 F = 9.02
In other words, only 45% of the change in ke could be accounted for by an increase in
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log D.
Linear analysis failed to find any correlations between any of the physico-chemical 
properties of the DME derivatives and ke or ti/2 in female rat or female dog hepatic 
microsomal fractions.
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DISCUSSION
Hepatic microsomal fractions were taken from untreated male and female rat as well as 
female dog in an attempt to determine any sex or species differences that may exist in 
the in vitro metabolism of the series of tertiary amines. It was hoped that this in turn 
would highlight differences in the substrate specificities of constitutive cytochrome 
P450s.
Initially all the microsomal fractions were characterized using marker substrates for 
specific isoenzymes of the cytochrome P450 superfamily. Several studies have 
highlighted the sex differences in constitutive cytochromes P450 (table 4.8). 
CYP2C11, CYP2C6 and CYP3A2 isoenzymes account for 75-80% of total constitutive 
cytochrome P450 in untreated male rat on a nmol/mg protein basis (Adesnik,1985). 
CYP2C11 has been identified as a male-specific P450 (Waxman, 1984) and CYP3A2 
is expressed at much higher levels in male rat than in the female (Waxman et al.,
1985). Other constitutively expressed cytochromes P450 in the male rat include
; and Atchison
CYP2A1, CYP2B1, CYP2B2 and CYP1A2 (Adesnik|l985) but at low levels.
CYP2C6 and CYP2C12 are the major P450 isoenzymes in untreated female rat liver 
(Imaoka et al., 1987). CYP2C12 has been identified as a female-specific isoenzyme 
(Waxman, 1984). Other constitutively expressed isoenzymes are the same as in the 
male rat. In summary, the main difference between untreated male and female rats is 
the presence of sex-specific isoenzymes of the CYP2C subfamily and the absence of 
constitutive CYP3A2 in the female rat (table 4.8).
Very little information has been compiled on the relative levels of constitutive 
cytochromes P450 in dog (table 4.8), even though this species is widely used for 
metabolic studies by the pharmaceutical industry. Isoenzymes of the CYP3 A (Ciaccio 
etal., 1989; Ciaccio etal., 1991), CYP2C (Komori é ta l, 1989b; Uchida et al., 1990)
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Table 4.8. Cytochrome P450 isoenzymes found constitutively in untreated male and 
female rat and male dog livers.
P450 isoenzyme3 Male rat Female rat Male dogb
CYP3A2 ++ trace +++
CYP2C11 +++ trace +c
CYP2C12 trace ++ +c
CYP2C6 ++++ ++++ +c
CYP2A1 + ++ -
CYP2B1 + + +++
CYP1A1 trace trace d
CYP1A2 + + d
+, ++, etc. represents the relative levels of the constitutive isoenzymes 
trace - <0.03 nmol P450 isoenzyme/mg protein, as determined by immunoquantitation 
a nomenclature for cytochrome P450 isoenzymes in rat (Nelson et a/.,1993) 
b homologous cytochrome P450 isoenzymes identified in dog
c isoenzyme of the CYP2C subfamily has been isolated from male dog and constitutes 
0.6% of total immunologically determined cytochrome P450 (Komori et a/.,1989b)
d isoenzymes of these subfamilies not isolated from untreated dog to date 
Adapted from Waxman et ûZ.,1985; Duignan et oZ.,1988; Ciaccio et al., 1989.
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and CYP2B (Duignan e tal.y 1988; Graves etal., 1990) subfamilies have been isolated 
from untreated dog hepatic microsomal fractions. These isoenzymes are now identified 
according to the most recent nomenclature (Nelson et al., 1993) as CYP3A12, 
CYP2C21 and CYP2B11, respectively. CYP1A has also been identified in 
polychlorinated biphenyl (PCB)-induced dog microsomes (Uchida et al., 1990). It has 
been reported that CYP3A12 and CYP2B11 (PBD-1 and PBD-2, respectively 
according to the authors' nomenclature) make up the bulk of spectrally determined basal 
levels of cytochrome P450 in dog liver (Ciaccio et al., 1989). Levels of 
immunodetectable CYP3A were greater or equal to that in rat and basal levels of 
CYP2B were 10-fold higher in dog than in rat (Duignan et al., 1988).
Most of the isoenzymes mentioned above can be characterized by specific marker 
substrates in the rat. The CYP3A subfamily in rat is responsible for more than 85% of 
microsomal steroid 66-hydroxylase activity (Waxman et al., 1985) and CYP2C11 is the 
major steroid 16a-hydroxylase (Waxman, 1984). These distinct catalytic specificities 
for male rat isoenzymes partly explain the differences in rat hepatic xenobiotic 
metabolism. For example, the plasma clearance of nivaldipine, a dihydropyridine 
calcium channel blocker and a substrate for CYP3A, is ten-fold higher in the male rat 
than in the female (Tokuma et al., 1988). However, substrate overlap is also a 
characteristic of the rat CYP3A and CYP2C subfamilies (Smith, 1991). N- 
demethylation of ethylmorphine has been shown to be catalyzed by isolated CYP2C but 
antibody inhibition experiments indicate that CYP3A is the major contributor in rat 
hepatic microsomal fraction.
A lower level of total spectrally determined cytochrome P450 is a characteristic of 
female compared with male rat (Waxman et al., 1985). The marker enzyme activities 
measured in this study indicate the similar basal levels of CYP1A1 (EROD activity), 
CYP2B1 (PROD activity) and CYP2D (codeine O-demethylation) in male and female 
rat The marked difference in constitutive CYP3A between the sexes is highlighted by
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a 20-fold higher activity of codeine N-demethylase in male rat compared with female
a c t iv i ty
rat. Isoenzymesj^of the CYP4A subfamily have been measured at low levels in 
untreated rat (Orton et al, 1984). No CYP4A activity was detected in the female rat in 
this study. Sex differences in the responsiveness of the CYP4A subfamily to inducers, 
such as clofibrate, have been observed and a male-specific member of this subfamily, 
CYP4A2 has recently been identified; (Sundseth and Waxman, 1992)
It may be misleading to attribute the same specificity for these substrates to dog 
cytochromes P450 since a single amino acid substitution can markedly change the 
substrate specificity of an isoenzyme (Johnson, 1992). Although enzymes of the same 
P450 subfamilies as rat have been isolated from dog some differences in their substrate 
specificities have been noted. The CYP2B11 (PBD-1) isoenzyme isolated from dog 
readily metabolized polychlorinated biphenyls (PCBs), such as 2,2I,4,4',5,5'- 
hexachlorobiphenyl, whereas CYP2B1 from rat did not (Duignan et a l, 1988). The 
isoenzymes from the two species also differed in their regioselective metabolism of 
progesterone. In this study benzphetamine N-demethylase activity was relatively low 
in dog. Benzphetamine was shown to be metabolized by CYP2C and CYP1A 
isoenzymes in dog (Komori et al, 1989b). The level of EROD activity was markedly 
higher in dog than in rat. This supports the observations of McKillop et a l  (1985) who 
reported a 5-fold higher EROD activity in dog compared with rat. Whether this reflects 
a higher constitutive level of CYP1A in dog is unclear since it is not known if 
ethoxyresorufin is a specific marker for this isoenzyme in dog. For the same reason 
little can be concluded from the higher level of PROD activity in dog, although 
constitutive levels of CYP2B are believed to be greater in dog than in rat (Duignan et 
a l, 1988). Although CYP2D has not been isolated from dog as yet, the presence of a 
similar enzyme to rat has been inferred from metabolism data on known substrates of 
this isoenzyme subfamily (Smith, 1991). Consequently the very low level of codeine 
O-demethylation in this study is perhaps to be expected. Codeine was N-demethylated 
at a slower rate in dog than in rat and this supports previous work where clearance
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values of CYP3A substrates were consistently lower in dog than in rat (Smith, 1991). 
The presence of the CYP4A subfamily has not been reported in dog although the level 
of lauric acid hydroxylase activity is considered to be a specific marker for CYP4A 
activity and has been applied to various species, such as rat, hamster, dog and 
marmoset (Orton et al., 1984). A level of lauric acid hydroxylase activity similar to 
male rat seen in this study may reflect the presence of CYP4A at a constitutive level in 
dog or could be due to CYP2B-supported (co-l)-hydroxylation (Tamburini et a l, 
1984).
All of the DME derivatives were metabolized efficiently by the hepatic microsomal 
fractions studied. It is interesting to note the similarities seen between the in vitro 
metabolism models. In all three models the compounds containing branched alkyl 
substituents (iso-propylDME and tert-butylDME) had the lowest metabolic rate 
constants. Devinsky et al. (1987) noted that in a series of N,N-dimethylalkylamines 
branching in the substituent group led to a lower rate of N-oxidation than they would 
have predicted from the compound's log P value. They concluded that branching in the 
molecule had a crowding effect around the lone pair of electrons of the nitrogen which 
become less available for attack by enzyme(s). The inclusion of an aromatic system in 
the substituent group of the DME derivatives led to an increase in ke (relative to 
methylDME) in all the microsomal fractions studied. Similarly, increasing the degree 
of unsaturation from fully saturated (n-propylDME) to fully unsaturated 
(propynylDME) caused an increase in ke. Thus for a high value of ke a degree of 
unsaturation in the substituent group (aromatic, alkenyl, alkynyl) was required.
In general, metabolic rate constants for the DME derivatives were lower in the female 
rat than the male (table 4.9). A lower rate of metabolism in female rat has been reported 
previously for a series of 7-hydroxycoumarin O-alkyl derivatives (Kamataki et a l, 
1980) and although the level of total cytochrome P450 in female is generally lower than 
in male, the difference can mainly be attributed to the presence of sex-specific P450s
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Table 4.9. Comparison of rate constants for metabolism in male 
and female rat and dog microsomal fractions
Substituent
Rat
ke-male/ke-female ke-male rat/k^-dog
1. Methyl 1.65 1.49
2. Ethyl 1.39 1.17
3. n-Propyl 1.26 0.97
4. iso-Propyl 2.33 1.69
5. n-Butyl 1.01 1.33
6 . tert-Butyl 1.87 1.16
7. n-Pentyl 1.09 1.20
8 . Phenyl 5.41 0.51
9. Benzyl 2.21 1.41
10. Phenethyl 0.99 1.16
11. Propenyl 1.67 0.79
12. Propynyl 5.17 3.35
13. Bis 15.8 12.30
ke = nmol P450.min-1
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethylmethylamine
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(Waxman et al., 1985). In this study, the difference in P450 level has been accounted 
for by expressing the results (kg) per nmol P450, therefore any difference between the 
sexes is probably attributable to differences in constitutive P450 isoenzymes. The 
change in ke value with increasing alkyl chain length of the substituent group (C1-C5) 
was the same for male and female rat with the difference between the two sexes 
becoming progressively less as chain length increased (table 4.9). This similarity is 
illustrated in figure 4.1 where the rates of N-demethylation and N-dealkylation are 
compared between the sexes for C1-C5 . The rate of N-dealkylation decreased with 
increasing chain length in both sexes, with the male rat showing an excellent linear 
dependence of rate on chain length (r=0.962).
kda = 0.39 (±0.03) - 0.061 (±0.01) chain length 
s = 0.03 r = 0.962 F = 36.8
These similarities between the sexes highlight the substrate overlap that is thought to 
exist between the isoenzymes of the CYP3A and CYP2C subfamilies in rat. The 
greatest difference between the two sexes was seen in the metabolism of bisDME, with 
male rat having a 16-fold higher ke than female. It has been suggested that the 
CYP3A/2C substrate overlap is true for compounds that have a calculated molar 
refractivity (CMR) less than 9 (Smith, 1991). CMR may be viewed as similar to molar 
volume and some very bulky (i.e. large CMR) compounds are substrates for CYP3A. 
Cyclosporine, for example, is a substrate for CYP3A and has a CMR of 32.5 
(Kronbach et al., 1988). All of the DME derivatives, except for bisDME, have a CMR 
less than 9 (see appendix, table 5) and may be expected to be substrates for CYP3A or 
CYP2C. The metabolism of bisDME because of its size may be directed towards 
CYP3A and its low kç value in female rat could reflect the absence of this subfamily at 
a constitutive level.
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Figure 4.1. Change in rate constants for (a) N-demethylation and (b) N-dealkylation 
with alkyl chain length of the substituent group in male and female rat
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The ke values obtained in dog were generally lower than those in male rat (table 4.9). 
There is little evidence for a dependence of ke on chain length for the alkyl substituents. 
The slight increase in ke for C4 and C5 was attributable to an increase in N- 
demethylation rate, since the rate of N-dealkylation varied very little from C1-C5. The 
N-demethylation profile for C1-C5 was remarkably similar for all three in vitro 
metabolism models studied (figure 4.2) so the differences seen between rat and dog in 
ke for these compounds was attributable to a variation in N-dealkylation rate. For dog, 
N-dealkylation was a minor route for all of the DME derivatives, except propynylDME 
and bisDME. This species difference indicates that the enzyme(s) responsible for the 
metabolism of these compounds in dog is more restrictive than in rat, preferentially 
removing the smaller methyl group than the bulkier alkyl substituents.
It was not possible to identify the third metabolite which was formed from some of the 
DME derivatives since they were not present in the phenobarbitone-induced rat hepatic 
microsomal fraction used for atmospheric pressure ionization-mass spectrometry 
(section 3.2). The unknown metabolite of ethylDME was identical in all the 
microsomal fractions studied. It was less polar than the N-demethylated metabolite. 
The same was true for the unidentified metabolite of propenylDME. In contrast the 
third metabolites formed from propylDME and tert-butylDME in female rat and dog 
microsomal fractions were different. Although these metabolites remain unidentified 
their formation was taken into account when calculating k^m and kda-
No significant correlations were found between ke and any physico-chemical properties 
of the DME derivatives for female rat or dog microsomal fractions. A trend was seen in 
male rat for an increase in metabolic rate constant with increasing log D. Log D 
describes the partitioning of a compound between octanol and buffer at pH 7.4 and 
therefore is a measure of the lipophilicity of the compound. A dependence of rate of 
metabolism on lipophilicity is well documented (Gaudette and Brodie, 1959; 
McMahon, 1961;Devinsky et a i, 1987) and it is now attributed to the fact that the
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Figure 4.2. Change in rate constants for N-demethylation with alkyl chain length of 
the substituent group in male and female rat and dog microsomal fractions.
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mixed function oxygenase system exists in a lipoidal barrier through which only 
lipophilic compounds can penetrate. The correlation with log D can only be interpreted 
in these general terms since no one particular P450 isoenzyme is predominant at a 
constitutive level. The "mixture" of isoenzymes in untreated animals could account for 
the lack of correlation with physico-chemical parameters since any metabolism seen is 
almost certainly due to a combination of isoenzymes.
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CHAPTER 5
Metabolism of the series of DME derivatives using phenobarbitone- and 
dexamethasone-induced hepatic microsomal fractions as in vitro models.
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SUMMARY
The first order rate constants (ke) for metabolism of the DME derivatives have been 
determined using phenobarbitone- and dexamethasone-induced rat hepatic microsomal 
fractions. Probe substrates were used to confirm that phenobarbitone and 
dexamethasone administration had caused induction of CYP2B1 and CYP3A, 
respectively.
The values of ke were higher in the phenobarbitone-induced model than those 
determined in the dexamethasone-induced rat hepatic microsomal fraction. Despite this 
the trends within the series were very similar for both induced models indicating that 
the DME derivatives are substrates for both CYP2B and CYP3A subfamilies. In both 
induced models the DME derivatives containing an aromatic system were the most 
rapidly metabolized. The hydrophobicity of the substrate, as measured by log D, was 
an important determinant of the rate of metabolism of the substrates in both induced 
hepatic microsomal fractions. In addition, the metabolic half-life of the DME 
derivatives correlated with the strength of binding of the substrate to the enzyme (Ks, 
K3 and K4) in the phenobarbitone-induced rat hepatic microsomal fraction. In the 
dexamethasone-induced in vitro model a significant dependence on the size of the 
molecule (CMR, length, area) was found for increasing rate of metabolism of the DME 
derivatives.
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INTRODUCTION
The administration of certain chemicals in vivo can substantially alter the metabolism of 
a wide range of lipophilic compounds. Enzyme induction due to drugs and other 
xenobiotic chemicals was initially discovered by virtue of the profound effects that 
induction can have on pharmacological responses (Conney, 1967). Not all cytochrome 
P450 subfamilies are inducible, but for those that are induction seems to be greatest in 
the liver. In rat, mouse or rabbit, pretreatment with phenobarbitone causes a significant 
increase in total hepatic cytochrome P450 concentration, proliferation of smooth 
endoplasmic reticulum and an increase in liver weight (Remmer and Merker, 1963).
Two cytochrome P450 inducers were chosen to provide different models for the in 
vitro metabolism of the series of DME derivatives. Phenobarbitone was chosen 
because the previous work done on these compounds was carried out using 
phenobarbitone-induced rat hepatic microsomal fraction since it was determined that the 
DME derivatives were metabolized most efficiently by this in vitro model (Jones, 
1989). The major P450 isoenzymes induced by phenobarbitone are CYP2B1 and 
CYP2B2 (Ryan et al., 1979). Dexamethasone, an inducer of CYP3A, was also chosen 
since this subfamily is considered the most important for metabolism of drugs in man 
(Smith, 1991). In the induced hepatic microsomal fraction a particular cytochrome 
P450 subfamily should predominate and therefore any quantitative structure-activity 
relationships (QSAR's) seen can be attributed primarily to this subfamily.
This chapter describes the metabolism of the DME derivatives using phenobarbitone- 
and dexamethasone-induced in vitro metabolism models. Quantitative structure-activity 
relationships have been searched for in an attempt to relate rate of metabolism to 
changes in physico-chemical and molecular mechanical properties through the DME 
series. This analysis gives an insight into the substrate structure-activity relationships 
for CYP2B and CYP3A.
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RESULTS
5.1. Characterization of microsomal fractions.
1 Wistar
Microsomal fractions from màldrats induced with phenobarbitone or dexamethasone-
Sprague-Dawley
induced femalejjats (section 2 .2) were characterized for various enzyme activities, 
using methods outlined in section 2.6. Enzyme activities are summarized in table 5.1.
Levels of benzphetamine N-demethylase, codeine O-demethylase and codeine N- 
demethylase activity were similar in both the microsomal fractions studied. 
Ethoxyresorufin O-deethylase (EROD) activity was 6 -fold higher in the 
phenobarbitone-induced microsomal fraction compared with the dexamethasone- 
induced. Similarly, pentoxyresorufin O-depentylase (PROD) was substantially higher 
(100-fold) in the phenobarbitone-induced microsomal fraction. In contrast, the level of 
lauric acid hydroxylase activity was 2-fold higher in the dexamethasone-induced 
microsomal fraction.
5.2. Determination of metabolic rate constants for the DME derivatives 
in vitro.
The metabolic rate constants (ke) for the DME derivatives were determined in vitro 
using microsomal fractions from rats induced with either phenobarbitone or 
dexamethasone, as described in section 2.7. An initial substrate concentration of IpM 
was employed. The ke value for methylDME has been halved (see section 4.2).
5.2.1. Phenobarbitone-induced male ra t hepatic microsomal fraction.
The values for ke and half-life (ti/2) in phenobarbitone-induced male rat hepatic 
microsomal fraction are given in table 5.2. All of the DME derivatives were
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Table 5.1. Characterization of hepatic microsomal fractions from induced rats.
Enzyme marker Phenobarbitone- 
induced male
Dexamethasone- 
induced female
Cytochrome P450a 1.29 2.03
Benzphetamine N-demethylase^ 21.11 20.39
Ethoxyresorufin O-deethylase^ 0.107 0.019
Pentoxyresorufin O-depentylase^ 0.549 0.006
Codeine O-demethylase^ 0.028 0.038
Codeine N-demethylase^ 0.208 0.189
Lauric acid hydroxylase^ 0.576 1.08
Results are mean of at least 3 determinations, s.e.m. values did not exceed 10% of the 
mean value, 
a = nmol/mg protein 
b = nmol/min/mg protein
Dexamethasone-induced female rats were of the Sprague-Dawley strain and 
phenobarbitone-induced male rats were of the Wistar strain.
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Table 5.2. Metabolic rate constants and half-life values for the DME derivatives in
phenobarbitone-induced male rat hepatic microsomal fraction.
Substituent ke Half-life
1. Methyl 0.12 ±0.005 5.68 ± 0.23
2. Ethyl 0.25 ± 0.009 2.83 ±0.11
3. n-Propyl 0.68 ± 0.013 1.02 ± 0.02
4. iso-Propyl 0.27 ± 0.008 2.59 ± 0.08
5. n-Butyl 1.26 ± 0.025 0.55 ± 0.01
6 . tert-Butyl 0.29 ± 0.005 2.37 ± 0.04
7. n-Pentyl 1.21 ± 0.063 0.58 ± 0.03
8 . Phenyl 13.4 ±0.190 0.05 ± 0.01
9. Benzyl 3.77 ± 0.035 0.18 ± 0.01
10. Phenethyl 1.70 ± 0.086 0.41 ± 0.02
11. Propenyl 1.80 ± 0.046 0.39 ±0.01
12. Propynyl 2.69 ± 0.051 0.26 ± 0.01
13. Bis 3.28 ±0.102 0.21 ± 0.02
ke = nmol P450.min_l. Values were derived from the slope of the semilogarithmic plot 
of substrate concentration against time. Linear regression analysis yielded the standard 
error of the slope from which the standard error for ke was derived.
Half-life = min.nmol P450"1. Values were derived from ke.
Note: after calculation of ti/2, values of ke were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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metabolized efficiently with half-life values ranging from 0.05min.nmol P450"1 
(phenylDME) to 5.68min.nmol P450-1 (methylDME).
The values of ke for the n-alkyl series increased from C1-C4, but this, trend was 
reversed for pentylDME (C5). Increasing the number of branches in the alkyl chain 
from zero (methylDME) to three (tert-butylDME) had the effect of increasing values of 
ke- Increasing the degree of unsaturation in the alkyl substituent from fully saturated 
(n-propylDME) to fully unsaturated (propynylDME) caused a 4-fold increase in ke. 
The inclusion of an aromatic system in the substituent group led to a dramatic increase 
in ke value relative to methylDME. The insertion of successive methylene units 
between the nitrogen and the aromatic ring (benzylDME, phenethylDME) caused a 
reduction in ke compared with phenylDME.
5.2.2. Dexamethasone-induced female rat hepatic microsomal fraction.
The values for ke and ti/2 determined in dexamethasone-induced female rat hepatic 
microsomal fraction are given in table 5.3. All of the DME derivatives were rapidly 
metabolized with half-life values ranging from 0.23min.nmol P450'1 (phenylDME and 
benzylDME) to 7.37min.nmol P450"1 (methylDME). The values for ke increased with 
increasing chain length from Ci to C5 in the n-alkyl series. Increasing the degree of 
unsaturation in the substituent group from fully saturated (n-propylDME) to fully 
unsaturated (propynylDME) had the effect of increasing ke- The value for ke increased 
slightly when the number of branches in the alkyl group increased from zero 
(methylDME) to three (tert-butylDME). The introduction of an aromatic ring into the 
substituent group (phenylDME) caused a 32-fold increase in ke relative to methylDME. 
As the aromatic group became further away from the nitrogen atom (phenethylDME and 
bisDME), ke decreased compared with phenylDME.
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Table 5.3. Metabolic rate constants and half-life values for the DME derivatives in
dexamethasone-induced female rat hepatic microsomal fraction.
Substituent ke Half-life
1. Methyl 0.09 ± 0.004 7.37 ± 0.30
2. Ethyl 0.18 ±0.004 3.89 ± 0.09
3. n-Propyl 0.50 ± 0.010 1.39 ± 0.03
4. iso-Propyl 0.12 ±0.004 5.78 ±0.19
5. n-Butyl 0.78 ±0.014 0.89 ± 0.02
6 . tert-Butyl 0.16 ± 0.003 4.23 ± 0.08
7. n-Pentyl 1.09 ± 0.012 0.64 ± 0.01
8. Phenyl 2.98 ±0.162 0.23 ± 0.02
9. Benzyl 2.98 ± 0.088 0.23 ± 0.01
10. Phenethyl 1.79 ± 0.028 0.39 ± 0.01
11. Propenyl 0.68 ± 0.014 1.02 ± 0.02
12. Propynyl 1.45 ±0.115 0.48 ± 0.04
13. Bis 1.61 ± 0.120 0.43 ± 0.03
ke = nmol P450.min‘1. Values were derived from the slope of the semilogarithmic plot 
of substrate concentration against time. Linear regression analysis yielded the standard 
error of the slope from which the standard error for ke was derived.
Half-life = min.nmol P450-1. Values were derived from ke.
Note: after calculation of ti/2, values of ke were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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5.3. Quantification of metabolites of the DME derivatives formed in 
vitro.
Metabolites of the DME derivatives formed in the incubation systems described in 
section 5.2 were identified and quantified (section 2.7).
5.3.1. Phenobarbitone-induced male rat hepatic microsomal fraction.
The rate constants for formation of metabolites of the DME derivatives formed in 
phenobarbitone-induced male rat hepatic microsomal fraction are summarized in table
5.4. A maximum of two metabolites were detected for each of the compounds. These 
were the N-desmethyl and N-desalkyl derivatives. Two compounds (iso-propylDME 
and tert-butylDME) underwent N-demethylation exclusively. In general, N- 
demethylation was the major route of metabolism for the series, except for 
propynylDME, benzylDME and bisDME. It was not possible to quantify metabolites 
for phenylDME because this compound was metabolized very rapidly (ti/2 = 
0.05min.nmol P450-1) and consequently any primary metabolites formed were 
presumably converted very quickly to secondary metabolites (see section 3.3).
The ratio of N-demethylation:N-dealkylation increased as the chain length of the n-alkyl 
substituent increased from C1-C4 . This was mirrored by an increase in the rate 
constant for N-demethylation (kdm) for these compounds. The metabolite ratio for 
pentylDME decreased compared with n-butylDME due to attenuation of N- 
demethylation, since kda increased steadily from C1-C5. The introduction of two (iso- 
propylDME) or three (tert-butylDME) branches into the substituent group prevented N- 
dealkyladon. In contrast, kdm increased as the number of branches increased. N- 
demethylation was the major route of metabolism when the alkyl substituent was fully 
saturated (n-propylDME) but N-dealkylation prevailed when the substituent was fully 
unsaturated (propynylDME). The rate constant for N-dealkylation increased as the 
degree of unsaturation increased. The inclusion of an aromatic system in the
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Table 5.4. Rate constants for formation of metabolites in phenobarbitone-induced
male rat hepatic microsomal fraction.
No. Substituent Ratio
(kdm’kda)
kdm kda
1 Methyl 1.00 0.061 ± 0.003 0.061 ± 0.003
2 Ethyl 1.61 ± 0.09 0.151 ±0.009 0.094 ± 0.007
3 n-Propyl 2.60 ±0.19 0.492 ± 0.020 0.189 ±0.014
5 n-Butyl 2.71 ±0.12 0.920 ± 0.029 0.339 ± 0.017
7 n-Pentyl 1.43 ± 0.09 0.709 ± 0.055 0.496 ± 0.043
1 Methyl 1.00 0.061 ± 0.003 0.061 ± 0.003
2 Ethyl 1.61 ± 0.09 0.151 ±0.009 0.094 ± 0.007
4 iso-Propyl * 0.268 ± 0.008 0
6 tert-Butyl * 0.292 ± 0.005 0
3 n-Propyl 2.60 ± 0.19 0.492 ± 0.020 0.189 ±0.014
11 Propenyl 2.18 ±0.13 1.233 ± 0.055 0.566 ± 0.037
12 Propynyl 0.55 ± 0.04 0.955 ± 0.063 1.737 ± 0.076
8 Phenyl n.d. n.d. n.d.
9 Benzyl 0.59 ± 0.04 1.398 ± 0.071 2.369 ± 0.071
10 Phenethyl 3.43 ± 0.15 1.315 ± 0.079 0.384 ± 0.032
13 Bis 0.19 ±0.02 0.524 ± 0.062 2.756 ±0.130
ke = kdm + kda Equation 5.1.
kdm = rate constant for N-demethylation. 
kda = rate constant for N-dealkylation.
Both rate constants are in units of nmol P450.min-1 and were calculated using equation
5.1.
* = compound only N-demethylated. 
n.d. = not determined
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substituent group (benzylDME) caused a marked increase in kdm and k<ja, relative to 
methylDME. BenzylDME had the highest kdm value of the whole series. The rate 
constant for N-demethylation decreased as the aromatic group became further away 
from the nitrogen atom (phenethylDME and bisDME). By contrast, bisDME had the 
highest rate constant for N-dealkylation of the whole series.
5.3.2. Dexamethasone-induced female rat hepatic microsomal fraction.
The rate constants for formation of metabolites of the DME derivatives in 
dexamethasone-induced female rat hepatic microsomal fraction are given in table 5.5. 
In general only two metabolites were formed from each compound and these were the 
N-desmethyl and N-desalkyl derivatives. Two metabolites were detected for 
phenylDME. These were tentatively identified as the N-desmethyl derivative and a 
hydroxylated metabolite, as explained in section 3.3. The ratio of these two metabolites 
(N-demethylated:hydroxylated = 0.95 ± 0.09) was used to calculate a value for kdm 
(section 2.7). Two of the DME derivatives (iso-propylDME and tert-butylDME) 
underwent N-demethylation exclusively.
The ratio of N-demethylation:N-dealkylation increased with increasing chain length of 
the n-alkyl substituent group from C1-C4. This trend was reversed for C5. The values 
of kdm and kda both increased with increasing alkyl chain length from C1-C5. The 
introduction of two (iso-propylDME) or three (tert-butylDME) branches into the alkyl 
substituent group prevented N-dealkylation. The rate of N-demethylation increased as 
the branching of the alkyl substituent increased. Increasing the degree of unsaturation 
from fully saturated (n-propylDME) to fully unsaturated (propynylDME) caused N- 
dealkylation to become the predominant route of metabolism. The kda value for 
propynylDME was 5-fold that of n-propylDME. The values of kdm also increased 
with increasing degree of unsaturation but this change was not as marked as for N- 
dealkylation. The introduction of an aromatic system into the substituent group 
(phenylDME) prevented N-dephenylation, and a hydroxylated product unique to this
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Table 5.5. Rate constants for formation of metabolites in dexamethasone-induced
female rat hepatic microsomal fraction.
No. Substituent Ratio
(kdm-kda)
kdm kda
1 Methyl 1.00 0.047 ± 0.002 0.047 ± 0.002
2 Ethyl 0.83 ± 0.02 0.081 ± 0.003 0.097 ± 0.003
3 n-Propyl 1.23 ± 0.07 0.276 ± 0.012 0.224 ±0.011
5 n-Butyl 2.33 + 0.12 0.548 ± 0.018 0.235 ± 0.012
7 n-Pentyl 1.92 ±0.10 0.713 ± 0.020 0.372 ± 0.017
1 Methyl 1.00 0.047 ± 0.002 0.047 ± 0.002
2 Ethyl 0.83 ± 0.02 0.081 ±0.003 0.097 ± 0.003
4 iso-Propyl * 0.120 ± 0.004 0
6 tert-Butyl * 0.164 ± 0.003 0
3 n-Propyl 1.23 ± 0.07 0.276 ± 0.012 0.224 ±0.011
11 Propenyl 0.90 ± 0.02 0.323 ± 0.010 0.359 ±0.011
12 Propynyl 0.28 ± 0.02 0.317 ± 0.042 1.130 ±0.110
8 Phenyla * 1.452 ± 0.089 0
9 Benzyl 0.78 ± 0.05 1.306 ± 0.085 1.674 ± 0.094
10 Phenethyl 1.17 ±0.11 0.966 ± 0.057 0.826 ± 0.052
13 Bis 0.56 ± 0.03 0.579 ± 0.062 1.033 ± 0.095
ke = kdm + kda Equation 5.1.
kdm = rate constant for N-demethylation. 
kda = rate constant for N-dealkylation.
Both rate constants are in units of nmol P450.min-1 and were calculated using equation
5.1.
* = compound only N-demethylated.
a = hydroxylated metabolite tentatively identified for phenylDME (rate constant for 
formation = 1.528 ± 0.112)
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compound was tentatively identified. The introduction of a methylene group between 
the aromatic ring and the nitrogen atom (benzylDME) allowed N-dealkylation to 
proceed, and this pathway predominated over N-demethylation for this compound. As 
the aromatic group became progressively futher away from the nitrogen atom through 
the series phenylDME, benzylDME, phenethylDME, bisDME the value for kdm 
decreased.
5.4. Structure-activity relationships derived for the DME derivatives 
incubated with phenobarbitone-induced hepatic microsomal fraction.
Quantitative structure-activity relationships (QSAR's) were sought for the biological 
data obtained for the DME derivatives incubated in hepatic microsomal fractions from 
phenobarbitone-induced rats. The biological data was correlated with various 
hydrophobic, spectral and steric descriptors of the DME derivatives, as described in 
section 2.12. Even though ke and ti/2 are related in a reciprocal manner (section 2.7) 
correlations were searched for with both of these parameters. The correlation 
coefficients obtained for ke and ti/% with any particular descriptor of the DME 
derivatives, were compared using a Student's t-test (section 2.12) and were not 
significantly different. Therefore, it has been concluded that when a slightly better 
correlation is seen with ti/2 than ke (or vice versa) it is due to chance. In all cases the 
correlation with the higher r value is presented.
5.4.1. Relationships obtained for ke and ti/2 .
Initially, simple linear relationships for ke and ti/2 with various physico-chemical, 
molecular mechanical and spectral parameters of the DME derivatives were searched 
for. All the regression equations are summarized in table 5.6.
Several relationships were seen for the "alkyl" series of compounds (n=7, section 
2.12.) but since the same relationships were more significant (pcO.OOl) for the full
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Table 5.6. Regression equations for ti/2 of DME derivatives in phenobarbitone-
induced rat hepatic microsomal fraction.
ti/2 = -0.28 (±0.24) + 0.07(10.008) K3
n = 13; s = 0.59; r = 0.939; F = 82.6; pcO.OOl (1)
ti/2 = 0.23 (±0.21) + 0.10 (±0.01) K4 
n = 13; s = 0.62; r = 0.932; F = 72.0; p<0.001
ti/2 = -0.62 (±0.43) + 0.06 (±0.01) Ks 
n = 13; s = 0.88; r = 0.858; F = 30.7; pcO.OOl
ti/2 = 7.29 (±1.10) - 1.96 (±0.35) log D 
n = 13; s = 0.88; r = 0.858; F = 30.7; pcO.OOl
ti/2 = 8.19 (±1.64) - 0.03 (±0.007) volume 
n = 13; s = 1.05; r = 0.790; F = 18.2; pcO.005
ti/2 = 8.24 (±1.79) - 1.42 (±0.37) log P 
n = 11; s = 1.12 ; r = 0.788; F = 18.5; pcO.005
ti/2 = 101 (±27.8) qN - 2.42 (±0.27) log D + 25.5 (±5.08) 
n = 13; s = 0.61; r = 0.941; F = 38.9; pcO.OOl (7)
ti/2 = half-life of metabolism (min.nmol P450-1)
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations are listed in order of decreasing r value.
n=l 1, full series omitting propenylDME and propynylDME.
n=13, full series.
(2)
(3)
(4)
(5)
(6)
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series, only these regression equations are reported in table 5.6. For the full series, 
only relationships with a correlation coefficient greater than 0.79 (p<0.005) were 
examined.
A relationship was searched for that linked the rate of metabolism of the DME 
derivatives to their lipophilicity. Initially it appeared that there was no correlation 
between ti/2 and log P (r = 0.486) but an examination of the plot (fig. 5.1a) indicated 
that propenylDME and propynylDME (compounds 11 and 12, respectively) were 
outliers from the regression line. When these two compounds were omitted from the 
correlation, the relationship was significantly improved (equation 6 , table 5.6). The 
relationship shows a negative dependence of ti/2 on log P. Therefore, for a short half- 
life of metabolism the DME derivatives should have a high value of log P.
A relationship was found that related the half-life values for the DME derivatives with 
log D (equation 4, table 5.6). This equation shows that the half-life of metabolism 
increased with decreasing lipophilicity of the substrate, as measured by the partition 
coefficient log D. Linear correlations also existed between ti/2 and the spectral binding 
parameters Ks, Kg and K4. These constants describe the binding to cytochrome P450, 
as defined in section 1.3. The relationship between ti/2 and Ks (equation 3, table 5.6) 
is such that as Ks increases (i.e. the substrate is bound less tightly to the enzyme) the 
half-life of metabolism is increased. Similar relationships were seen for ti/2 with Kg 
and K4 (equations 1 & 2, table 5.6). These two relationships indicate that as the 
strength of binding of the substrate to low- or high-spin cytochrome P450 (Kg and K4, 
respectively) became weaker, the metabolic half-life became longer.
In addition, a relationship was found between ti/2 and the molecular volume of the 
DME derivatives (equation 5, table 5.6). The equation indicates a negative dependence 
of half-life of metabolism on molecular volume. This means that ti/2 becomes shorter 
as the molecular volume increases.
I l l
(a)
6-1
y = 8.24 - 1.42x 
r = 0.786
3 4 62 5 7
Log P
(b)
y = 12.23 - 2.09x 
r = 0.779
2 -
3 4 5 62 7
LogP
Figure 5.1. Regression plots of log P with metabolic half-life of the DME 
derivatives in (a) phenobarbitone- and (b) dexamethasone-induced hepatic microsomal 
fractions.
Half-life is in units of min.nmol P450'1.
r = correlation coefficient of linear regression, ignoring propenylDME and 
propynylDME (compounds 11&12, respectively).
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Multilinear analysis yielded one equation that improved on the linear relationship 
between ti/2 and log D (equation 7, table 5.6). It involved the atomic partial charge on 
the nitrogen atom (q^) and indicated that as the charge on the nitrogen atom became 
more negative the half-life of metabolism became shorter.
5.4.2. Relationships obtained for rate of individual metabolic routes.
Simple linear correlations were searched for that might relate the rate constants for 
metabolite formation (kdm and kda) to any physico-chemical, molecular mechanical or 
spectral parameters. Since better correlations had been found with the metabolic half- 
life (section 5.4.1) of the DME derivatives, the half-life values attributable to N- 
demethylation and N-dealkylation (HLdm and HLda» respectively) were calculated 
using the equation in section 2.7. The half-life values for metabolite formation are 
given in the appendix (table 1).
Several relationships were seen for both the rate constant and half-life of formation of 
the N-desmethyl metabolite (table 5.7). A correlation was seen between kdm and log D 
(equation 1, table 5.7) for the "alkyl" series. The equation indicates that the rate of N- 
demethylation increased with increasing lipophilicity of the substrate, as measured by 
log D. A similar relationship was seen for the kdm values of the whole series and log 
D (r = 0.78). The half-life for formation of the N-desmethyl metabolite was found to 
correlate with the spectral binding parameters Ks, Kg and K4 (equations 2-4, table 
5.7). The relationship with K§ indicates that as the substrate was bound less tightly to 
the enzyme (i.e. Ks increased) the half-life for formation of the N-desmethyl derivative 
became longer. Similarly, the relationships of HLdm with Kg and K4 indicate the 
importance of tightness of binding of the substrate to the low- and high-spin forms of 
cytochrome P450, respectively. An attempt to correlate HLdm with log P gave a poor 
correlation coefficient (r = 0.387), but an examination of the regression line indicated 
that propenylDME and propynylDME were outliers. Omitting these two compounds 
from the equation gave a correlation coefficient of 0.636. This correlation was not
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Table 5.7. Regression equations for N-demethylation of the DME derivatives in
phenobarbitone-induced rat hepatic microsomal fraction.
kdm = -0.83 (±0.11) + 0.47 (±0.04) log D 
n = 7; s = 0.06; r = 0.982; F = 137; p<0.001 (1)
HLdm = -0.082 (±0.76) + 0.19 (±0.03) K4 
n = 7; s = 1.37; r = 0.942; F = 39.5; p<0.005 (2)
HLdm = -2.21 (±1.41) + 0.16 (±0.04) K3 
n = 7; s = 1.80; r = 0.898; F = 20.9; p<0.010 (3)
HLdm = -9.83 (±3.04) + 0.24 (±0.05) Ks 
n = 7; s = 1.82; r = 0.895; F = 20.1; p<0.010 (4)
kdm = rate constant for fomation of the N-desmethyl metabolite (nmol P450.min"1). 
HLdm = half-life for formation of N-desmethyl metabolite (min.nmol P450'1). 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations are listed in order of decreasing r value. 
n=7, "alkyl" series (section 2.12).
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significant at the 0 .5% level, but was interesting since the same outliers had been noted 
on the regression plot of log P with ti/2 (section 5.4.1).
Several relationships were seen for the kda values of the "alkyl" group with steric 
descriptors of the DME derivatives (equations 1-3, table 5.8). These equations indicate 
that the rate of formation of the N-desalkyl metabolite increased with increasing molar 
refractivity (CMR), length and surface area of the substrate. Molar refractivity is 
related to the volume of a molecule so an increase in the size of the substrate caused an 
increase in kda- No relationships were found involving the kda values for the full 
series of DME derivatives. In contrast, several relationships were seen for HLda 
values of the full series (table 5.8). Equation 6 indicates a negative dependence of 
HLda on the log D value of the substrate. This means that as the lipophilicity of the 
substrate increased, the half-life for formation of the N-desalkyl derivative shortened. 
Relationships were seen between HLda and the spectral binding parameters Ks, K3 and 
K4 for the full series of DME derivatives (equations 4,5 & 7 table 5.8). The equations 
indicate that for a low value of HLda the substrate should be tightly bound to the 
enzyme (i.e. low values of Kg.Kg and K4). As was seen with HLdm and ti/2 for the 
total metabolism, a correlation of kda with log P indicated that propenylDME and 
propynylDME were outliers. A correlation coefficient of 0.458 was obtained when the 
full series of DME derivatives was included in the regression equation with log P. 
Omitting propenylDME and propynylDME gave a regression equation with a 
correlation coefficient of 0.837.
5.5 Structure-activity relationships derived for the DME derivatives 
incubated with dexamethasone-induced hepatic microsomal fraction.
Relationships were searched for between the biological data and various physico­
chemical and molecular mechanical descriptors of the DME derivatives. Relationships 
with the spectral binding constants were not looked for since these parameters were
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Table 5.8. Regression equations for N-dealkylation of the DME derivatives in
phenobarbitone-induced rat hepatic microsomal fraction.
kda = -1.25 (±0.14) + 0.001 (±0.0001) area 
n = 5; s = 0.03; r = 0.988; F = 122; p<0.005 (1)
kda = -1.44 (±0.23) + 0.24 (±0.03) CMR 
n = 5; s = 0.05; r = 0.974; F = 54.2; p<0.005 (2)
kda = -1.18 (±0 .21) + 0.12  (±0 .02 ) length 
n = 5; s = 0.05; r = 0.968; F = 44.3; p<0.010 (3)
HLda = 0.51 (±0.26) + 0.20 (±0 .01) K4 
n = 10; s = 0.67; r = 0.985; F = 260; pcO.001 (4)
HLda = -0.43 (±0.31) + 0.16 (±0 .01) K3 
n = 10; s = 0.69; r = 0.984; F = 239; pcO.001 (5)
HLda = 20.1 (±2 .11) -  5.39 (±0.83) log D 
n = 10; s = 1.54; r = 0.917; F =42.1; p<0.001 (6)
HLda = -1.33 (±0.89) + 0.13(±0.02) Ks 
n = 10; s = 1.66; r = 0.903; F =35.3; p<0.001 (7)
kda = rate constant for fomation of the N-desalkyl metabolite (nmol P450.mnr1).
HLda = half-life for formation of N-desalkyl metabolite (min.nmol P450"1). 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations are listed in order of decreasing r value. 
n=5, n-alkyl series.
n=10, full series excluding iso-propylDME, tert-butylDME and phenylDME for which 
there are no values of kda (section 5.3.1).
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determined in phenobarbitone-induced rat microsomal fraction (Jones,1989).
5.5.1. Relationships obtained for ke and ti/2 .
For the "alkyl" series, relationships were examined where the correlation coefficient 
was greater than 0.9 (p<0.005). A relationship was seen between the metabolic rate 
constants for the "alkyl" series and the length of the molecule (equation 1, table 5.9). 
The equation indicates that the metabolic rate constant increased as the length of the 
molecule increased. In addition, a correlation was found that related increasing ke to an 
increase in lipophilicity, as measured by log D (equation 2, table 5.9). The correlation 
with log D (r=0.938) was more significant than that with log P (r=0.887), which is 
another measure of lipophilicity. A similar correlation between ke and log D was found 
when the full series of DME derivatives was examined (equation 3, table 5.9).
For the full series of DME derivatives, a relationship was looked for between ti/2 and 
log P. Initially there appeared to be no correlation (r=0.491). However, examination 
of the regression line indicated that propenylDME and propynylDME were outliers 
(figure 5.1b). This was interesting since the same compounds were outliers on the log 
P regression plot for ti/2 in phenobarbitone-induced rat microsomal fraction (section 
5.4). Omitting propenylDME and propynylDME from the regression equation gave a 
correlation coefficient of 0.779 for ti/2 in dexamethasone-induced rat microsomal 
fraction.
Multilinear analysis yielded one equation that related the rate constants for metabolism 
to molar refractivity (CMR) and the Taft inductive parameter (a*) (equation 4, table 
5.9). This equation was considered significant because no simple correlation was seen 
with either parameter (CMR , r=0.639; a*, r=0.646). The equation indicates that k© 
increased with increasing CMR, (which correlates with molecular volume with a value 
of r=0.90), and increasing inductive effect of the substituent group.
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Table 5.9. Regression equations for ke of DME derivatives in dexamethasone-
induced rat hepatic microsomal fraction.
ke = -2.98 (±0.33) + 0.28 (±0.03) length
n = 7; s = 0.09; r = 0.977; F = 106; p<0.001 (1)
ke = -1.07 (±0.25) + 0.57(±0.09) log D
n = 7; s = 0.15; r = 0.938; F = 36.6; p<0.005 (2)
ke = -2.34 (±0.77) + 1.14 (±0.25) log D
n = 13; s = 0.62; r = 0.809; F = 20.8; p<0.001 (3)
ke = 0.40 (±0.02) CMR + 1.12 (±0.05) a* - 2.08 (±1.50) 
n = 13; s = 0.71; r = 0.767; F = 7.15; p<0.005 (4)
ke = metabolic rate constant (min.nmol P450"1)
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value. 
n=7, "alkyl" series (section 2.12). 
n=13, full series.
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5.5.2. Relationships obtained for rate of individual metabolic routes.
Simple linear correlations were searched for that might relate the rate constants for 
metabolite formation (kdm and kda) to any physico-chemical or molecular mechanical 
parameters for the DME derivatives. The corresponding half-life values for N- 
demethylation (HLdm) and N-dealkylation (HLda) were calculated from the rate 
constants (see appendix, table 2).
Several relationships were found for the rate of N-demethyladon (table 5.10). The rate 
constants for formation of the N-desmethyl metabolite were found to correlate with log 
D for the "alkyl" series as well as the full series of DME derivatives (equations 4 & 5, 
table 5.10). The equations indicate that the rate constants for N-demethylation 
increased as the value for log D increased. Significant correlations were also found 
with CMR and area for compounds 1,2,3,5 and 7, i.e. the n-alkyl series of DME 
derivatives (equations 1 & 2, table 5.10). The equations indicate that for a closely 
related group of the DME derivatives, kdm increased as the size of the molecule 
increased. A relationship was also seen between kdm for the "alkyl" series and 
increasing molecular length (equation 3, table 5.10).
The regression equations found for kda and HLda are given in table 5.11. Several 
relationships were seen for kda values of the "alkyl" series of DME derivatives. 
Equations 1, 3 and 4 (table 5.11) indicate the importance of steric descriptors of the 
DME derivatives on their rate of N-dealkylation, since kda showed a positive 
dependence on molecular length, CMR and area. One significant correlation was seen 
between HLda for the n-alkyl series and the atomic charge on the a-carbon atom of the 
substituent group (qa-c) (equation 2, table 5.11). The relationship indicates that as the 
charge on the a-carbon atom became more positive the half-life for N-dealkylation 
increased. One relationship was found for the HLda values of the full series of DME 
derivatives (equation 5, table 5.11). The equation indicates that as the log D value of 
the compound decreased, HLda increased.
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Table 5.10. Regression equations for N-demethylation of the DME derivatives in
dexamethasone-induced rat hepatic microsomal fraction.
kdm = -2.07 (±0.21) + 0.002 (±0.0002) area 
n = 5; s = 0.05; r = 0.989; F = 133; p<0.005 (1)
kdm = -2.37 (±0.34) + 0.39 (±0.05) CMR 
n = 5; s = 0.07; r = 0.977; F = 62.5; p<0.005 (2)
kdm = -1.94 (±0.26) + 0.18 (±0.02) length 
n = 7; s = 0.07; r = 0.968; F = 74.8; p<0.001 (3)
kdm = -0.71 (±0.15) + 0.38 (±0.05) log D 
n = 7; s = 0.09; r = 0.904; F = 47.1; pcO.010 (4)
kdm = -1.11 (±0.32) + 0.54 (±0.10) log D 
n = 13; s = 0.26; r = 0.844; F = 27.2; p<0.001 (5)
kdm = rate constant for formation of the N-desmethyl metabolite (nmol P450.min"l)
n = number of observations; s = standard error, r ^correlation coefficient; F = variance
ratio; p = level of significance of r value.
n=5, n-alkyl series.
n=7, "alkyl" series (section 2.12).
n=13, full series.
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Table 5.11. Regression equations for N-dealkylation of the DME derivatives in
dexamethasone-induced rat hepatic microsomal fraction.
kda = -0.84 (±0.03) + 0.08 (±0.003) length 
n = 5; s = 0.009; r = 0.997; F = 880; p<0.001 (1)
HLda = -221 (±14.7) + 1966 (±95.0) qa .C 
n = 5; s = 0.68; r = 0.994; F = 238; p<0.001 (2)
kda = -0.85 (±0.13) + 0.0009 (±0.0001) area 
n = 5; s = 0.03; r = 0.978; F = 64.9; p<0.005 (3)
kda = -0.99 (±0.16) + 0.17 (±0.02) CMR 
n = 5; s = 0.03; r = 0.975; F = 58.5; p<0.005 (4)
HLda = 22.40 (±3.87) - 6.25 (±1.25) log D 
n = 10; s = 2.33; r = 0.870; F = 24.9; p<0.005 (5)
kda = rate constant for formation of the N-desalkyl metabolite (nmol P450.mhr1)
HLda = half-life for formation of N-desalkyl metabolite (min.nmol P450"1) 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations listed in order of decreasing r value. 
n=5, n-alkyl series.
n=10, full series excluding iso-propylDME, tert-butylDME and phenylDME for which 
there are no values of kda (section 5.3.2).
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DISCUSSION
Hepatic microsomal fractions were taken from phenobarbitone-induced male rats and 
dexamethasone-induced female rats to determine the effect of different cytochrome 
P450 inducers on the in vitro metabolism of the series of DME derivatives. In turn it 
was hoped that this would lead to the identification of specific characteristics of the 
substrates for the induced isoenzymes.
It has been previously shown (Jones, 1989) that this series of compounds is 
metabolized efficiently by phenobarbitone-induced hepatic microsomes. The author 
concluded that the major cytochrome P450 isoenzymes involved in the metabolism of 
the DME derivatives were CYP2B1 and CYP2B2, since these are the major cytochrome 
P450 isoforms induced by phenobarbitone (Ryan et al.t 1979). In addition, 
phenobarbitone-induction causes an increase in CYP2C6 (2-fold) and CYP3A1 (2.5- 
fold) (Guengerich et a i, 1982). The O-depentyladon of pentoxyresorufin is regarded 
as a specific marker for CYP2B1 activity in rats (Lubet et al., 1985), and a significant 
level of this particular activity was seen in the phenobarbitone-induced hepatic 
microsomal fraction (section 5.1) when compared with dexamethasone-induced or 
control (section 4.1) rat hepatic microsomal fractions.
Dexamethasone is a member of the family of cytochrome P450 inducers known as 
glucocorticoids. The prototype inducer of this group of compounds is pregnenelone- 
16a-carbonitrile (PCN) which was found to induce a cytochrome P450 isoenzyme 
quite distinct from those induced by the traditional inducers, phenobarbitone and 3- 
methylcholanthrene (Lu et al., 1972). The P450 isoenzyme induced by PCN was 
identified as CYP3A1 (Heuman et al., 1982). The authors found that dexamethasone 
was a more potent inducer of CYP3A1 than PCN in female rats, and reported a 30-fold 
induction of this isoenzyme. The level of codeine N-demethylase activity is an 
indicator of CYP3A activity (Ladona et al., 1991) and this was raised 5-fold by
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dexamethasone induction when compared with control female rat hepatic microsomal 
fraction (section 4.1). The level of codeine N-demethylase activity was equivalent in 
dexamethasone- and phenobarbitone-induced hepatic microsomal fractions (section 5.1) 
and this may indicate some induction of CYP3 A activity by phenobarbitone.
All of the DME derivatives had higher metabolic rate constants when incubated with rat 
microsomal fraction induced with phenobarbitone than that induced with 
dexamethasone. This supports the observations of Jones (1989) who utilized a range 
of cytochrome P450 inducers, and concluded that the series of DME derivatives was 
most rapidly metabolized by phenobarbitone-induced rat hepatic microsomal fraction. 
In both dexamethasone- and phenobarbitone-induced microsomes the DME derivatives 
containing an aromatic group or an unsaturated alkyl substituent were the most rapidly 
metabolized. So for a high value of ke a degree of unsaturation seems to be required. 
The metabolic rate constants followed the same trends through the series of DME 
derivatives in both phenobarbitone- and dexamethasone-induced microsomal fractions, 
although actual values of ke were lower in the latter. This indicates that the compounds 
are substrates for both the CYP2B and CYP3A subfamilies. It is possible that the 
presence of both subfamilies in phenobarbitone-induced microsomes enabled the DME 
derivatives to be metabolized more efficiently.
Both the N-desmethyl and N-desalkyl metabolites were identified for all the DME 
derivatives, except iso-propylDME, tert-butylDME and phenylDME, in both 
microsomal preparations. There was no evidence for N-dealkylation of the 
aforementioned substrates and this supported previous observations (sections 3.2 & 
3.3).
One way to rationalize the change in ke (and l\p) through the series of DME derivatives 
was to search for quantitative stmcture-activity relationships (QSAR's) with physico­
chemical, spectral and molecular mechanical descriptors of the compounds. Several
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significant correlations were seen for the biological data obtained in both 
phenobarbitone- and dexamethasone-induced hepatic microsomal fractions. The 
correlation between intrinsic lipophilicity (log P) and the metabolic half-life values of 
the DME derivatives in both induced incubation systems was interesting. 
PropenylDME and propynylDME were outliers from the regression line indicating that 
these compounds had shorter ti/% values than would be predicted from their log P 
values. Jones (1989) found that these same two compounds were outliers from a 
correlation between log P and the spectral binding parameter Kg, and concluded that 
they bound unusually tightly to cytochrome P450 due to the formation of pi-pi 
interactions with the enzyme. Alternatively, since the common parameter in these 
correlations is log P, the calculated values of intrinsic lipophilicity for propenylDME 
and propynylDME could be inaccurate. Log P is calculated by addition of fragmental 
constants to yield a value for the whole molecule (section 2.10.1). It is possible that 
the fragmental constant used for the unsaturated substituents is not a true reflection of 
their contribution to the lipophilicity in the whole molecule.
Omission of propenylDME and propynylDME from the log P regression with ti/2 gave 
a significant improvement in correlation coefficient, indicating the important role 
lipophilicity plays in determining rate of metabolism. There have been many reports 
relating increased metabolic clearance of a variety of compounds with increasing 
lipophilicity (McMahon, 1961; Tong and Lien, 1976; Devinsky and Gorrod, 1987). It 
has become increasingly clear, though, that log P is only a true representation of the 
intrinsic lipophilicity of a compound if it is not ionizable. Hansch (1972) corrected 
values of Km for ionization and obtained a better correlation with log P. The 
distribution of an ionizable compound between two phases is dependent on the 
ionization state of the molecule at the pH of the assay, as well as its lipophilicity, since 
it is assumed that only the unionized form of the drug will penetrate the organic phase. 
This can be expressed by the following scheme;
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[Ionized dmgJaq <-> [Unionized drug]aq [Unionized dmg]iipid
The distribution coefficient (log D) takes the ionization of the compound into account 
and is defined as the octanol/water partition coefficient at physiological pH (section 
2.10.2). Since the DME derivatives are tertiary amines they would be ionized to 
varying extents at the pH of the incubation, so their log D values should be a better 
reflection of their distribution between lipid and aqueous phases than log P. In both 
dexamethasone- and phenobarbitone-induced microsomes the correlation of rate of 
metabolism with log D was an improvement on that with log P. In addition, the 
correlation of log D with ti/2 in phenobarbitone-induced microsomes was improved 
when the atomic charge on the nitrogen atom was included in multilinear analysis. A 
decrease in metabolic half-life with increasing negative charge on the nitrogen atom 
could be related to the mechanism of N-dealkylation. As the nitrogen becomes more 
electron-rich it may become easier to remove one of its lone pair electrons, and this is 
believed to be the first step in the mechanism of N-dealkylation (section 1.3.1).
Significant correlations were seen relating decreasing metabolic half-life in 
phenobarbitone-induced microsomes to increasing strength of binding of the substrate 
as measured by K§, K3 and K4 . Several studies have attempted to correlate Kg with 
lipophilicity (Jansson et al., 1972; Duquette et a i, 1983) but not with rate of 
metabolism. For the series of DME derivatives, K§ correlates weakly with log P (r = 
0.424) so the relationship between ti/2 and Kg cannot be attributed simply to increasing 
lipophilicity. However, the relationship indicates that for a short half-life the substrate 
should bind tightly to the enzyme. The same relationship was seen for the individual 
routes of N-demethylation and N-dealkylation.
The rate of formation of the N-desalkyl metabolite in phenobarbitone-induced 
microsomes showed some reliance on steric descriptors of the DME derivatives. 
Correlations were seen relating increased kda to increasing molecular length, CMR and
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area. Presumably these relationships must be finite, otherwise an infinitely large active 
site would be implied. Relationships seen previously between rate of metabolism and 
increasing chain length of the substituent group (Duquette et a/., 1983; Devinsky and 
Gorrod, 1987) have indicated a maximum chain length beyond which no metabolism 
was seen.
Several correlations were seen relating biological data obtained in dexamethasone- 
induced microsomes with physico-chemical and molecular mechanical descriptors of 
the DME derivatives. A significant dependence of ke, kdm and kda on the size of the 
substrate (i.e. molecular length, CMR and area) was seen. The idea that the size of a 
molecule may affect its interaction with cytochrome P450 has been investigated (Lewis 
et a i, 1987). The authors concluded that binding to P450 (particularly CYP1A1) could 
be described in terms of the molecule's area/depth2 ratio. The correlation between 
CMR and ke was improved when the Taft inductive parameter (a*) was included in 
multilinear analysis. The relationship showed that a higher ke value was achieved with 
increasing CMR (which is related to molecular volume) and increasing inductive effect 
of the substituent group on the nitrogen atom. Increasing a* has the effect of 
increasing the electron density on the nitrogen and this may facilitate removal of a lone 
pair electron for N-dealkylation. An interesting correlation was also seen between 
increasing HLda and increasing positive charge on the a-carbon atom of the substituent 
group. This may also be related to the mechanism for N-dealkylation, since an 
increasing charge on the a-carbon atom would cause a decreased electron density on 
the nitrogen thus hindering removal of a lone pair electron. In terms of CYP3A, these 
correlations are supported by the work of Baamhielm and Westerlund (1986). They 
studied QSAR's for a series of 1,4-dihydropyridines which are substrates of CYP3A 
(Smith, 1991) and found that the oxidation rate of these compounds increased with 
increasing steric bulk and lipophilicity.
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Interpretation of QSAR's is only possible in very general terms, due to the presence of
multiple cytochrome P450 isoenzymes, even in the induced animal. This fact is
\
highlighted by the similar correlations obtained for dexamethasone- and 
phenobarbitone-induced hepatic microsomal fractions, i.e. a general dependence of 
metabolic rate on lipophilicity and molecular size.
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CHAPTER 6
Metabolism of the DME derivatives attributable to CYP2B1 determined by 
the use of a specific inhibitor in phenobarbitone-induced rat hepatic
microsomal fraction.
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SUMMARY
A specific inhibitor (orphenadrine) has been used to determine the rate constants for 
metabolism of the DME derivatives attributable to CYP2B1 (Iq b) in phenobarbitone- 
induced rat hepatic microsomal fraction. Orphenadrine gave specific, mechanism-based 
inhibition of CYP2B1 (Ki = 0.15pM).
All of the DME derivatives were substrates for CYP2B1, except bisDME. PhenylDME 
had the highest k^B value of the series and it is suggested that this is due to interaction 
of its two aromatic rings with complementary amino acids in the active site of CYP2B1. 
The rate of metabolism of the DME series by CYP2B1 showed a dependence on the 
lipophilicity, as measured by log D, and binding affinity of the substrates. In addition, 
the electron density of the nitrogen atom was an important determinant of metabolism 
and this may be related to the mechanism of N-dealkylation.
Non-linear relationships were seen for the individual routes of metabolism (N- 
demethyladon and N-dealkylation) with the molar refractivity (CMR) and area of the 
molecules. Optimum values for these parameters have been calculated and it is 
speculated that the active site of CYP2B1 is too constrained to interact with bisDME.
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INTRODUCTION
The rate of metabolism of the series of DME derivatives in induced rat hepatic 
microsomal fractions could be described by relationships with various physico­
chemical descriptors of the molecules. This in vitro metabolism model has the 
disadvantage of being heterogeneous so that any QSAR's seen could only be 
interpreted in very general terms. In order to obtain QSAR's attributable to one 
cytochrome P450 isoenzyme studies have been carried out using a range of structurally 
diverse substrates and purified P450 isoenzymes (Petzold et a i, 1985; White and 
McCarthy, 1986), but the disadvantage of reconstituted systems is that, although 
catalytically competent, they do not necessarily reflect the true in vivo situation. This is 
because the membrane with which the P450 enzymes are associated, and which is 
thought to be important for their activity, is disrupted during the purification process. 
Specific inhibitors of P450 isoenzymes could be used in vitro to determine the 
importance of particular isoenzymes in the metabolism of a series of substrates. This 
would at least have the advantage that in the microsomal incubation the enzymes would 
still be associated with the membrane of the endoplasmic reticulum.
Since CYP2B1 is one of the major P450 isoenzymes induced by phenobarbitone (Ryan 
et aL, 1979) a specific inhibitor of this isoenzyme was searched for. The anti­
parkinsonian agent orphenadrine has been reported to be a specific inhibitor of 
CYP2B1 (Reidy et aL, 1989). This chapter describes the kinetics of inhibition by 
orphenadrine and the effect that this inhibitor has on the metabolism of the DME 
derivatives in phenobarbitone-induced rat hepatic microsomal fraction. First order rate 
constants of metabolism attributable to CYP2B1 have been calculated and QSAR's 
employed to determine any dependence of the activity of this isoenzyme on physico­
chemical descriptors of the DME derivatives. In addition, it has been possible to 
determine the separate rate constants for N-demethylation and N-dealkylation by 
CYP2B1.
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RESULTS
6.1. Specific inhibition of CYP2B1.
In order to determine the importance of CYP2B1 in the metabolism of the series of 
DME derivatives, specific inhibition studies were carried out. Orphenadrine has been 
reported to be a specific inhibitor of CYP2B1 (Reidy et aL, 1989) and this possibility 
was investigated using pentoxyresorufin as substrate.
6.1.1. Kinetics of inhibition by orphenadrine.
The kinetics of orphenadrine inhibition in phenobarbitone-induced rat hepatic 
microsomal fraction was examined using pentoxyresorufin as the marker substrate for 
CYP2B1 activity (Lubet et aL, 1985). Pentoxyresorufin O-depentylase activity was 
monitored using the method described in section 2 .6 .2 .
Initially, the kinetics of orphenadrine inhibition without preincubation was determined. 
Orphenadrine (ImM in 0.1M potassium phosphate buffer, pH 7.4) was added to the 
reaction mixture containing pentoxyresorufin and the rate of pentoxyresorufin O- 
depentylase activity determined. Three different concentrations of pentoxyresorufin 
were employed (l-4gM) with varying concentrations of orphenadrine (l-5|iM). This 
enabled construction of a Dixon plot for the determination of the type of inhibition as 
well as the inhibitor constant, Ki (Dixon, 1953). Ki is defined as the equilibrium 
constant for the combination of enzyme with an inhibitor. The Dixon plot indicated that 
without preincubation orphenadrine caused competitive or mixed-type inhibition of 
pentoxyresorufin O-depentylase activity with an apparent Ki of 1.5|iM (figure 6.1a).
The effect of preincubation of orphenadrine with NADPH prior to addition of 
pentoxyresorufin was investigated. Orphenadrine (O-SgM) was added to the reaction 
mixture (section 2.6.2) and incubated with lOpl NADPH (50mM) for 4min at 37°C.
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Figure 6.1. Dixon plots (inhibitor concentration versus reciprocal reaction velocity) of 
the inhibition of pentoxyresorufin O-depentylase activity by orphenadrine (a) without 
preincubation and (b) after 4min preincubation in phenobarbitone-induced rat hepatic 
microsomal fraction. Figures in square brackets indicate concentration of pentoxyresorufin 
(gM).
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After this time, pentoxyresorufin (1-5jiM) was added and the rate of pentoxyresorufin 
O-depentylase activity determined. Construction of a Dixon plot revealed apparent non­
competitive kinetics (figure 6.1b). Orphenadrine preincubation was associated with a 
10-fold lowering of apparent Ki to 0.15|iM. In addition, varying concentrations of 
orphenadrine (0.01-10|iM) were preincubated for 4min prior to addition of 
pentoxyresorufin (2.5|iM) in order to determine an IC50 value. The construction of a 
plot of % pentoxyresorufin O-depentylase activity remaining (ie. % control) against the 
logarithm of inhibitor concentration gave a sigmoid curve from which an IC50 value of 
0.42(±0.05)|iM was determined. It was also determined from the sigmoid curve that 
orphenadrine (5|iM) gave 98% inibition of pentoxyresorufin O-depentylase activity, 
and this concentration was selected for use in inhibition studies with the DME 
derivatives.
6.1.2. Specificity of orphenadrine inhibition.
It was necessary to determine that orphenadrine did not inhibit any cytochrome P450 
isoenzymes other that CYP2B1. Marker substrates were chosen to test the effect of 
preincubation with orphenadrine (5pM) on the activities of isoenzymes of the CYP1A 
and CYP3A subfamilies.
The dihydropyridine calcium channel blockers, such as nifedipine and felodipine, have 
been shown to be metabolized by two rat cytochrome P450 isoenzymes - CYP2C11 
and CYP3A2 (Guengerich et aL, 1986). The rate of oxidation of felodipine in 
phenobarbitone-induced rat hepatic microsomal fraction was determined as described in 
section 2.8. The effect of preincubation with orphenadrine (5|iM) on this activity was 
investigated. The first order metabolic rate constants for the oxidation of felodipine 
were calculated in the absence and presence of orphenadrine (figure 6 .2) and were 
found to be 0.53 and 0.52nmol P450.min_l, respectively.
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Figure 6 .2 . Semilogarithmic plot for the calculation of metabolic rate constants for 
metabolism of felodipine before and after inhibition with orphenadrine (5pM).
(•) Uninhibited incubation: slope = 0.14(±0.01)time-1; r = 0.980
(o) Inhibited incubation: slope = 0.15±(0.01)time-l; r = 0.990
The slope of the line was used to calculate values of ke for the uninhibited and inhibited
incubations (section 2.7).
Log C is the logarithm of felodipine concentration (|iM).
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The effect of orphenadrine preincubation on CYP1A1 was investigated using the 
marker substrate ethoxyresorufin (Burke and Mayer, 1974). The ethoxyresorufin O- 
deethylase activity of phenobarbitone-induced rat hepatic microsomal fraction was 
measured as described in section 2.6.2. An activity of 0.11nmol/min/mg protein was 
obtained. Preincubation with orphenadrine (SgM) for 4min prior to addition of 
ethoxyresorufin had no significant effect on ethoxyresorufin O-deethylase activity.
6.2. Inhibition of metabolism of the DME derivatives by orphenadrine.
The effect of preincubation with orphenadrine (5pM) on the rate of metabolism of the 
DME derivatives was determined using the same phenobarbitone-induced rat hepatic 
microsomal fraction as was described in chapter 5. The incubation system described in 
section 2.7 was employed. Orphenadrine (5pM) was preincubated for 4min at 37°C, in 
the presence of an NADPH-generating system, prior to addition of the substrate (IgM). 
Timed samples were removed at appropriate intervals and the first order rate constants 
for metabolism of the DME derivatives calculated (section 2.7). An example of the 
effect of preincubation with orphenadrine on the metabolic rate constant is given for n- 
propylDME in figure 6.3. The value for ke in the uninhibited incubation was 0.68nmol 
P450.min-1 and this was reduced to 0.25nmol P450.min-1 after preincubation with 
orphenadrine. All of the metabolic rate constants determined in the orphenadrine- 
inhibited incubation (kinhib) are given in table 6 .1.
6.2.1. Calculation of first order metabolic rate constants for CYP2B1.
The metabolic rate constants for the DME derivatives obtained after preincubation with 
orphenadrine are attributable to cytochrome P450 isoenzymes remaining active after 
inhibition of CYP2B1. The overall rate constant for metabolism (ke) can be considered 
to be a sum of the contributive metabolic rate constants for each cytochrome P450 
isoenzyme, as indicated by the following equation:
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Figure 6.3. Semilogarithmic plot for the calculation of metabolic rate constants for 
metabolism of n-propylDME before and after inhibition with orphenadrine (5|iM).
(•) Uninhibited incubation: slope = 0.15±(0.004)time_1; r = 0.997
(o) Inhibited incubation: slope = 0.05±(0.001)time_1; r = 0.997
The slope of the line was used to calculate values of ke for the uninhibited and inhibited
incubations (section 2.7).
Log C is the logarithm of n-propylDME concentration (jiM).
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Table 6.1. Calculation of rate constants of metabolism for the DME derivatives
attributable to CYP2B1 in phenobarbitone-induced hepatic microsomal fraction.
Substituent kinhib ke k2B %contribution
1. Methyl 0.04 ± 0.003 0.12 ± 0.005 0.08 ± 0.008 67
2. Ethyl 0.11 ±0.016 0.25 ± 0.009 0.14 ± 0.025 56
3. n-Propyl 0.25 ± 0.010 0.68 ± 0.013 0.43 ± 0.023 63
4. iso-Propyl 0.13 ± 0.005 0.27 ± 0.008 0.14 ±0.013 52
5. n-Butyl 0.39 ± 0.023 1.26 ± 0.025 0.87 ± 0.048 69
6 . tert-Butyl 0.11 ±0.007 0.29 ± 0.005 0.18 ± 0.012 62
7. n-Pentyl 0.65 ± 0.032 1.21 ± 0.063 0.55 ± 0.095 45
8 . Phenyl 10.0 ±0.190 13.4 ±0.190 3.36 ± 0.870 25
9. Benzyl 3.11 ±0.029 3.77 ± 0.035 0.65 ± 0.064 17
10. Phenethyl 1.36 ± 0.055 1.70 ±0.086 0.34 ±0.141 20
11. Propenyl 1.30 ± 0.020 1.80 ± 0.046 0.50 ± 0.066 28
12. Propynyl 1.87 ± 0.034 2.69 ± 0.051 0.82 ± 0.085 30
13. Bis 4.12 ± 0.286 3.28 ±0.102 0 0
kinhib = rate constants for metabolism of the DME derivatives in phenobarbitone-induced 
hepatic microsomal fraction after inhibition with orphenadrine (5jjM). Values were derived 
from the slope of the semilogarithmic plot of substrate concentration against time. Linear 
regression analysis yielded the standard error of the slope from which the standard error for 
kinhib was derived.
ke = rate constants for metabolism of the DME derivatives in phenobarbitone-induced 
hepatic microsomal fraction (section 5.2.1).
k2B = rate constants for metabolism of the DME derivatives attributable to CYP2B1, 
derived from equation 6.3.
% contribution = (k2B/ke)xl00 , contribution of CYP2B1 to overall metabolism.
All rate constants for metabolism are in units of nmol P450.min-1 
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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ke = kA + kfi + kc +  kn - equation 6.1.
where, kA, kg and kc are rate constants for metabolism attributable to n number of 
specific P450 isoenzymes. It was possible, therefore, to calculate the rate constant for 
metabolism attributable to one P450 isoenzyme from the difference between the 
experimentally determined metabolic rate constants in the inhibited and uninhibited 
incubations:
where ke and kinhib are the rate constants for metabolism in the uninhibited and 
inhibited incubations, respectively. The metabolic rate constant attributable to the P450 
isoenzyme that has been rendered inactive by inhibition is represented by kA.
Thus the rate constants for metabolism of the DME series attributable to CYP2B1 (k2B) 
were calculated from a rearrangement of equation 6 .2 :
(assuming that the inhibitor, orphenadrine, had negligible effect on P450 isoenzymes 
other than CYP2B1).
The ke values for the DME derivatives are given in table 6.1. and are the same as those 
determined in section 5.2.1. The calculated rate constants for metabolism attributable to 
CYP2B1 are also given in table 6.1.
CYP2B1 was responsible for between 17% (benzylDME) and 67% (methylDME) of 
the total metabolism of the DME derivatives (table 6.1). In general, this isoenzyme 
accounted for >50% of the metabolism of the "alkyl” series (compounds 1-7) but <30% 
of the metabolism of the rest of the series. There was a wide range of k^B values with 
phenylDME being the most rapidly metabolized (k2B=3.36nmol P450.min'1) and
ke = kinhib+ kA - equation 6 .2 .
k2B - k e  - kinhib - equation 6.3.
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methylDME having the lowest value for k2B of O.OSnmol P450.min-1. An examination 
of the values for kiB revealed several trends. The rate constants for metabolism 
attributable to CYP2B1 increased with increasing chain length of the n-alkyl substituent 
up to C4. This trend was reversed for n-pentylDME. Increasing the number of 
branches in the alkyl substituent from zero (methylDME) to one (ethylDME) caused a 
slight increase in k2B* The introduction of two (iso-propylDME) or three (tert- 
butylDME) branches had little effect thereafter. Increasing the degree of unsaturation of 
the substituent group from fully saturated (n-propylDME) to fully unsaturated 
(propynylDME) had the effect of doubling k2B- The introduction of an aromatic system 
into the substituent group (phenylDME) caused a dramatic increase in k2B relative to 
methylDME. As the aromatic ring became further from the nitrogen atom by insertion 
of successive methylene units (benzylDME, phenethylDME) k2B decreased. The 
metabolism of bisDME was not supported by CYP2B1.
6.2.2. Quantification of metabolites of the DME derivatives.
Metabolites of the DME derivatives formed in the inhibited incubation system were 
identified and quantified as described in section 2.7.
The rate constants for formation of the N-desmethyl and N-desalkyl metabolites (kdm 
and kda, respectively) of the DME derivatives in the orphenadrine-inhibited incubation 
are given in table 6.2. It was not possible to quantify the metabolites for phenylDME, 
benzylDME or phenethylDME because they either co-chromatographed with 
orphenadrine or with one of two orphenadrine metabolites. A mobile phase of 
30:80(v/v) acetonitrileioctane sulphonate (section 2.7) did separate the peaks of interest 
but their shape was so poor that any quantification was highly inaccurate.
All of the DME derivatives underwent N-demethylation as well as N-dealkylation, 
except for iso-propylDME and tert-butylDME which were only N-demethylated. It was 
necessary to determine the rate constants for formation of metabolites in the inhibited
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Table 6.2. Rate constants for formation of metabolites in phenobarbitone-induced
hepatic microsomal fraction after inhibition with orphenadrine.
No. Substituent Ratio
(kdm*kda)
kdm kda
1 Methyl 1.00 0.018 ± 0.002 0.018 ± 0.002
2 Ethyl 2.5 ±0.19 0.076 ± 0.009 0.030 ± 0.009
3 n-Propyl 3.46 ±0.14 0.195 ± 0.009 0.056 ± 0.004
5 n-Butyl 2.03 ±0.13 0.261 ± 0.021 0.128 ± 0.012
7 n-Pentyl 0.99 ± 0.03 0.325 ± 0.020 0.329 ± 0.021
1 Methyl 1.00 0.018 ± 0.002 0.018 ± 0.002
2 Ethyl 2.5 ±0.19 0.076 ± 0.009 0.030 ± 0.009
4 iso-Propyl * 0.127 ±0.010 0
6 tert-Butyl * 0.109 ±0.007 0
3 n-Propyl 3.46 ±0.14 0.195 ± 0.009 0.056 ± 0.004
11 Propenyl 1.61 ± 0.01 0.801 ± 0.014 0.498 ± 0.009
12 Propynyl 0.61 ± 0.02 0.709 ±0.027 1.161 ±0.035
8 Phenyl n.d. n.d. n.d.
9 Benzyl n.d. n.d. n.d.
10 Phenethyl n.d. n.d. n.d.
13 Bis 0.12  ± 0.01 0.441 ± 0.061 3.677 ± 0.286
kdm = rate constant for N-demethylation. 
kda = rate constant for N-dealkylation.
Both rate constants are in units of nmol P450.min'1, and were calculated from kinhib 
using the following equation:
kinhib = kdm + kda 
* = compound only N-demethylated. 
n.d. = not determined.
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incubation in order to calculate kdm and ktfa attributable to CYP2B1. The rate constant 
for N-demethylation in the uninhibited incubation is the sum of the kym values for each 
P450 isoenzyme in the incubation. Thus, using an analogy of equation 6.3 (section 
6.2.1) the kdm values attributable to CYP2B1 were calculated:
(kdm)2B = (kdm)uninhib - (kdm)inhib - equation 6.4.
where, (kdm)uninhib and (kdm)inhib are the rate constants for formation of the N- 
desmethyl metabolite in the uninhibited and inhibited incubations, respectively. The 
rate constant for N-demethylation attributable to CYP2B1 is represented by (kcjm)2B- 
The rate constants for N-dealkylation were calculated in a similar manner.
The rate constants for formation of metabolites by CYP2B1 were calculated from the 
difference between the experimentally determined values in the uninhibited incubation 
(table 5.4) and the inhibited incubation (table 6.2). The values of kdm and kda 
attributable to CYP2B1 are given in table 6.3.
The rates of formation of the N-desmethyl and N-desalkyl metabolites increased from 
C 1-C4 for the n-alkyl substituents. This trend was reversed, however, for n- 
pentylDME. The rate constant for formation of the N-desmethyl metabolite of n- 
butylDME was the highest of the whole series. Increasing the number of branches in 
the alkyl substituent from none (methylDME) to three (tert-butylDME) had the effect of 
increasing kdm- When two (iso-propylDME) or three branches were present, N- 
dealkylation was prevented. Increasing the degree of unsaturation of the alkyl 
substituent group from fully saturated (n-propylDME) to fully unsaturated 
(propynylDME) caused a dramatic increase in kda and this was the predominant 
metabolic route for propynylDME.
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Table 6.3. Rate constants for formation of metabolites attributable to CYP2B1
determined in phenobarbitone-induced hepatic microsomal fraction.
No. Substituent kdm kda Ratio
(kdm-kda)
1 Methyl 0.042 ± 0.004 0.042 ± 0.004 1.00
2 Ethyl 0.075 ±0.018 0.064 ±0.011 1.17
3 n-Propyl 0.297 ± 0.029 0.133 ±0.018 2.23
5 n-Butyl 0.659 ± 0.050 0.211 ±0.029 3.12
7 n-Pentyl 0.384 ± 0.075 0.167 ± 0.064 2.30
1 Methyl 0.042 ± 0.004 0.042 ± 0.004 1.00
2 Ethyl 0.075 ± 0.018 0.064 ±0.011 1.17
4 iso-Propyl 0.141 ±0.013 0 *
6 tert-Butyl 0.183 ±0.012 0 *
3 n-Propyl 0.297 ± 0.029 0.133 ± 0.018 2.23
11 Propenyl 0.432 ± 0.069 0.068 ± 0.046 6.35
12 Propynyl 0.246 ± 0.090 0.576 ±0.111 0.43
8 Phenyl n.d. n.d. n.d.
9 Benzyl n.d. n.d. n.d.
10 Phenethyl n.d. n.d. n.d.
13 Bis 0 0 0
kdm = rate constant for N-demethylation; k<ja = rate constant for N-dealkylation.
Both rate constants are in units of nmol P450.min-1, and were calculated using the 
following equations:
(kdm)2B -  (kdm)uninhib ~ (kdm)inhib - equation 6.4.
(kda)2B = (kda)uninhib " (kda)inhib - equation 6.5.
* = compound only N-demethylated; n.d. = not determined.
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6.3. Structure-activity relationships derived for metabolism of the DME 
derivatives by CYP2B1.
Quantitative structure-activity relationships (QSAR's) were sought for the biological 
data obtained for the DME derivatives attributable to CYP2B1. Both Iqb and ti/2 were 
correlated with various hydrophobic, spectral and steric descriptors of the DME 
derivatives, as described in section 2.12. The correlation with the higher r value is 
presented (see section 5.4).
6.3.1. Relationships obtained for k2 B*
Initially, simple linear relationships for the biological data with various physico­
chemical, molecular mechanical and spectral parameters of the DME derivatives were 
searched for. For this purpose the metabolic half-life values attributable to CYP2B1 
were derived from k2B, as described in section 2.7. The values for k^B and 
corresponding ti/2 are summarized in table 6.4. All the regression equations found for 
the biological data attributable to CYP2B1 are given in table 6.5.
Several relationships were seen for the "alkyl" series of compounds (n=7, section 2.12) 
with log P and log D as well as the spectral binding constants Ks, K3 and K4 . 
However, since these relationships held for the full series (n=12) only these regression 
equations are reported in table 6.5. All the relationships reported are significant at the 
0.5% level (r>0.79).
Equation 1 (table 6.5) indicates a dependence for decreasing metabolic half-life of the 
DME derivatives on increasing lipophilicity of the substrate, as measured by log P. 
Initially there appeared to be no relationship with this parameter (r=0.462) but since a 
correlation had been seen for the "alkyl" series (r=0.884), the relationship was 
examined more closely. Figure 6.4. shows clearly that propenylDME and 
propynylDME (compounds 11 and 12, respectively) are outliers from the regression
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Table 6.4. Metabolic rate constants and half-life values for the DME derivatives
attributable to CYP2B1 determined in phenobarbitone-induced hepatic microsomal
fraction.
Substituent k2B Half-life
1. Methyl 0.08 ± 0.008 8.35 ±0.81
2. Ethyl 0.14 ±0.025 4.99 ± 0.76
3. n-Propyl 0.43 ± 0.023 1.61 ±0.09
4. iso-Propyl 0.14 ±0.013 4.91 ± 0.46
5. n-Butyl 0.87 ± 0.048 0.80 ± 0.05
6 . tert-Butyl 0.18 ± 0.012 3.79 ± 0.23
7. n-Pentyl 0.55 ± 0.095 1.26 ± 0.23
8 . Phenyl 3.36 ± 0.870 0.21 ±0.06
9. Benzyl 0.65 ± 0.064 1.06 ± 0.09
10. Phenethyl 0.34 ±0.141 2.06 ± 0.61
11. Propenyl 0.50 ± 0.066 1.39 ±0.17
12. Propynyl 0.82 ± 0.085 0.84 ±0.08
13. Bis 0 oo
k2B = metabolic rate constants attributable to CYP2B1 (nmol P450.min-1) 
Half-life = min.nmol P450-1. Values derived from k2B (section 2.7)
Note: after calculation of ti/2, values of k2B were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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Table 6.5. Regression equations for metabolism of the DME derivatives by CYP2B1.
ti/2 = 17.5 (±2.82) - 3.22 (±62) log P
n = 10; s = 1.29; r = 0.879; F = 45.4; pcO.OOl (1)
tl/2 = 0.24 (±0.44) + 0.10 (±0.02) K3
n = 12; s = 1.02; r = 0.916; F = 52.1; p<0.001 (2)
ti/2 = 0.99 (±0.38) + 0.13 (±0.02) K4
n = 12; s = 1.05; r = 0.910; F = 48.5; p<0.001 (3)
tl/2 = 11.3 (±1.56) - 2.91 (±0.51) log D
n = 12; s = 1.23; r = 0.874; F = 32.3; p<0.001 (4)
ti/2 = -0.29 (±0.76) + 0.08 (±0.02) Ks
n = 12; s = 1.45; r = 0.821; F = 20.7; p<0.005 (5)
tl/2 = 138 (±40.3) qN - 3.47 (±0.39) log D - 36.0 (±7.31) 
n = 12; s = 0.86; r = 0.947; F = 39.3; pcO.OOl (6)
k2B = 2.21 (±0.35) a* -16.5 (±3.56) qa.c  + 3.23(±0.58) 
n = 12; s = 0.40; r = 0.916; F = 23.4; pcO.OOl (7)
ti/2 = half-life of metabolism attributable to CYP2B1 (min.nmol P450‘l) 
k2B = first order metabolic rate constant attributable to CYP2B1 (nmol P450.min-1) 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations are listed in order of decreasing r value. 
n=10, full series omitting propenylDME and propynylDME. 
n=12, full series, no value for bisDME (section 6.2.1).
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Figure 6.4. Regression plot of log P with half-life for metabolism of the DME 
derivatives attributable to CYP2B1. Half-life is in units of min.nmol P450-1. 
r = correlation coefficient of the regression line, ignoring propenylDME and 
propynylDME (compounds 11 & 12, respectively).
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line. When these two compounds are omitted from the correlation, a significant 
improvement is obtained (r=0.879). This phenomenon has been noted previously for 
correlations of log P with ti/2  values of the DME derivatives in phenobarbitone- and 
dexamethasone-induced microsomal fractions (chapter 5).
A relationship was also seen between decreasing metabolic half-life attributable to 
CYP2B1 and increasing values of log D (equation 4, table 6.5). Log D is a measure of 
the distribution of a compound between aqueous and lipid phases at physiological pH, 
so this relationship again emphasizes the influence that lipid partitioning of the substrate 
has on the rate of metabolism.
Linear correlations existed between ti/2  and the spectral binding constants Ks, K3 and 
K4 . The relationship between ti/2  and Ks (equation 5, table 6.5) is such that as Ks 
increased (i.e. the substrate was bound less tightly to the enzyme) the half-life for 
metabolism attributable to CYP2B1 increased. Similar relationships were seen for ti/2  
with K3 and K4  (equations 2 and 3, table 6.5). These two relationships indicate that the 
strength of binding of the substrate to low- and high-spin cytochrome P450 (K3 and 
K4 , respectively) were also important determinants of metabolic rate.
Multilinear analysis yielded two equations. The first (equation 6 , table 6.5) was an 
improvement on the simple linear relationship between ti/2  and log D. It involved the 
atomic partial charge on the nitrogen atom (q^) and indicated that as the charge on this 
atom became more negative, the ti/2  attributable to CYP2B1 became shorter. A second 
multilinear correlation related k2B to the Taft inductive parameter (a*) and the atomic 
partial charge on the a-carbon atom of the substituent group (qa-c) (equation 7 , table 
6.5). The equation indicates that as the inductive effect of the substituent group and the 
positive charge on the a-carbon increased, k^ B increased.
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6.3.2. Relationships obtained for rate of individual metabolic routes.
Analysis of the rate constants for N-demethylation and N-dealkylation yielded several 
relationships. The half-life values for each process were calculated (section 2.7) and 
are given in the appendix (table 3).
The simple linear relationships found for N-demethylation are given in table 6 .6 . 
Equation 3 relates increasing kdm to increasing log D and this indicates the importance 
of the lipophilicity of the substrate for this process. In addition, a second measure of 
lipophilicity (log P) was related to the half-life for N-demethylation (HLdm) (equation 
1, table 6 .6) for the "alkyl" series of compounds (1-7). Linear correlations were found 
for HLdm with the spectral binding parameters Ks, Kg and K4 (equations 2, 4 & 6 , 
table 6 .6). All these relationships indicate that as the binding affinity of the substrate 
increased, the half-life for N-demethylation decreased. An equation was also seen 
indicating a negative dependence of HLdm on the molar reffactivity (CMR) of the DME 
derivatives (equation 5, table 6.6). Closer examination of the plot of this equation 
revealed that there was an optimum value of CMR for HLdm (figure 6.5). This led to 
the derivation of the following quadratic equation:
HLdm = 7.52 (±1.84) CMR2 - 112 (±25.7) CMR + 420 (±89.5) 
n =9 s =1.81 r = 0.950
The correlation coefficient for the parabola (r-O.95O) was a marked improvement on 
that for the simple linear correlation (r=0.794). Setting the derivative 
d(HLdm)/d(CMR) equal to zero and solving the resulting equation for CMR yielded an 
optimum value of 7.45(±0.15) for N-demethylation of the DME derivatives by 
CYP2B1 in the phenobarbitone-induced rat hepatic microsomal incubation studied.
Several simple linear relationships were seen for the rate of N-dealkylation by CYP2B1 
with physicochemical descriptors of the DME derivatives (table 6.7). In general.
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Table 6.6. Regression equations for N-demethylation of the DME derivatives by
CYP2B1.
HLdm = 38.4 (±8.99) - 7.75 (±2 .11) log P 
n = 7; s = 3.13; r = 0.854; F = 13.5; p<0.01
HLdm = 0.27 (±0.03) + 0.69 (±0.60) K4 
n = 9; s = 1.32; r = 0.969; F = 108; pcO.OOl
kdm = -0.54 (±0.13) + 0.30 (±0.05) log D 
n = 9; s = 0.08; r = 0.928; F = 43.5; pcO.OOl
HLdm = -1.07 (±1.30) + 0.21 (±0.04) K3 
n = 9; s = 2.28; r = 0.905; F = 31.7; pcO.OOl
HLdm = 55.8 (±14.8) - 7.27 (±2.10) CMR 
n = 9; s = 3.26; r = 0.794; F = 12.0; pcO.Ol
HLdm = -2.20  (±2.87) + 0.16 (±0.06) Ks 
n = 9; s = 3.72; r = 0.719; F = 7.5; pcO.Ol
kdm = rate constant for N-demethylation attributable to CYP2B1 (nmol P450.min_1) 
HLdm = half-life for N-demethylation attributable to CYP2B1 (min.nmol P450"1) 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations listed in order of decreasing r value. 
n=9, full series of kdm values (section 6.2.2). 
n=7, "alkyl" series (section 2.12).
(1)
(2)
(3)
(4)
(5)
(6)
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Figure 6.5. Non-linear regression plot for half-life of formation of the N-desmethyl 
metabolites (HLdm) attributable to CYP2B1 with calculated molar refractivity (CMR). 
r = correlation coefficient of the polynomial regression.
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Table 6.7. Regression equations for N-dealkylation of the DME derivatives by
CYP2B1.
HLda = 2.55 (±0.72) + 0.25 (±0 .02) K4 
n = 5; s = 1.08; r = 0.986; F = 104; p<0.005
HLda = 27.7 (±3.50) - 7.19 (±1.23) log D 
n = 5; s = 1.85; r = 0.958; F = 33.7; p<0.01
HLda = -10.5 (±2 .66) + 0.34 (±0.05) Ks 
n = 5; s = 1.51; r = 0.972; F = 51.9; pcO.Ol
HLda = 0.03 (±1.63) + 0.22  (±0.04) K3 
n = 5; s = 1.88; r = 0.957; F = 32.3; pcO.Ol
HLda = 37.1 (±8.37) - 6.84 (±1.95) log P 
n = 5; s = 2.85; r = 0.897; F = 12.4; pcO.Ol
HLda = 49.0 (±12.8) - 0.03 (±0 .01) area 
n = 5; s = 3.05; r = 0.881; F = 10.5; pc0.05
HLda = 233 (±57.9) + 1344 (±345) qN 
n = 7; s = 2.95; r = 0.868; F = 15.2; pc0.05 (7)
HLda = half-life for N-dealkylation attributable to CYP2B1 (min.nmol P450'1) 
n = number of observations; s = standard error; r = correlation coefficient; F = variance 
ratio; p = level of significance of r value.
Equations listed in order of decreasing r value.
n=5, n-alkyl series.
n=7, "alkyl" series (section 2.12).
(1)
(2)
(3)
(4)
(5)
(6)
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relationships were seen for the n-alkyl series of compounds (n=5). A significant 
relationship was seen for decreasing half-life of N-dealkylation (HLda) and increasing 
log D for the n-alkyl series (equation 2, table 6.7). However, when the values of HLda 
for propenylDME and propynylDME were added to the correlation the significance of 
the relationship decreased (r = 0.706). A relationship was also seen between 
decreasing HLda and increasing log P (equation 5, table 6.7) but again the relationship 
did not hold when propenylDME and propynylDME were added (r = 0.293). The 
simple linear relationships seen for ti/2 and HLdm with the spectral binding parameters 
were also found for HLda (equations 1, 3 & 4, table 6.7). The equations indicate that 
increased binding affinity of the substrate led to a decrease in the value for HLda- A 
linear relationship was also found for HLda with the surface area of the DME 
derivatives (equation 6 , table 6.7). However, closer examination of the plot of this 
equation revealed that there was an optimum value of area for HLda of the n-alkyl 
series of compounds. A similar relationship was found when propenylDME was added 
to the non-linear regression equation and this led to the derivation of the following 
quadratic equation:
HLda = 1-78x10-4 (±1.39x10-5) area^ - 0.47 (±0.03) area + 310 (±20 .6) 
n = 6 s = 0.42 r = 0.998
Setting the derivative d(HLda)/d(area) equal to zero and solving the resulting equation 
for area yielded an optimum value of 1320(±21)Â2 for N-dealkylation of the DME 
derivatives by CYP2B1 in the phenobarbitone-induced rat microsomal fraction studied. 
However, when propynylDME was added to the plot of the above equation it proved to 
be an outlier. The plot for area against HLda, given in figure 6 .6 , illustrates this and 
indicates that propynylDME had a shorter HLda value than would be predicted from its 
area.
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Figure 6 .6 . Non-linear regression plot for half-life of formation of the N-desalkyl 
metabolite (HLda) attributable to CYP2B1 with the area of the molecule.
HLda is in units of min.nmol P450-1.
Area is in units of Â2.
r = correlation coefficient of the polynomial regression, ignoring propynylDME 
(compound 12).
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A simple linear relationship was found, which included all the compounds studied, that 
showed a dependence of HLda on the atomic partial charge on the nitrogen atom 
(equation 7, table 6.7). The equation indicates that as the charge on the nitrogen 
became more negative, the half-life for N-dealkylation decreased.
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DISCUSSION
Inhibition studies have been employed to determine the role that CYP2B1 plays in the 
metabolism of the series of DME derivatives. The same phenobarbitone-induced rat 
hepatic microsomal fraction was employed as was described in chapter 5 .
The anti-Parldnsonian agent orphenadrine was selected as an inhibitor of CYP2B1. A 
discrepancy between single dose and multiple dose pharmacokinetics of this compound 
first suggested the occurrence of product inhibition under multiple dosage conditions 
(Labout et al.t 1982). Research into the mechanism of inhibition by orphenadrine has 
shown that it exerts its effect by undergoing cytochrome P450-catalyzed metabolic 
conversions leading to a metabolic intermediate (MI) that complexes P450 and renders 
it inactive (Bast and Noordhoek, 1982). Subsequently, Reidy et al. (1989) provided 
evidence that orphenadrine inhibited CYP2B1 specifically.
It was necessary to determine the kinetics of inhibition by orphenadrine. In the absence 
of preincubation orphenadrine exerted mixed-type (competitive/non-competitive) 
inhibition of pentoxyresorufin O-depentylase activity with a Ki of 1.5jiM. After a 4min 
preincubation with NADPH-supplemented rat hepatic microsomal fraction a 10-fold 
lowering of the apparent inhibitor constant (Ki=0.15|iM) was observed and there was a 
change in the apparent inhibition kinetics to non-competitive. These findings confirm 
the work of Reidy et al. (1989) who reported mixed-type inhibition of pentoxyresorufin 
O-depentylase activity (Ki=3.8gM) by orphenadrine without preincubation, and a 
lowering of apparent Ki to 0.13|iM after a 4min preincubation as well as a change to 
apparent non-competitive kinetics.
Studies with felodipine, a substrate of CYP3A2 and CYP2C11 (Guengerich et al., 
1986), indicated that the activity of these isoenzymes was unaffected by preincubation 
with orphenadrine. In addition, preincubation of orphenadrine had no effect on
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ethoxyresorufin O-deethylase activity, which is regarded as a specific marker for 
CYP1A1 (Burke and Mayer, 1974). Again this supports the findings of Reidy et al. 
(1989) who reported that orphenadrine was a specific inhibtor of CYP2B1, and that 
preincubation did not affect this selectivity. Since then, evidence has been presented 
for complexation of CYP2C6 by orphenadrine (Reidy and Murray, 1990). CYP2C6- 
dependent progesterone 21-hydroxylase activity was inhibited after a 4min 
preincubation with orphenadrine with an apparent Ki of 151jiM. However, compared 
with a Ki of 0.13pM for inhibition of CYP2B1, orphenadrine may be regarded as 
much more selective for the latter isoenzyme.
A concentration of 5|iM orphenadrine was chosen for inhibition studies with the series 
of DME derivatives because this concentration gave 98% inhibition of pentoxyresorufin 
O-depentylase activity. Preincubation with orphenadrine led to a reduction in rate 
constant for metabolism for all the DME derivatives, except bisDME. This indicated 
that, apart from bisDME, all the compounds in the series were substrates for CYP2B1. 
The rate constants for metabolism attributable to CYP2B1 were calculated from the 
difference between the experimentally determined values for ke in the uninhibited and 
inhibited incubations. CYP2B1 was responsible for between 17 and 67% of the total 
metabolism of the DME derivatives in phenobarbitone-induced rat hepatic microsomal 
fraction. The activity of this isoenzyme accounted for most of the metabolism of the 
"alkyl" series of compounds (compounds 1-7), but it was clear that another isoenzyme 
was important in the metabolism of the compounds that had unsaturated substituent 
groups (i.e. aromatic or unsaturated alkyl). Even so, the compound with the highest 
value for k ^  was phenylDME so CYP2B1 is capable of metabolizing such substrates 
but it was not the most important isoenzyme involved in their metabolism in 
phenobarbitone-induced rat hepatic microsomal fraction.
The observation that phenylDME had the highest k ^  value may be due to interaction of 
its two aromatic systems (phenyl and 2,4-dichlorophenyl) with aromatic amino acids in
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the active site of CYP2B1. It has been postulated from model-building studies on 
CYP2B1 and CYP2B4 (Lewis et aL, 1987; Schwarze et a/., 1988) that two aromatic 
amino acids in the active site of these isoenzymes interact with complementary phenyl 
and secondary alkyl groups in the substrate and this lends them their substrate 
specificity. The decrease in k ^  in the series phenylDME>benzylDME>phenethylDME 
may be rationalized from the studies of Schwarze et al. (1988). They used a series of 
benzphetamine analogues to predict that a "butterfly-like" conformation, characterized 
by approximately parallel aromatic rings, was favoured for substrate binding and 
biotransformation by rabbit cytochrome P450 LM2 (CYP2B4). Substrate 1 (figure 
6.7) exists only in the stable butterfly-like conformation and had the highest binding 
affinity for CYP2B4. Substrate 3 (figure 6.7) cannot form this conformation and had a 
6-fold lower binding affinity than substrate 1. The authors suggested a binding site in 
which aromatic amino acids were incapable of interacting with the extended 
conformation of substrate 3. The series phenylDME, benzylDME, phenethylDME, 
bisDME is somewhat analogous structurally to the benzphetamine series and k2B 
decreased as the molecule became more extended. This suggests that bisDME is too 
extended to interact with CYP2B1 and hence was not metabolized by this isoenzyme.
Examination of the k^B values for the series revealed several trends which are probably 
best examined in the light of QSAR's obtained with various physico-chemical 
descriptors of the DME derivatives. All of the simple linear correlations seen for the 
metabolic half-life attributable to CYP2B1 were the same as those seen in the 
uninhibited incubation with phenobarbitone-induced rat hepatic microsomal fraction 
(section 5.4.1). This indicates that the structure-activity relationships seen in the 
uninhibited incubation were mainly attributable to the contribution of CYP2B1. This is 
not totally unexpected since CYP2B1 is one of the major isoenzymes present in 
phenobarbitone-induced rat hepatic microsomal fraction (Ryan et al., 1979), the other 
being CYP2B2. The substrate specificities of these two P450 isoenzymes are
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Figure 6.7. Structure of the benzphetamine derivatives used to derive an active site 
model for cytochrome P450 LM2 (CYP2B4).
Adapted from Schwarze et aL, 1988.
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overlapping, but the activity of CYP2B1 is much greater than CYP2B2 for the majority 
of substrates (Guengerich et aL, 1982).
Correlations were seen that indicated the importance of lipophilicity in the metabolism 
of the DME derivatives by CYP2B1. A relationship was seen between decreasing ti/2 
attributable to CYP2B1 and increasing log P, a measure of intrinsic lipophilicity. 
PropenylDME and propynylDME were outliers from the regression line. This has been 
noted previously in correlations of log P with ti/2 values (chapter 5) and may be 
attributable to inaccurate values of log P for these two compounds. A correlation was 
also seen between log D and ti/2 attributable to CYP2B1 and this emphasizes the 
importance of partitioning of the substrate into lipid as a determining factor in rate of 
metabolism. The relationships between ti/2 attributable to CYP2B1 and the spectral 
binding parameters Ks, Kg and K4 indicate the importance of the binding affinity of the 
substrate to the activity of CYP2B1. A similar dependence on lipophilicity and binding 
affinity was seen for the individual routes of N-demethylation and N-dealkylation of the 
DME derivatives.
In addition to simple linear analyses, two multilinear relationships were found for 
CYP2B1. The relationship involving log D and the atomic partial charge on the 
nitrogen atom (qx) is similar to the one seen in the uninhibited incubation (section 
5.4.1). A second multilinear equation related increasing k2B to the increasing inductive 
effect of the substituent group (a*) and decreasing positive charge on the a-carbon 
atom of this group. All the above changes (increasing a*, as well as decreasing qa_c 
and qx) relate an increased activity of CYP2B1 to an increased electron density on the 
nitrogen atom. This may be related to the mechanism of N-dealkylation which is 
thought to proceed by initial removal of a lone pair electron from the nitrogen atom. 
This step may be facilitated by an increased electron density on the nitrogen. Petzold et 
al. (1985) reported the importance of substituent-induced electron density changes on 
the nitrogen atom of a series of tertiary amines on the affinity of binding of these
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substrates to purified cytochrome P450 LM2 (CYP2B4). The appearance of this term 
in a kinetic relationship suggests that this phenomenon has relevance to the rate- 
determining step in the lengthy P450 reaction sequence.
The use of orphenadrine as a specific inhibitor of CYP2B1 enabled calculation of the 
rate constants for N-demethylation and N-dealkylation attributable to this isoenzyme for 
most of the DME derivatives. Both routes of metabolism were supported by CYP2B1 
for most of the compounds, except iso-propylDME and tert-butylDME which were 
only N-demethylated. The rates of both N-demethylation and N-dealkylation increased 
with increasing length of the n-alkyl series up to C4 . Both kdm and kda were 
decreased for n-pentylDME. A non-linear relationship described the change in kdm 
with calculated molar refractivity (CMR). Such relationships have been used to 
describe the dependence of biological response on lipophilicity (Hansch et al.t 1968). 
Devinsky and Gorrod (1987) also found that for a series of long chain N,N- 
dimethylalkylamines their rate of N-oxidation was related parabolically to lipophilicity 
as well as increasing chain length. This type of relationship indicates that an optimum 
value for the physicochemical parameter involved exists. An optimum value of CMR 
(7.45) for metabolism of the DME derivatives by CYP2B1 was calculated.
For the n-alkyl series, the change in N-dealkylation rate was described by a parabolic 
relationship with the surface area of the DME derivatives. An optimum value of 
1320Â2 for metabolism of the DME derivatives by CYP2B1 was calculated. Shape 
parameters have been used before to characterize the spatial requirements of the binding 
sites of P450 isoenzymes (Lewis et al., 1987). The authors suggested that the 
area/depth2 ratio could be employed to differentiate between the substrates of the 
CYP1A and CYP2B subfamilies. They found that substrates of CYP1A had larger 
area/depth2 ratios than those of CYP2B. The calculation of optimum values of CMR 
and area for metabolism of the DME derivatives by CYP2B1 implies that the active site 
of this isoenzyme is constrained and that CYP2B1 is not capable of metabolizing very
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large molecules. Some support for this comes from the observation that bisDME 
(CMR=10.16; area=1585Â2) was not metabolized by CYP2B1. In addition, the 
compound with the highest value of kdm (n-butylDME) has a CMR value very close to 
the optimum (7.44).
When HLda values for propenylDME and propynylDME were added to the regression 
plot with area it was found that propynylDME was an outlier. This indicated that this 
compound was N-dealkylated more efficiently than would be predicted from the area of 
the molecule, so some other factor must be affecting its rate of N-dealkylation. One 
possibility is the charge on the a-carbon atom (qa-c) of the propynyl substituent 
group. PropynylDME has a high qa .c compared with the rest of the series (see 
appendix, table 7). The rate of metabolism of the DME derivatives by CYP2B1 was 
related to qa-c by a multilinear equation (section 6.3.1) and it has been suggested that 
an increased positive charge on the a-carbon atom causes an increased rate of N- 
dealkylation by increasing the electron density of the nitrogen atom. Since a simple 
linear relationship was seen relating decreased HLda attributable to CYP2B1 to 
increased negativity of the nitrogen atom it is possible that the high value of qa-c for 
propynylDME facilitates removal of the propynyl substituent
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CHAPTER 7
Metabolism of the DME derivatives attributable to CYP3A determined by the 
use of a dihydropyridine derivative as an inhibitor in phenobarbitone-induced
rat hepatic microsomal fraction.
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SUMMARY
An inhibitor (UK-122,802) has been designed that causes mechanism-based inhibition 
of CYP3A. UK-122,802 was specific for CYP3A in dexamethasone-induced female 
rat hepatic microsomal fraction but interacted with CYP2B1 in phenobarbitone-induced 
rat hepatic microsomal fraction. This cross-reaction has been corrected for and the rate 
constants for metabolism attributable to CYP3A (Iqa) in phenobarbitone-induced rat 
hepatic microsomal fraction have been determined.
All of the DME derivatives were substrates for CYP3 A . No correlation was seen with 
lipophilicity for rate of metabolism. MethylDME had the lowest kgA value of the series 
and was an outlier from the regression plots with steric descriptors of the DME 
derivatives (CMR, area, volume). It is speculated that this compound is too small to 
interact efficiently with the active site of CYP3A. No constraint on the size of the 
molecule for metabolism by CYP3A was seen for the series of DME derivatives.
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INTRODUCTION
The CYP3A subfamily is considered to be important for human drug metabolism and is 
thought to be responsible for some clinically observed drug interactions with, for 
example, cyclosporine (Kronbach et aL, 1988). Consequently, structure-activity 
relationship studies for CYP3A are important to provide an insight into its substrate 
selectivity.
CYP3A metabolizes a wide range of structurally diverse substrates (Smith and Jones, 
1992) mainly carrying out aliphatic oxidation and N-dealkylation at widely differing 
steric positions. As yet no specific inhibitor of CYP3A has been reported that is 
specific and effective at low concentrations (ie. low jiM Ki values). Ketoconazole is 
effective as an inhibitor of CYP3A (Ki<l|iM) in human and rat hepatic microsomal 
fractions, but also causes some inhibition of CYP2C (Maurice et al..y 1992; Houston et 
al.y 1988). The observation that dihydropyridines are substrates for CYP3A 
(Guengerich et aL, 1986) led to the design of an inhibitor (UK-122,802) based on a 
dihydropyridine template (Dr. B.C. Jones, personal communication). 
Dihydropyridines undergo a single electron oxidation at the nitrogen atom with the 
subsequent release of a radical from carbon-4 to yield the corresponding pyridine 
(Auguste et aL, 1982). Incorporation of a cyclopropyl substituent on the nitrogen atom 
could, following the single electron transfer to CYP3A, produce a cation radical which 
irreversibly deactivates this isoenzyme (section 1.4.3). The structure of UK-122,802 
is given in figure 7.1.
This chapter describes preliminary investigations into the potency and selectivity of 
UK-122,802. The inhibitor was then utilized to determine the contribution that CYP3A 
made to the metabolism of the series of DME derivatives in phenobarbitone-induced rat 
hepatic microsomal fraction. First order rate constants attributable to CYP3A have been 
calculated and QSAR's employed to determine any dependence of the activity seen on
164
CHLCO
CHCH
v Dihydropyridine template- 
'  substrate for CYP3A
Cyclopropyl substituent- 
suicide inhibitor of P450
Figure 7.1. Rationale for design of UK-122,802 as a mechanism-based inhibitor of 
CYP3A.
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physico-chemical descriptors of the DME series. In addition, the contribution of 
CYP3A to the routes of N-demethylation and N-dealkylation was determined for most 
members of the series.
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RESULTS
7.1. Inhibition of CYP3A.
7.1.1. Characterization of UK-122,802 inhibition in dexamethasone- 
induced hepatic microsomal fraction.
Characterization of UK-122,802 as an inhibitor of CYP3A activity was carried out at 
Pfizer Central Research (Kent, UK) by Miss R.C. Halliday.
Preliminary studies were carried out using female rat hepatic microsomal fraction 
obtained following pretreatment with dexamethasone (section 2 .2) because this 
compound preferentially induces CYP3A in female rat (Heuman et al., 1982). The 
dihydropyridine felodipine was chosen as the marker substrate for CYP3A activity.
Initially, the kinetics of inhibition by UK-122,802 without preincubation were 
determined. UK-122,802 (2mM in methanol) was added to the incubation system 
containing felodipine (l|iM final concentration) and the disappearance of substrate was 
monitored as described in section 2.8. The half-life for metabolism of felodipine was 
calculated (section 2.7) with varying concentrations of inhibitor (0.05-100|iM) and this 
enabled the construction of a plot for determination of the IC50 (figure 7.2), although 
this value could not be calculated because the top concentration of inhibitor only caused 
a 25% reduction in control enzyme activity.
To determine if UK-122,802 was causing mechanism-based inhibition of CYP3A, 
felodipine oxidase activity was calculated after preincubation with the inhibitor. UK-
122,802 (0.05-100pM) was incubated at 37°C for 15min in the NADPH-supplemented 
incubation system (section 2.7) prior to addition of felodipine (IjiM). The half-life for 
disappearance of substrate was calculated as described in section 2.7. The plot for 
determination of IC50 (figure 7.2) shows clearly that preincubation with UK-122,802
167
100-1
80-
60-
40 -
T fT 'llj----
100
TTTT]
1000.01 .1 1 10
[UK-122,802]
Figure 7.2. Plot of log UK-122,802 concentration against felodipine oxidase activity 
remaining (% control) for determination of IC50, showing the effect of preincubation, 
(o) No preincubation 
(•) 15min preincubation
[UK-122,802] is the concentration of inhibitor (pM).
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caused a decrease in IC50 to 6.9|iM, suggesting that inhibition was mechanism-based.
In addition, it was determined that in dexamethasone-induced female rat hepatic 
microsomal fraction the half-life for disappearance of felodipine was increased from 
Smin.nmol P450-1 (ke=0.23 nmol P450.min-1) in the absence of UK-122,802, to 
>200min.nmol P450"1 (ke<0.003 nmol P450.min-1) after a 15min preincubation with 
UK-122,802 (5pM).
7.1.2. Specificity of inhibition by UK-122,802.
The specificity of UK-122,802 as an inhibitor of CYP3A was assessed by Miss R.C. 
Halliday at Pfizer Central Research (Kent, UK).
Probe substrates were used to determine the effect of UK-122,802 (IQjjM) on the 
activity of various P450 isoenzymes (table 7.1). UK-122,802 did not inhibit the 
activities of CYP1A, CYP2B, CYP2D or CYP2E but exhibited apparent non­
competitive inhibition of CYP3A (Ki = 28|iM).
It was concluded that in dexamethasone-induced rat hepatic microsomal fraction, UK-
122,802 was a specific mechanism-based inhibitor of CYP3A activity (Dr. B.C. Jones, 
personal communication).
7.1.3. Characterization of UK-122,802 inhibition in phenobarbitone- 
induced hepatic microsomal fraction.
The potential of UK-122,802 to inhibit felodipine oxidase activity in phenobarbitone- 
induced male rat hepatic microsomal fraction (section 2.2) was investigated. After 
examining data obtained in dexamethasone-induced rat hepatic microsomal fraction 
(section 7.1.1) it was decided that the inhibitor should be preincubated for 15min prior 
to addition of the substrate.
169
Table 7.1. Effect of UK-122,802 (lOpM) on the activity of several P450 
isoenzymes.
Cytochrome P450a Probe substrate Inhibition
CYP1A Ethoxyresorufin No interaction
CYP2B Pentoxyresorufin No interaction
CYP2D Codeine No interaction 
(21% inhibition at 100|iM)
CYP2E 4-nitrophenol No interaction
CYP3A Felodipine Non-compedtive inhibition 
(Kl = 28|iM)
a = nomenclature for cytochrome P450 according to Nebert et al., 1993.
Specificity of probe substrates obtained from Burke and Mayer, 1974; Lubet et al., 
1985; Ladona et al., 1991; Guengerich et al., 1986; Koop, 1986.
170
UK-122,802 (1-lOjiM) was incubated with the NADPH-supplemented incubation 
system described in section 2.7. After 15min felodipine (IjiM) was added and samples 
were removed at appropriate time points for determination of the first order metabolic 
rate constant (ke) (section 2.8). Felodipine had a ke value of 0.88nmol P450.mhr1 in 
the uninhibited incubation system. Preincubation with 1, 5 and 10|iM UK-122,802 
caused a progressive decrease in ke (figure 7.3). UK-122,802 (lOpM) caused a 
decrease in ke value to 0.06nmol P450.min_1 and the remaining activity was only 7% 
of control. A concentration of IOjjM  was chosen for subsequent studies with UK-
122,802 in phenobarbitone-induced hepatic microsomal fraction.
7.2. Inhibition of metabolism of DME derivatives by UK-122,802.
The effect of preincubation with UK-122,802 (10|iM) on the rate of metabolism of the 
DME derivatives was determined using the same phenobarbitone-induced rat hepatic 
microsomal fraction as was described in chapter 5, and that had already been 
characterized for CYP2B1 activity (chapter 6).
The incubation system described in section 2.7 was employed. UK-122,802 (lOjiM) 
was incubated for 15min at 370C, in the presence of an NADPH-generating system, 
prior to addition of the substrate (IjiM). Timed samples were removed at appropriate 
intervals and the first order rate constants for metabolism (ke) of the DME derivatives 
calculated (section 2.7). An example of the effect of preincubation with UK-122,802 
on the metabolic rate constant is given for n-propylDME in figure 7.4. The value for ke 
in the uninhibited incubation was 0.68nmol P450.min"1 and this was reduced to 
0.32nmol P450.min"1 after preincubation with UK-122,802. All of the metabolic rate 
constants determined in the UK-122,802-inhibited incubation are summarized in table
7.2.
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Figure 7.3. Effect of preincubation with UK-122,802 on the first order metabolic
rate constant for felodipine in phenobarbitone-induced rat hepatic microsomal fraction.
(•) Uninhibited incubation, ke = 0.91 nmol P450.min-1
(o) IpM UK-122,802, ke = 0.52 nmol P450.min-1
(♦) 5gM UK-122,802, ke = 0.35 nmol P450.min-1
(+) lOpM UK-122,802, ke = 0.06 nmol P450.min-1
Log C is the logarithm of felodipine concentration (jiM).
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Figure 7.4. Semilogarithmic plot for the calculation of metabolic rate constants for 
metabolism of n-propylDME before and after inhibition with UK-122,802 (10|iM).
(•) Uninhibited incubation, ke = 0.68(±0.013)nmol P450.min_l (r = 0.998)
(o) Inhibited incubation, ke = 0.32(±0.007)nmol P450.min_1 (r = 0.999)
Log C is the logarithm of n-propylDME concentration (pM).
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Table 7.2. Calculation of apparent rate constants for metabolism of the DME
derivatives attributable to CYP3A in phenobarbitone-induced rat hepatic microsomal
fraction.
Substituent kinhib ke k0bs
1. Methyl 0.067 ± 0.003 0.12 ± 0.005 0.055 ± 0.008
2. Ethyl 0.090 ± 0.005 0.25 ± 0.009 0.155 ±0.014
3. n-Propyl 0.316 ±0.007 0.68 ± 0.013 0.364 ± 0.020
4. iso-Propyl 0.157 ±0.002 0.27 ± 0.008 0.113 ±0.010
5. n-Butyl 0.583 ±0.014 1.26 ± 0.025 0.677 ± 0.039
6. tert-Butyl 0.134 ±0.007 0.29 ± 0.005 0.156 ±0.012
7. n-Pentyl 0.516 ±0.014 1.21 ± 0.063 0.694 ± 0.077
8. Phenyl 8.544 ± 0.622 13.4 ±0.190 4.856 ± 0.810
9. Benzyl 1.986 ±0.016 3.77 ± 0.035 1.784 ±0.051
10. Phenethyl 0.723 ± 0.037 1.70 ± 0.086 0.977 ± 0.123
11. Propenyl 0.585 ± 0.018 1.80 ± 0.046 1.214 ± 0.064
12. Propynyl 0.995 ±0.018 2.69 ± 0.051 1.695 ± 0.069
13. Bis 2.916 ± 0.050 3.28 ± 0.102 0.364 ±0.152
kinhib = rate constants for metabolism of the DME derivatives in phenobarbitone- 
induced hepatic microsomal fraction after inhibition with UK-122,802 (IOjjM). Values 
were derived from the slope of the semilogarithmic plot of substrate concentration 
against time. Linear regression analysis yielded the standard error of the slope from 
which the standard error for kinhib was derived.
ke = rate constants for metabolism of the DME derivatives in phenobarbitone-induced 
hepatic microsomal fraction (section 5.2.1).
kobs = apparent rate constants for metabolism of the DME derivatives attributable to 
CYP3A derived using equation 7.1.
All rate constants for metabolism are in units of nmol P450.min-1.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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7.2.1. Calculation of first order metabolic rate constants attributable to 
CYP3A.
The metabolic rate constants attributable to CYP3A (kobs) were calculated as described 
in section 6.2.1 using the following equation:
kobs = ke - kinhib - equation 7.1.
where, ke and kinhib are the rate constants for metabolism in the uninhibited and 
inhibited incubations, respectively. The metabolic rate constant attributable to CYP3A 
is represented by k0bs-
The ke values for the DME derivatives were determined in section 5.2.1 and are given 
in table 7.2, as are the calculated values for kobs-
Subsequent to performing all of the inhibition studies with UK-122,802 it was found 
that this compound was not specific for CYP3A in phenobarbitone-induced hepatic 
microsomal fraction. The effect of preincubation with UK-122,802 (lOjiM) on the rate 
of pentoxyresorufin O-depentylase activity, a marker substrate for CYP2B1 (Lubet et 
al., 1985), was investigated. Pentoxyresorufin O-depentylase activity was monitored 
using the method described in section 2.6.2. UK-122,802 (0.1-100|iM) was added to 
the reaction mixture and incubated with lOjil NADPH (50mM) at 37°C. After 15min, 
pentoxyresorufin (2.5pM) was added and the rate of pentoxyresorufin O-depentylase 
activity determined. A plot of log inhibitor concentration against % pentoxyresorufin 
'O-depentylase activity remaining enabled the calculation of an IC50 value of 8(±0.6)|iM 
(figure 7.5). It was determined from the sigmoid curve that UK-122,802 (IOjjM) gave 
62% inhibition of pentoxyresorufin O-depentylase activity in phenobarbitone-induced 
hepatic microsomal fraction.
The additional, partial inhibition of CYP2B1 as well as CYP3A in phenobarbitone- 
induced hepatic microsomal fraction was corrected for in the following manner. It was
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Figure 7.5. Plot of log UK-122,802 concentration QiM) against pentoxyresorufin O- 
depentylase (PROD) activity remaining (% control) for determination of IC5 0 .
[UK-122,802] is the concentration of inhibitor (pM).
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known that 62% of CYP2B1 activity had been inhibited by UK-122,802. Thus the 
calculated values of kobs were attributable to CYP3A plus a fraction of CYP2B1 
activity:
kobs = k3A + 0.62k2B - equation 7.2.
where, k0bs is the apparent rate constant for metabolism by CYP3A and k^B is the 
metabolic rate constant attributable to CYP2B1. Equation 7.2 was used to correct the 
values of kobs f°r 62% inhibition of CYP2B1 activity thus yielding the metabolic rate 
constant attributable to CYP3A alone (kga).
The k2B values for the DME derivatives were determined in section 6.2.1 and are given 
in table 7.3, as are the corrected values for kgA-
CYP3A was responsible for from 4% (methylDME) to 50% (propenylDME) of the total 
metabolism of the DME derivatives (table 7.3). There was a wide range of kgA values 
with phenylDME being the most rapidly metabolized (kgA=2.77nmol P450.min-1) and 
methylDME having the lowest value for kgA of 0.005nmol P450.min-1. The rate 
constants for metabolism attributable to CYP3A increased with increasing n-alkyl chain 
length. Increasing the number of branches in the alkyl substituent from zero 
(methylDME) to one (ethylDME) caused a 14-fold increase in kgA. The introduction of 
two (iso-propylDME) or three (tert-butylDME) branches led to a decrease in kgA 
compared with ethylDME. Increasing the degree of unsaturation from fully saturated 
(n-propylDME) to fully unsaturated (propynylDME) caused a 12-fold increase in kgA. 
The introduction of an aromatic system into the substituent group (phenylDME) led to a 
dramatic increase in kgA relative to methylDME. As the aromatic ring of the substituent 
group became further away from the nitrogen atom (benzylDME, phenethylDME, 
bisDME), the value for kgA decreased.
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Table 7.3. Correction of apparent metabolic rate constants attributable to CYP3A for
inhibition of CYP2B1 by UK-122,802.
Substituent kobs k2B kgA %contribution
1. Methyl 0.055 0.08 0.005 ± 0.001 4
2. Ethyl 0.155 0.14 0.069 ± 0.014 28
3. n-Propyl 0.364 0.43 0.097 ±0.020 14
4. iso-Propyl 0.113 0.14 0.026 ± 0.010 10
5. n-Butyl 0.677 0.87 0.138 ±0.039 11
6. tert-Butyl 0.156 0.18 0.044 ± 0.012 15
7. n-Pentyl 0.694 0.55 0.353 ± 0.077 29
8. Phenyl 4.856 3.36 2.77 ±0.810 21
9. Benzyl 1.784 0.65 1.381 ±0.051 37
10. Phenethyl 0.977 0.34 0.766 ± 0.123 45
11. Propenyl 1.214 0.50 0.904 ± 0.064 50
12. Propynyl 1.695 0.82 1.187 ± 0.069 44
13. Bis 0.364 0 0.364 ±0.152 11
kobs = apparent rate constants for metabolism of the DME derivatives attributable to
CYP3A in phenobarbitone-induced hepatic microsomal fraction.
k2B = rate constants for metabolism of the DME derivatives attributable to CYP2B1 in
phenobarbitone-induced hepatic microsomal fraction (section 6.2.1).
kgA = rate constants for metabolism (±sem) of the DME derivatives attributable to
CYP3A derived from equation 7.2.
% contribution = (kgA/ke)xlOO, contribution of CYP3A to overall metabolism.
All rate constants are in units of nmol P450.min-1.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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7.2.2. Quantification of metabolites of the DME derivatives.
Metabolites of the DME derivatives formed in the inhibited incubation system were 
identified and quantified as described in section 2.7.
The rate constants for formation of the N-desmethyl and N-desalkyl metabolites (kym 
and kda, respectively) of the DME derivatives in the UK-122,802-inhibited incubation 
are given in table 7.4. It was not possible to quantify the metabolites for phenylDME 
or phenethylDME. The former compound was rapidly metabolized and consequently 
any primary metabolites formed were converted very quickly to secondary metabolites 
(see section 3.3) and the metabolites of the latter compound co-chromatographed with 
the inhibitor.
The apparent rate constants for formation of metabolites attributable to CYP3A were 
calculated from the difference between the experimentally determined values in the 
uninhibited incubation (table 5.4) and the inhibited incubation (table 7.4) as described 
in section 6.2.2. The apparent values of kym and kda attributable to CYP3A are given 
in table 7.5. These values were then corrected for 62% inhibition of CYP2B1 activity 
by UK-122,802, as described in section 7.2.1.
(kdm)obs = (kdm)3A + 0.62(kdm)2B - equation 7.3.
where, (kdm)obs is the apparent rate constant for formation of the N-desmethyl 
metabolite by CYP3A and (k(im)2B is the rate constant for N-demethylation by 
CYP2B1. Equation 7.3 was used to correct the values of (kdm)obs for 62% inhibition 
of CYP2B1 activity thus yielding the rate constant for N-demethylation attributable to 
CYP3A alone - (kdm)3A-
The values of kdm and kda attributable to CYP2B1 were determined in section 6.2.2 
and were used to calculate the values of kdm and kda attributable to CYP3A which are 
given in table 7.6.
179
Table 7.4. Rate constants for formation of metabolites in phenobarbitone-induced
hepatic microsomal fraction after inhibition with UK-122,802.
Substituent Ratio
(kdm’kda)
kdm kda
1. Methyl 1.00 0.034 ± 0.002 0.034 ± 0.002
2. Ethyl 1.77 ± 0.04 0.058 ± 0.003 0.032 ± 0.002
3. n-Propyl 2.90 ± 0.09 0.235 ± 0.007 0.081 ± 0.004
4. iso-Propyl * 0.157 ± 0.002 0
5. n-Butyl 2.37 ±0.11 0.410 ± 0.015 0.173 ±0.009
6 . tert-Butyl * 0.134 ±0.007 0
7. n-Pentyl 1.09 ± 0.05 0.269 ± 0.013 0.247 ± 0.012
8. Phenyl n.d. n.d. n.d.
9. Benzyl 0.63 ± 0.05 0.768 ± 0.042 0.183 ±0.009
10. Phenethyl n.d. n.d. n.d.
11. Propenyl 2.19 ±0.06 0.402 ± 0.015 0.183 ±0.009
12. Propynyl 0.82 ± 0.03 0.448 ± 0.017 0.547 ± 0.019
13. Bis 0.23 ± 0.01 0.545 ± 0.028 2.371 ± 0.060
kdm = rate constant for N-demethylation 
kda = rate constant for N-dealkylation
Both rate constants are in units of nmol P450.mhr1 and were calculated from kinhib 
using the following equation:
kinhib = kdm + kda 
* = compound only N-demethylated. 
n.d. = not determined.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine.
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Table 7.5. Apparent rate constants for formation of metabolites attributable to CYP3A
determined in phenobarbitone-induced hepatic microsomal fraction.
Substituent
Apparent
kdm
Apparent
kda
1. Methyl 0.029 ± 0.002 0.029 ± 0.002
2. Ethyl 0.093 ± 0.012 0.062 ± 0.009
3. n-Propyl 0.257 ± 0.027 0.108 ±0.018
4. iso-Propyl 0.113 ±0.010 0
5. n-Butyl 0.510 ± 0.044 0.166 ±0.026
6 . tert-Butyl 0.156 ±0.012 0
7. n-Pentyl 0.440 ± 0.068 0.249 ± 0.055
8. Phenyl n.d. n.d.
9. Benzyl 1.601 ±0.133 0.180 ±0.116
10. Phenethyl n.d. n.d.
11. Propenyl 0.831 ± 0.070 0.383 ± 0.046
12. Propynyl 0.507 ± 0.080 1.190 ±0.095
13. Bis 0 0.385 ±0.190
apparent kdm = rate constant for N-demethylation 
apparent kja = rate constant for N-dealkylation 
Both rate constants are in units of nmol P450.min-1 
n.d. = not determined
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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Table 7.6. Rate constants for formation of metabolites attributable to CYP3A
determined in phenobarbitone-induced hepatic microsomal fraction.
No. Substituent kdm kda Ratio
(kdm'kda)
1 Methyl 0.003 ± 0.001 0.003 ± 0.001 1.00
2 Ethyl 0.047 ± 0.012 0.022  ± 0.009 2.14
3 n-Propyl 0.073 ± 0.027 0.026 ± 0.009 2.81
5 n-Butyl 0.101 ± 0.044 0.035 ± 0.015 2.89
7 n-Pentyl 0.202  ± 0.068 0.145 ± 0.055 1.39
1 Methyl 0.003 ± 0.001 0.003 ± 0.001 1.00
2 Ethyl 0.047 ± 0.012 0.022 ± 0.009 2.14
4 iso-Propyl 0.026 ± 0.010 0 *
6 tert-Butyl 0.043 ± 0.012 0 *
3 n-Propyl 0.073 ± 0.027 0.026 ± 0.009 2.81
11 Propenyl 0.563 ± 0.070 0.341 ± 0.046 1.65
12 Propynyl 0.354 ± 0.080 0.832 ± 0.095 0.43
8 Phenyl n.d. n.d. n.d.
9 Benzyl n.d. n.d. n.d.
10 Phenethyl n.d. n.d. n.d.
13 Bis 0 0.385 ±0.190 +
kdm -  rate constant for N-demethylation 
kda = rate constant for N-dealkylation
Both rate constants are in units of nmol P450.min-1 and were calculated from equation
7.3.
* = compound only N-demethylated; + = compound only N-dealkylated 
n.d. = not determined
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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No values of kdm or k^a for phenylDME, benzylDME or phenethylDME attributable to 
CYP3A could be calculated because these values had not been determined for CYP2B1 
(section 6.2.2). All the remaining DME derivatives were N-demethylated and N- 
dealkylated by CYP3A, except for iso-propylDME, tert-butylDME and bisDME. The 
former two compounds were only N-demethylated and bisDME underwent N- 
dealkylation exclusively. The rate of formation of the N-desmethyl metabolite 
attributable to CYP3A increased from Ci to C5 for the n-alkyl substituents. The 
increase in kda was not as marked from C1-C4 but a dramatic increase in this value was 
seen for pentylDME compared with n-butylDME. Increasing the degree of unsaturation 
from fully saturated (n-propylDME) to fully unsaturated (propynylDME) caused an 
increase in kda and N-dealkylation was the predominant pathway for propynylDME.
7.3. Structure-activity relationships derived for metabolism of the DME 
derivatives by CYP3A.
Quantitative structure-activity relationships (QSAR's) were sought for the biological 
data obtained for the DME derivatives attributable to CYP3A. Both kgA and ti/2 were 
compared with various hydrophobic, spectral and steric descriptors of the DME 
derivatives as described in section 2.12. The correlation with the higher r value is 
presented (see section 5.4).
7.3.1. Relationships obtained for kgA.
Initially, simple linear relationships for the biological data with various physico­
chemical, molecular mechanical and spectral parameters of the DME derivatives were 
searched for. For this purpose the metabolic half-life values attributable to CYP3A 
were derived from kgA, as described in section 2.7. The values for kgA and 
corresponding metabolic half-life are summarized in table 7.7. All the regression 
equations found for the biological data attributable to CYP3A are given in table 7.8.
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Table 7.7. Summary of metabolic rate constant and half-life values attributable to
CYP3A.
Substituent k3A Half-life
1. Methyl 0.005 ± 0.001 137 ± 21
2. Ethyl 0.069 ±0.014 10.0 ± 1.7
3. n-Propyl 0.097 ± 0.020 7.10 ± 1.2
4. iso-Propyl 0.026 ± 0.010 26.7 ± 7.4
5. n-Butyl 0.138 + 0.039 5.00 ± 1.1
6 . tert-Butyl 0.044 ± 0.012 15.8 ± 3.4
7. n-Pentyl 0.353 ± 0.077 2.00 ± 0.4
8 . Phenyl 2.77 ± 0.810 0.25 ±0.06
9. Benzyl 1.381 ±0.051 0.52 ±0.02
10. Phenethyl 0.766 ± 0.123 0.90 ±0.12
11. Propenyl 0.904 ± 0.064 0.77 ±0.05
12. Propynyl 1.187 ±0.069 0.58 ±0.04
13. Bis 0.364 ± 0.152 1.90 ±0.56
kgA = metabolic rate constant attributable to CYP3A (nmol P450.min'1) 
Half-life = min.nmol P450'1. Values derived from kgA (section 2.7)
Note: after calculation of ti/2, values of kgA were expressed to 2 decimal places.
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
Table 7.8. Regression equations for metabolism of the DME derivatives by CYP3A.
ti/2 = 39.5 (±1.47) - 0.03 (±0.001) area
n = 4 ;s  = 0.26; r = 0.998; F = 518; p<0.005 (1)
ti/2 = 47.1 (±1.91) - 5.69 (±0.26) CMR
n = 4; s = 0.27; r = 0.998; F = 463; p<0.005 (2)
ti/2 = 44.0 (±1.80) - 0.16 (±0.01) volume
n = 4; s = 0.28; r = 0.998; F = 450; p<0.005 (3)
k3A = -0.89 (±0.17) + 0.08 (±0.01) length
n = 7; s — 0.05; r = 0.938; F = 36.3; p<0.005 (4)
k3A = first order metabolic rate constant attributable to CYP3A (nmol P450.min-1)
ti/2 = half-life of metabolism attributable to CYP3A (min.nmol P450-1)
n = number of observations; s = standard error; r = correlation coefficient; F = variance
ratio; p = level of significance of r value.
n=4, n-alkyl series
n=7, "alkyl series (section 2.12).
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A relationship was found for the "alkyl" series of compounds (section 2.12) that was 
significant at the 0.5% level (r>0.90). Equation 4 (table 7.8) indicates that kgA 
increased as the length of the molecule increased. No relationships were found for the 
kgA values of the full series of DME derivatives.
Initially, there appeared to be no correlations for metabolic half-life attributable to 
CYP3A with any of the physico-chemical parameters of the DME derivatives. 
However, examination of the plots for molar refractivity (CMR), area and volume 
indicated some dependence of half-life on these parameters. The n-alkyl series of 
compounds from C2 to C5 (ethylDME, n-propylDME, n-butylDME, pentylDME) 
showed an excellent linear dependence of half-life attributable to CYP3A on CMR, area 
and volume (equations 1-3, table 7.8). MethylDME was an outlier from all these plots, 
as is illustrated in figure 7.6a which shows the plot of half-life against CMR. This 
indicates that methylDME was metabolized less efficiently by CYP3A than would be 
predicted from its size. For the rest of the n-alkyl series, half-life increased with 
increasing size of the molecule as measured by CMR, area and volume.
Examination of the plots of half-life attributable to CYP3A for the full series against 
CMR, area and volume indicated that methylDME was again an outlier. The plot for 
CMR is given in figure 7.6b. Omitting methylDME from the correlation gave a poor 
correlation coefficient (r = 0.402), but the plot is interesting because it indicates that the 
difference in half-life between methylDME and the rest of the series may be attributable 
to its difference in size.
Multilinear analysis did not yield any equations that were a significant improvement on 
the simple linear relationships.
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Figure 7.6. Regression plots of molar refractivity (CMR) with the half-life of 
metabolism attributable to CYP3A for (a) the n-alkyl and (b) the full series of DME 
derivatives, illustrating that methylDME (ti/2=137min.nmol P450-1; CMR=6.05) was 
an outlier.
Half-life values are in units of min.nmol P450"l. 
r = correlation coefficient of the linear regression, ignoring methylDME.
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7.3.2. Relationships obtained for rate of individual metabolic routes.
Analysis of the rate constants for N-demethylation and N-dealkylation (kdm and kda, 
respectively) yielded one simple linear relationship:
kdm = -0.50 (±0.07) + 0.05 (±0.01) length 
n=7; s=0.02; r=0.969; F=77; p<0.001
The correlation related increasing kdm to increasing length of the molecule for the 
"alkyl" series of compounds (section 2 .12).
7.4. Inhibition of metabolism of the DME derivatives by UK-122,802 
and orphenadrine.
In order to assess the accuracy of the correction factor used to allow for 62% inhibition 
of CYP2B1 by UK-122,802, a study was performed to determine the effect of 
orphenadrine and UK-122,802 together on metabolism of the DME series.
The standard incubation system described in section 2.7 was employed. UK-122,802 
(IOjiM) was incubated for 15min at 37°C with phenobarbitone-induced hepatic 
microsomal fraction in the presence of an NADPH-generating system. Orphenadrine 
(5|iM) was added to the incubation after llm in so that it had a preincubation time of 
4min prior to addition of the substrate (section 6.2). When the substrate (IjiM) had 
been added, timed samples were removed at appropriate intervals for determination of 
the first order rate constants of metabolism (section 2.7). All of the metabolic rate 
constants determined in the inhibited incubation (kinhib) are given in table 7.9.
The values of kinhib are attributable to P450 isoenzymes that remain active after 
inhibition of CYP3A and CYP2B1. Therefore, the rate constants for metabolism 
attributable to the inhibited isoenzymes may be calculated from the following equation:
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Table 7.9. Experimental and calculated rate constants for metabolism of the DME
derivatives attributable to CYP3A and CYP2B1.
Substituent kinhib kx-obs kx-calc
1. Methyl 0.049 ± 0.003 0.07 ± 0.008 0.09
2. Ethyl 0.051 ±0.005 0.20 ±0.014 0.21
3. n-Propyl 0.083 ± 0.005 0.54 ±0.018 0.53
4. iso-Propyl 0.134 ±0.004 0.14 ±0.013 0.17
5. n-Butyl 0.493 ± 0.028 0.77 ± 0.053 1.01
6 . tert-Butyl 0.138 ±0.005 0.15 ± 0.010 0 .22
7. n-Pentyl 0.525 ±0.018 0.69 ± 0.081 0.9
8 . Phenyl n.d. n.d. 6.13
9. Benzyl 2.423 ± 0.083 1.35 ±0.118 2.03
10. Phenethyl 0.590 ± 0.037 1.11 ±0.123 1.11
11. Propenyl 0.415 ± 0.028 1.39 ± 0.074 1.40
12. Propynyl 1.032 ± 0.083 1.66 ±0.134 2.01
13. Bis 3.132 ±0.008 0.15 ±0.110 0.36
kinhib = rate constants for metabolism of the DME derivatives after inhibition with 
orphenadrine (5pM) and UK-122,802 (IOjjM). Values were derived from the slope of 
the semilogarithmic plot of substrate concentration against time. Linear regression 
analysis yielded the standard error of the slope which was used to assess the accuracy 
° f  kinhib-
kx-obs = experimentally determined rate constants for metabolism attributable to 
CYP3A and CYP2B1 derived from equation 7.4.
kx-calc = sum of the rate constants for metabolism attributable to CYP3A and CYP2B1 
derived from equation 7.5.
All rate constants are in units of min.nmol P450"1 
n.d. = not determined
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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ke = kinhib + kx-obs - equation 7.4.
where, ke and kinhib are the metabolic rate constants in the uninhibited and inhibited 
incubations, respectively. The metabolic rate constant attributable to CYP3A and 
CYP2B1 is represented by kx-obs-
The values for ke were determined in section 5.2.1 and are given in table 7.2. The 
calculated values of kx-obs are given in table 7.9 and represent the experimentally 
determined rate constants for metabolism attributable to CYP3A and CYP2B1.
The equivalent calculated values for kx, kx-calc, (i.e. rate constant for metabolism 
attributable to CYP3A and CYP2B1) have been determined using the two inhibitors 
separately (sections 6.2.1 & 7.2.1).
kx-calc = ksA + k2B -equation 7.5.
where, kgA and k^B are the calculated rate constants for metabolism attributable to 
CYP3A and CYP2B1, respectively. The sum of these two rate constants gives the 
value for kx-calc-
The values of kgA and k^B are given in tables 7.3 and 6 .1, respectively. The calculated 
values of kx-calc are given in table 7.9.
The values of kx-obs and kx-calc were plotted against each other (figure 7.7). The 
regression equation was generated and is shown below:
kx-calc = 0.03 (±0.09) + 1.18 (±0.10) kx-obs 
n = 12; s = 0.19; r = 0.967; F =144
Ideally, the gradient and intercept of this equation should be 1 and 0, respectively, and 
the correlation coefficient should be 1. However, the equation is significant at the
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Figure 7.7. Regression plot of the experimentally determined rate constants of 
metabolism attributable to CYP3A and CYP2B1 (kx-obs) against the same calculated 
values (kx-calc)-
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0 .1% level so the calculated data (kx-calc) is a good reflection of the experimental 
data (kx-obs)-
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DISCUSSION
Based on the observation that dihydropyridines are substrates for CYP3A, an inhibitor 
of this isoenzyme has been designed using a dihydropyridine template. Preliminary 
investigations indicated that UK-122,802 was a mechanism-based inhibitor of 
felodipine oxidase activity and was specific for CYP3A in hepatic microsomal fractions 
obtained from dexamethasone-induced female rats. However, studies using 
pentoxyresorufin as a marker substrate for CYP2B1 activity (Lubet et al., 1985) in 
phenobarbitone-induced rat hepatic microsomal fraction show that UK-122,802 was 
also an inhibitor of this isoenzyme with an IC50 of 8|iM. This value can be compared 
with that for orphenadrine, a specific inhibitor of CYP2B1 (Reidy et al., 1989), in the 
same phenobarbitone-induced rat hepatic microsomal fraction (ICso=0.42|iM, section 
6.1.1). Cross-reaction of UK-122,802 with CYP2B1 as well as CYP3A should not 
cause a problem in untreated rat hepatic microsomal fraction since the former isoenzyme 
is present at relatively low levels constitutively (Waxman et al., 1985). Use of UK- 
122,802 as a specific inhibitor of CYP3A in induced rat hepatic microsomal fractions 
should be approached with caution since many chemicals are known to induce 
CYP2B1.
The inhibition of CYP3A by UK-122,802 has been characterized using felodipine as a 
marker substrate for this isoenzyme. It has been reported that dihydropyridines are 
substrates for both CYP3A and CYP2C in rat (Guengerich et al., 1986) and the 
substrate overlap of these two isoenzyme subfamilies in rat is well documented (Smith, 
1991). Thus, the possibility that UK-122,802 is also inhibiting CYP2C cannot be 
discounted, especially in the induced model since levels of CYP2C are elevated by 
pretreatment with some chemicals (e.g. phenobarbitone). Consequently, the calculated 
metabolic rate constants attributable to CYP3A for the DME derivatives should perhaps 
be regarded as attributable to CYP2C and CYP3A. It may prove difficult to
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characterize these two subfamilies separately in the rat because of their overlap in 
substrate specificity.
It was possible to correct for inhibition of CYP2B1 by UK-122,802 since it was 
determined that at a concentration of 10pM, 62% of pentoxyresorufin O-depentylase 
activity was inhibited. The validity of this correction factor was checked by using the 
inhibitors of CYP2B1 and CYP3A (orphenadrine and UK-122,802, respectively) 
together to experimentally determine the metabolic rate constants attributable to these 
two isoenzymes. These values compared favourably with the values that had been 
calculated using the two inhibitors separately.
Correction for inhibition of CYP2B1 enabled the calculation of rate constants for 
metabolism attributable to CYP3A. As has been noted previously, the DME derivatives 
containing an aromatic substituent had the highest rate constants of the series. It is 
possible that the two aromatic rings in these compounds interact with complementary 
amino acids in the enzyme active site thus facilitating substrate binding and metabolism. 
Such a possibility has been suggested for the interaction of dihydropyridines with 
nifedipine oxidase (CYP3A3/4) in a model-building study performed by Ferenczy and 
Morris (1989).
A simple linear correlation was seen for the "alkyl" series for ke and kdm with the 
length of the molecule. For these compounds the rate of metabolism by CYP3A 
increased as the length of the substrate increased. When other steric descriptors of the 
DME derivatives were examined some interesting relationships were found. For the n- 
alkyl derivatives C2-C5 (ethyl, n-propyl, n-butyl, pentylDME), an excellent linear 
dependence of half-life attributable to CYP3A on molar refractivity (CMR), area and 
volume was found. These relationships support the correlation seen with length for the 
"alkyl" series, ie. increasing rate of metabolism with increasing size of the substrate. 
Correlation of the above steric descriptors with the metabolic half-life attributable to
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CYP3A for the full series of DME derivatives failed to give any significant 
relationships. However, examination of the plots indicated that methylDME was an 
outlier. This compound had a very long half-life compared with the rest of the series 
and the plots with steric descriptors indicate that this may be due to its small size. 
CYP3A metabolizes a wide range of structurally diverse substrates mainly via aliphatic 
oxidation and N-dealkylation (Smith and Jones, 1992). A large active site has been 
proposed based on the wide range of substrate size and also on the observation that 
several metabolites may be produced from one substrate by the same isoenzyme. 
Studies utilizing a series of progesterone derivatives have shown that CYP3A is 
responsible for the further metabolism of primary oxidation products (Swinney et al., 
1988). For this to occur without the substrate leaving the enzyme active site the 
molecule would have to "flip and rotate" within the active site. Accordingly, a large 
active site is implied. It has been suggested, therefore, that the CYP3A active site may 
consist of a large chamber in which the substrate is relatively free to move until suitably 
exposed, and perhaps electron-rich, functions are presented for metabolism (Smith and 
Jones, 1992). This indicates that a substrate is metabolized almost by chance and may 
spend some time in non-productive positions. Based on this proposal it is possible to 
speculate that methylDME is too small to interact efficiently with CYP3A and spends 
most of its time moving around the large active site without being metabolized. The 
fact that there was little dependence of rate of metabolism on the size of the molecule for 
the rest of the series again supports the proposal for a large active site. It has been 
shown that cyclosporine is a substrate for CYP3A (Kronbach et al., 1988) and this 
compound is very bulky (CMR=32.5). The largest molecule of the DME derivatives is 
bisDME (CMR=10.2) and consequently the series does not cover a broad enough range 
for substrate size to affect their metabolism by CYP3A.
No dependence of the rate of metabolism of the DME derivatives by CYP3A on 
lipophilicity was observed. The relatively high lipophilicity of the DME derivatives 
(log D > 1.8) compared with other substrates of CYP3A (eg. codeine, log D=0.4)
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ensures their interaction with this isoenzyme. Hence, the DME series probably does 
not cover a wide enough range of lipophilicity for this to become a constraint on their 
interaction with CYP3A.
Two of the DME derivatives were not N-dealkylated by CYP3A (iso-propyl and tert- 
butylDME) and this is consistent with observations throughout studies with rat hepatic 
microsomal fractions (chapters 4,5 & 6). It is possible that the branched alkyl groups 
have a crowding effect around the nitrogen atom which makes it less susceptible to 
attack (chapter 4). One compound (bisDME) was N-dealkylated exclusively. It is 
difficult to speculate as to the reason for this since it was not possible to calculate k<jm 
and kda for the other compounds with aromatic substituents (phenyl, benzyl and 
phenethylDME) and these would have served as a comparison for bisDME. Kroemer 
et al. (1992) found that verapamil underwent N-demethylation and N-dealkylation in 
vitro but that N-dealkylation was the predominant route (figure 7.8). They showed 
using antibody inhibition studies that the metabolism of this compound was supported 
by CYP3A. It is possible that the bulky alkyl substituent of bisDME and verapamil 
hinders access to the N-methyl group and that this is the reason why N-dealkylation is 
preferred.
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Figure 7.8. Structure of verapamil. Arrows show sites of metabolism attributable to 
CYP3A: (1) N-dealkylation, which predominates, and (2) N-demethylation.
Adapted from Kroemer et al., 1992.
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CHAPTER 8
General discussion
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DISCUSSION
It was the aim of this research to investigate some of the structural features of tertiary 
amines that predispose them towards metabolism by particular isoenzymes of the 
cytochrome P450 superfamily. Quantitative structure activity relationships were used 
to determine any dependence on physico-chemical and molecular mechanical parameters 
for the activity seen in various hepatic microsomal fractions.
The series of tertiary amines, based on the 2-(2,4-dichlorophenoxy)-N- 
methylethanamine structure, had been synthesized by Dr. B.C. Jones (1989) in order to 
investigate the cytochrome P450-mediated N-demethylation reaction. In order to 
continue investigating P450-mediated N-dealkylation utilizing this series an HPLC 
assay has been developed enabling measurement of the DME derivatives and their 
metabolites at low concentrations (<l|iM) (chapter 3). In addition, atmospheric 
pressure ionization-mass spectrometry (APIMS) was employed to identify metabolites 
of the DME derivatives and thus aid in their tentative identification by HPLC (chapter 
3). Most of the DME series underwent N-demethylation and N-dealkylation (ie. 
removal of the R substituent) exclusively. Exceptions to this were iso-propylDME, 
tert-butylDME and phenylDME which were not N-dealkylated. In addition, a 
metabolite was detected for phenylDME which was indicative of hydroxylation. In 
general, N-demethylation was the preferred route of metabolism in all the hepatic 
microsomal fractions studied and this is consistent with the findings of Jones (1989).
The DME derivatives containing unsaturated substituents had the highest metabolic rate 
constants (ke) of the series in all the hepatic microsomal fractions studied. This may be 
attributed to interaction of the 2,4-dichlorophenol ring and the unsaturated substituent 
with complementary amino acids, such as phenylalanine, within the active site of the 
enzyme. Such interactions could lead to tighter binding of the substrate and facilitate 
metabolism. This possibility has been suggested for substrates of CYP1A (Lewis et
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al, 1987), CYP2B (Schwarze et al., 1988) and CYP3A (Ferenczy and Morris, 1989).
There was little sex difference in the in vitro metabolism of the DME derivatives 
(chapter 4). Although the compounds were generally metabolized more efficiently (ie. 
higher ke values) in male than female rat hepatic microsomal fraction, the trends for 
changes in ke within the series were very similar for both sexes. Significant sex 
differences have been reported for the metabolism of drugs, particularly in rat (Kato, 
1974), and these have been attributed to the existence of sex-specific cytochrome P450 
isoenzymes (Waxman, 1984; Waxman et a i, 1985). The female rat is lacking in the 
male-specific CYP3A2 isoenzyme and there are sex-specific CYP2C isoenzymes. The 
lack of a significant sex difference in the metabolism of the DME derivatives indicates 
that these compounds may be substrates for both CYP3A and CYP2C isoenzymes. 
Possibly the male rat exhibits higher ke values for the series than the female because 
CYP3A and CYP2C are expressed preferentially in the former. CYP2B1 would 
probably play a minor role in the metabolism of the DME derivatives in untreated rat 
since this isoenzyme is expressed at low levels constitutively in both the male and the 
female (Waxman et al., 1985).
Isoenzymes of the CYP2B and CYP3A subfamilies make up the bulk of spectrally 
determined basal levels of cytochrome P450 in dog (Ciaccio et al., 1989). The DME 
derivatives had higher ke values in male rat than in Beagle dog hepatic microsomal 
fraction, but the difference was not very pronounced (chapter 4). A preference for N- 
demethylation was apparent for dog hepatic microsomal fraction (ie. kym» k d a ) and 
this may indicate a slightly more constrained substrate specificity for the enzymes 
responsible for metabolism of the DME derivatives in this species.
No significant quantitative relationships were found for the biological data determined 
in untreated hepatic microsomal fractions with any physico-chemical descriptors of the 
DME derivatives (chapter 4). This is due to the heterogeneity of the constitutive
2 0 0
cytochrome P450 enzyme system. Hence, the majority of stmcture-activity relationship 
studies are performed using induced hepatic microsomal fractions so that one P450 
subfamily predominates and any relationships seen can be tentatively attributed to this 
subfamily (Jansson etal., 1972; Blanck et a i, 1983; Hall and Hanzlik, 1991).
The metabolism of the DME derivatives was studied in phenobarbitone-induced rat 
hepatic microsomal fraction (chapter 5). Several correlations were found that related 
increasing rate of metabolism of the series (ke or ti/2) to increasing lipophilicity and 
binding affinity of the substrate. The same relationships were seen for the rate of 
metabolism attributable to CYP2B1 (chapter 6) indicating that this isoenzyme was the 
main contributor to the structure-activity relationships seen in the phenobarbitone- 
induced hepatic microsomal fraction.
The importance of the lipophilicity of a molecule as a determining factor in its rate of 
metabolism has long been recognized (Gaudette and Brodie, 1959). The studies 
performed with the DME derivatives in induced hepatic microsomal fractions indicated 
that their in vitro rates of metabolism correlated better with the distribution coefficient 
(log D) than with the intrinsic lipophilicity (log P). Previous studies (Cho and Miwa, 
1973; Burstyn et al., 1991) have shown that the rate of N-demethylation of amines 
increased dramatically with increasing pH, with rate profiles that correlated with the 
pKa of the amine substrate. This effect was attributed to the limiting amounts of 
substrate available to the membrane-bound enzyme at the lower pH, due to the inability 
of charged species to partition into the lipophilic environment of the microsomal 
membrane. Since log D values are experimentally determined at physiological pH, they 
represent the "effective" lipophilicity of the compound taking into account both its 
intrinsic lipophilicity and its degree of ionization (Manners et a i, 1988). Therefore, an 
improved correlation of metabolic rate with log D compared with log P indicates that the 
concentration of substrate reaching the enzyme is of prime importance as a rate- 
determining step for its metabolism.
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Non-linear relationships with molar refractivity (CMR) and area of the DME derivatives 
for N-demethylation and N-dealkylation attributable to CYP2B1 provided evidence for 
a constrained active site (section 6.3). Optimum values of CMR (7.45) and area 
(1320Â2) for metabolism of the DME derivatives by CYP2B1 were calculated. The 
values of CMR and area for bisDME exceed the optima and this explains why the 
metabolism of this compound was not supported by CYP2B1. No such steric 
constraints were seen for metabolism of the DME derivatives attributable to CYP3A and 
for the closely related series of compounds (n-alkyl) the metabolic rate constant 
increased with increasing size of the molecule, as measured by length, CMR, area and 
volume (section 7.3). Some evidence was found that methylDME may be too small to 
be metabolized efficiently by CYP3A since it was an outlier from the regression plots 
with steric descriptors of the DME derivatives, indicating that it had a longer metabolic 
half-life than would be predicted from the size of the molecule. This is illustrated in 
figure 8.1 where plots of n-alkyl chain length against the rate constants for N- 
demethylation and N-dealkylation (kym and k<ja, respectively) have been constructed. 
The values of k^m and k j^a attributable to CYP3A for methylDME are very low 
compared with the rest of the n-alkyl series. Figure 8.1 illustrates another interesting 
feature concerning metabolism of pentylDME by CYP2B1 and CYP3A. For Q  to C4 
both kdm and kja  attributable to CYP2B1 increased with increasing chain length, but 
this trend is reversed for pentylDME. For metabolism attributable to CYP3A, kdm 
increased linearly with increasing chain length from Ci to C5 (r=0.958). The plot for 
N-dealkylation (figure 8.1b) clearly illustrates that as CYP2B1 becomes less efficient at 
N-depentylating pentylDME the role is taken over by CYP3A, which exhibits a 
dramatic increase in kda from C4 to C5. This leads to an apparent linear increase in kda 
with chain length (r=0.974) in the uninhibited incubation with phenobarbitone-induced 
rat hepatic microsomal fraction. Thus pentylDME provides an example of isoenzyme 
"switching" of a substrate between CYP2B1 and CYP3A.
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Figure 8.1. Plots of n-alkyl chain length against rate constants for (a) N- 
demethylation and (b) N-dealkylation of the DME derivatives in uninhibited 
phenobarbitone-induced rat hepatic microsomal fraction as well as the components 
attributable to CYP2B1 and CYP3A in the same induced microsomal fraction.
Rate constants are in units of nmol P450.min"1.
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The difference in N-dealkylation rate of pentylDME attributable to CYP3A and 
CYP2B1 prompted its choice for molecular modelling, which was carried out by Dr. 
D.F.V. Lewis at the University of Surrey (Guildford, UK). The only cytochrome 
P450 which has been characterized by x-ray crystallography is the bacterial enzyme 
P 4 5 0 c a m  (CYP101) (Poulos et al., 1987). Although there are inevitable differences 
between the protein sequences of cytochromes P450, it is generally believed that the 
overall tertiary structure is highly conserved because of considerable sequence 
homology between these isoenzymes and from similarities in their physical and 
functional properties. The active sites of 16 cytochromes P450 have been constructed 
by carrying out amino acid sequence alignment using 10 criteria for homology matching 
(Lewis and Moereels, 1992). The active site models were generated from the 3D 
structure of P 4 5 0 c a m  after substitution of appropriate residues, according to the 
sequence alignment, and a small degree of geometry minimization to relieve 
unfavourable van der Waals contacts. PentylDME was docked into the active site 
model for CYP2B1 (figure 8.2) and oriented with the site of oxygenation (ie. N- 
depentylation) close to the haem iron. The model indicates that the pentyl chain is too 
long to be accommodated easily within the active site. Figure 8.2 shows that the pentyl 
chain may interfere with a critical internal ion-pair bond between conserved amino acid 
residues (Lys-186 and Glu-251) that are thought to contribute to maintaining the shape 
of the hydrophobic pocket that forms the active site of the enzyme (D.F.V. Lewis, 
personal communication). When pentylDME was docked into the model of the active 
site of CYP3A1 (figure 8.3), again oriented for N-depentylation, it was found that the 
active site was large enough to accommodate the molecule easily.
In order to learn more about the active site of CYP2B1, three substrates of this 
isoenzyme were chosen for alignment with each other to determine any structural 
features of the molecules which may contribute to the specificity of metabolism 
attributable to CYP2B1. The O-depentylation of pentoxyresorufin is regarded as a 
specific marker of CYP2B1 activity (Lubet et al., 1985) so this was chosen as one of
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Figure 8.2. A postulated active site model for CYP2B1 based on the P450cam active 
site. Amino acids are coloured orange, the haem is shown in purple and the iron in 
yellow. PentylDME is displayed within the active site (atoms coloured by type) with 
the molecule oriented for N-depentylation (arrow).
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Figure 8.3. A postulated active site model for CYP3A based on the P450cam active 
site. Amino acids are coloured orange, the haem is shown in purple and the iron in 
yellow. PentylDME is displayed within the active site (atoms coloured by type) with 
the molecule oriented for N-depentylation (arrow).
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the model substrates (figure 8.4). Different cytochrome P450 isoenzymes catalyze 
distinct pathways of testosterone oxidation (Sonderfan et a/., 1987), CYP2B1 being 
responsible for the 16a- and 16p-hydroxylation of this molecule (figure 8.4). The 
DME derivative n-propylDME was also chosen since CYP2B1 was responsible for 
63% of its metabolism determined in phenobarbitone-induced rat hepatic microsomal 
fraction (section 6.2.1). Its structure is given in figure 8.4. These three substrates for 
CYP2B1 undergo different metabolic transformations (O-dealkylation, C-hydroxylation 
and N-dealkylation) and appear to have no structural similarities. An overlay of these 
molecules was performed by Dr. M. Tute at Pfizer Central Research (Kent, UK) using 
a computer program that matches "like" features of the molecules by Steric Electrostatic 
Alignment (SEA), assuming that these areas will tend to orient similarly within the 
active site. The three substrates are readily superimposable (figure 8.5) with their sites 
of attack by CYP2B1 falling within a small area (approximately 1.6Â apart). 
Coincidentally, electronegative areas of the molecules (4-C1 of n-propylDME, carbonyl 
groups of pentoxyresorufin and testosterone) are also superimposed, indicating that 
they may be interacting with a complementary area of the active site which facilitates 
binding of the substrate. A study investigating the structural requirements of CYP2B 
indicated that many of its substrates contained a carbonyl moiety and it was suggested 
that this group may interact with hydrophilic amino acids, such as serine or threonine, 
within the active site (Lewis et al., 1987). Such bonding could facilitate alignment of 
the substrate for the preferred route of metabolism exhibited by CYP2B1 for 
pentoxyresorufin and testosterone. The chlorine atom in n-propylDME could behave 
similarly and aid orientation of the molecule for oxidation of the nitrogen atom, ie. N- 
dealkyladon.
Increasing rate of metabolism of the DME derivatives in phenobarbitone-induced rat 
hepatic microsomal fraction showed a significant dependence on increasing electron 
density of the nitrogen atom (section 5.5). This was manifested by a multilinear 
correlation relating decreasing metabolic half-life to an increasing negative charge on the
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Pentoxyresorufin
OH
Testosterone
CH
CI
n-PropyIDME
Figure 8.4. Structures of pentoxyresorufin, testosterone and n-propylDME 
indicating, by an arrow, the position of metabolism by CYP2B1.
Figure 8.5. Superimposition of substrates for CYP2B1. Testosterone is shown in 
red, pentoxyresorufin in green and n-propylDME in blue. The sites of metabolic attack 
by CYP2B1 are shown in purple. The asterisk indicates where areas of 
electronegativity in the molecules are superimposed.
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nitrogen atom and the distribution coefficient for the substrate. The same relationship 
was seen for the metabolic half-life attributable to CYP2B1 (section 6.3). In addition, a 
second multilinear correlation related increasing rate constant for metabolism 
attributable to CYP2B1 (k2s) to increasing inductive effect of the substituent group 
(g*) and a decreased positive charge on the a-carbon atom of this group. The indicated 
changes in both these parameters would lead to an increased electron density on the 
nitrogen atom, and emphasizes the importance of this phenomenon for metabolism of 
the DME derivatives by CYP2B1. It is now generally accepted that the N-dealkylation 
reaction catalyzed by cytochrome P450 is a three step process involving (i) one electron 
oxidation of the nitrogen atom, (ii) proton abstraction from the a-carbon atom and (iii) 
oxygen rebound yielding the N-dealkylated amine and an aldehyde (Okazaki and 
Guengerich, 1993). An increased electron density on the nitrogen atom may facilitate 
the first step of the mechanism and a dependence on this factor for metabolism 
attributable to CYP2B1 indicates that it may be rate-limiting for this isoenzyme. This 
observation supports the work of Burstyn et al. (1991) who found that the N- 
demethylation of a series of N,N-dimethylanilines showed a significant dependence on 
the electron density of the nitrogen atom and suggested that oxidation of this atom could 
be the rate-determining step for CYP2B4.
As noted earlier, N-demethylation was the predominant route of metabolism for most of 
the DME derivatives. A consistent exception to this was propynylDME which was 
preferentially N-dealkylated (ie. kda» k d m) in phenobarbitone-induced rat hepatic 
microsomal fraction (section 5.3.1), and also by CYP2B1 (section 6.2.2) and CYP3A 
(section 7.2.2). One parameter sets propynylDME apart from the rest of the series and 
that is its charge on the a-carbon atom of the substituent group. PropynylDME has a 
value of 0.26 whereas the rest of the series have values of less than 0.18 (see appendix, 
table 7). It is possible that an increased positive charge on the a-carbon atom facilitates 
hydrogen ion transfer from this atom, which is thought to be the second step in the N- 
dealkylation mechanism. If this were the case then the propynyl group of
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propynylDME would be preferentially removed leading to the high value of kda 
compared with kdm» which was particularly noticeable for CYP2B1. This observation 
illustrates how a change in one parameter for one compound of a series can alter its 
metabolic profile in comparison with its congeners.
Examination of the rate constants for metabolism of the DME derivatives attributable to 
CYP2B1 (section 6.2.1) and CYP3A (section 7.2.1) in comparison with the ke values 
in the uninhibited incubation with phenobarbitone-induced rat hepatic microsomal 
fraction (section 5.2.1) indicates that these two isoenzymes are responsible for most of 
the metabolism of the "alkyl" series of DME derivatives (ie. compounds 1-7). It is 
apparent, however, that much of the metabolism of the DME derivatives with 
unsaturated substituents is unaccounted for. The DME derivatives may be substrates 
for CYP2D since this isoenzyme subfamily preferentially metabolizes nitrogen- 
containing molecules. Predictive models for CYP2D6 (the human form) have 
established the following substrate requirements: an extended hydrophobic region and a 
positively charged, basic nitrogen with the site of oxidation being 5-7Â from the 
nitrogen atom (Islam et al., 1991; Koymans et al., 1992). The DME derivatives fill 
these criteria but the potential site of metabolic attack by CYP2D is blocked by the 
presence of the chlorine atoms in the 2,4-dichlorophenol ring, although metabolism of 
the R substituent at the other end of the molecule may still be possible. The DME 
derivatives are unlikely to be metabolized by CYP1A since substrates for this subfamily 
tend to contain fused aromatic or heteroaromatic rings giving rise to overall molecular 
planarity with relatively small molecular depth (Lewis et al., 1987). Another subfamily 
that can probably be discounted is CYP2E since this has a preference for low molecular 
weight molecules that are relatively polar, including many solvents (Koop, 1992). This 
leaves CYP2C as a viable possibility for metabolism of the DME derivatives. The lack 
of sex difference in the metabolism of these compounds (chapter 4) indicates that they 
are substrates for both CYP2C and CYP3A and the substrate overlap of these two 
subfamilies in rat is well documented (Smith, 1991).
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In summary, the use of specific cytochrome P450 inhibitors has enabled structure- 
activity relationships to be constructed for the metabolism of a series of tertiary amines 
by CYP2B1 and CYP3A. These relationships, along with some molecular modelling, 
have indicated that CYP2B1 has a constrained active site while that of CYP3A is much 
more accommodating for large molecules. As long as specific cytochrome P450 
inhibitors are available, studies such as this may provide insight into the substrate 
selectivity of cytochrome P450 isoenzymes that are important in human xenobiotic 
metabolism and aid in the rational design of drugs.
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Future work
To understand further cytochrome P450-mediated N-dealkylation using the 2-(2,4- 
dichlorophenoxy)-N-methylethanamine series of compounds the following 
investigations should be undertaken:
The involvement of the CYP2C subfamily in the metabolism of the series by rat hepatic 
microsomal fraction has been deduced (see final discussion) but this could be 
confirmed by the use of a specific inhibitor, such as cimeddine.
The DME series could be extended by, for example, increasing the n-alkyl chain length 
beyond five carbon atoms or introducing a polar functional group into the R substituent 
(such as a hydroxyl group). This would provide an opportunity to demonstrate the role 
of the QS AR's already determined for predicting the biological activity of new members 
of the series. Another possibility would be to move away from the 2,4- 
dichlorophenoxy template by substituting fluorine for the chlorine atoms, for example.
The ultimate aim of in vitro studies is to provide information on the likely fate of a new 
molecule in vivo. The DME derivatives could be administered in vivo and the intrinsic 
clearance values obtained from pharmacokinetic experiments compared with the in vitro 
clearance rates to determine any in vitro/in vivo correlations.
The metabolism of the series could be investigated using human hepatic microsomal 
fraction which is becoming more readily available and provides a more relevant in vitro 
model for predicting the behaviour of drugs in man. The contribution of various 
human P450 isoenzymes to the metabolism of the DME derivatives could be 
characterized using specific inhibitors, such as quinidine for CYP2D6, sulphaphenazole 
for CYP2C9, ketoconazole for CYP3A4.
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APPENDIX
Table 1. Metabolic half-life values for formation of metabolites in phenobarbitone-
induced male rat hepatic microsomal fraction.
Substituent HLdm HLda
1. Methyl 11.4 ±0.60 11.4 ±0.60
2. Ethyl 4.56 ± 0.30 7.37 ± 0.60
3. n-Propyl 1.41 ± 0.06 3.67 ± 0.26
4. iso-Propyl 2.59 ± 0.08 *
5. n-Butyl 0.75 ± 0.05 2.04 ±0.19
6 . tert-Butyl 2.37 ± 0.04 *
7. n-Pentyl 0.98 ±0.11 1.40 ± 0.18
8 . Phenyl n.d. n.d.
9. Benzyl 0.50 ± 0.07 0.29 ± 0.02
10. Phenethyl 0.53 ± 0.04 1.80 ± 0.22
11. Propenyl 0.56 ± 0.02 1.22 ±0.07
12. Propynyl 0.73 ± 0.06 0.40 ± 0.03
13. Bis 1.32 ± 0.23 0.25 ± 0.03
HLdm = half-life for formation of N-desmethyl metabolite (min.nmol P450'1) 
HLtfa = half-life for formation of N-desalkyl metabolite (min.nmol P450"1)
* = compound not N-dealkylated 
n.d. = not determined
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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Table 2. Metabolic half-life values for formation of metabolites in dexamethasone-
induced male rat hepatic microsomal fraction.
Substituent HLdm HLda
1. Methyl 14.7 ± 0.56 14.7 ± 0.56
2. Ethyl 8.56 ± 0.31 7.14 ±0.21
3. n-Propyl 2.51 ±0.11 3.09 ±0.14
4. iso-Propyl 5.78 ± 0.19 *
5. n-Butyl 1.26 ± 0.04 2.95 ±0.14
6 . tert-Butyl 4.23 ± 0.08 *
7. n-Pentyl 0.97 ± 0.02 1.86 ± 0.08
8 . Phenyl 0.48 ± 0.03 *
9. Benzyl 0.53 ± 0.03 0.41 ± 0.02
10. Phenethyl 0.72 ± 0.04 0.84 ± 0.05
11. Propenyl 2.15 ±0.07 1.93 ± 0.06
12. Propynyl 2.19 ±0.26 0.61 ± 0.05
13. Bis 1.20 ± 0.12 0.67 ± 0.06
HLdm -  half-life for formation of N-desmethyl metabolite (min.nmol P450'1) 
HLda = half-life for formation of N-desalkyl metabolite (min.nmol P450"1)
* = compound not N-dealkylated
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
227
Table 3. Metabolic half-life values for formation of metabolites attributable to
CYP2B1 determined in phenobarbitone-induced hepatic microsomal fraction.
Substituent HLdm HLda
1. Methyl 16.5 ± 1.40 16.5 ± 1.4
2. Ethyl 9.24 ± 1.79 10.8 ± 1.56
3. n-Propyl 2.33 ± 0.20 5.21 ± 0.62
4. iso-Propyl 4.91 ± 0.41 *
5. n-Butyl 1.05 ± 0.07 3.28 ± 0.39
6 . tert-Butyl 3.79 ± 0.24 *
7. n-Pentyl 1.80 ± 0.29 4.15 ± 1.15
8. Phenyl n.d. n.d.
9. Benzyl n.d. n.d.
10. Phenethyl n.d. n.d.
11. Propenyl 1.60 ± 0.22 10.2 ±4.12
12. Propynyl 2.82 ± 0.76 1.20 ±0.19
13. Bis _a _a
HLdm = half-life for formation of N-desmethyl metabolite (min.nmol P450'1) 
HLda = half-life for formation of N-desalkyl metabolite (min.nmol P450"1)
* = compound not N-dealkylated
n.d. = not determined
a = compound not metabolized by CYP2B1
Bis = N,N-bis[2-(2,4-dichlorophenoxy)ethyl]methylamine
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Table 4. Log P and log D values for the DME derivatives.
Substituent Log P Log D
1. Methyl 3.34 1.80
2. Ethyl 3.79 2.18
3. n-Propyl 4.23 2.84
4. iso-Propyl 4.01 2.29
5. n-Butyl 4.68 3.49
6 . tert-Butyl 4.33 2.33
7. n-Pentyl 5.21 3.41
8. Phenyl 5.30 4.33
9. Benzyl 5.14 3.55
KXPhenethyl 5.27 3.25
11.Propenyl 3.69 3.36
12.Propynyl 2.83 2.84
13.Bis 6.83 3.63
Bis = N,N-Bis[2-(2,4-dichlorophenoxy)ethyl]methanamine. 
Adapted from Jones (1989).
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Table 5. Calculated molar refractivity, Taft inductive parameter and pKa values for 
the DME derivatives.
Substituent CMR G* pKa
1. Methyl 6.05 0.00 8.25
2. Ethyl 6.51 -0.10 8.58
3. n-Propyl 6.98 -0.12 8.65
4. iso-Propyl 6.98 -0.19 8.88
5. n-Butyl 7.44 -0.25 9.08
6 . tert-Butyl 7.44 -0.30 9.24
7. n-Pentyl 7.90 -0.25 9.08
8. Phenyl 8.10 0.75 5.78
9. Benzyl 8.56 0.27 7.36
lO.Phenethyl 9.02 -0.06 8.44
11.Propenyl 6.95 0 .00 8.25
12.Propynyl 6.77 0.81 5.58
13.Bis 10.16 0.82 6.89
Bis = N,N-Bis-[2-(2,4-dichlorophenoxy)ethyl]methanamine 
CMR = calculated molar refractivity 
a* = Taft inductive parameter
Adapted from Jones (1989).
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Table 6. Length, surface area and volume of the DME derivatives.
Substituent Length
(A)
Surface area
(A2)
Volume
(A3)
1. Methyl 10.54 1041.0 124.0
2. Ethyl 11.07 1105.6 209.1
3. n-Propyl 12.56 1201.0 225.3
4. iso-Propyl 11.05 1204.8 225.3
5. n-Butyl 12.91 1298.8 241.5
6. tert-Butyl 11.52 1322.6 241.5
7. n-Pentyl 14.35 1402.2 257.7
8. Phenyl 12.17 1306.7 246.5
9. Benzyl 13.22 1414.1 262.7
lO.Phenethyl 12.46 1531.2 278.9
11.Propenyl 12.18 1104.5 219.7
12.Propynyl 12.25 1078.0 215.3
13.Bis 14.53 1585.0 314.1
Bis = N,N-Bis[2-(2,4-dichlorophenoxy)ethyl]methanamine 
Adapted from Jones (1989).
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Table 7. Atomic partial charges on the nitrogen, a-carbon atom of the substituent 
group and the substituent group.
Substituent Nitrogen a-Carbon Substituent
1. Methyl -0.1607 0.1609 0.15
2. Ethyl -0.1677 0.1559 0.09
3. n-Propyl -0.1698 0.1534 0.20
4. iso-Propyl -0.1719 0.1537 0.10
5. n-Butyl -0.1702 0.1523 0.09
6. tert-Butyl -0.1761 0.1378 0.11
7. n-Pentyl -0.1680 0.1525 0.10
8. Phenyl -0.1486 0.1060 0.06
9. Benzyl -0.1714 0.1628 0.10
lO.Phenethyl -0.1648 0.1548 0.08
11.Propenyl -0.1690 0.1794 0.07
12.Propynyl -0.1711 0.2628 0.08
13.Bis -0.1598 0.1130 0.05
Bis = N,N-Bis[2-(2,4-dichlorophenoxy)ethyl]methanamine 
Adapted from Jones (1989).
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Table 8. Spectral binding constants for the DME derivatives.
Substituent Ks
OiM)
k 2 k 3
(liM)
K4
OiM)
1. Methyl 77.5 1.18 68.40 53.50
2. Ethyl 64.7 1.36 52.74 35.80
3. n-Propyl 50.0 2.04 31.65 14.32
4. iso-Propyl 60.7 2.18 36.81 15.66
5. n-Butyl 44.0 3.59 18.41 4.73
6. tert-Butyl 47.1 2.85 23.53 7.62
7. n-Pentyl 38.0 7.06 9.54 1.25
8. Phenyl 6.4 3.21 2.98 0.84
9. Benzyl 8.7 2.89 4.30 1.37
lO.Phenethyl 16.8 3.02 7.96 2.39
11.Propenyl 12.0 2.20 7.22 3.03
12.Propynyl 9.1 1.83 6.19 3.12
13.Bis 11.0 1.74 7.68 4.08
The spectral binding constants were obtained in phenobarbitone-induced rat hepatic 
microsomal fraction.
Bis = N,N-Bis[2-(2,4-dichlorophenoxy)ethyl]methanamine 
Adapted from Jones (1989).
